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“The important thing is not to stop questioning.  
Curiosity has its own reason for existing” 
 
-  Albert Einstein 
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Summary 
 
Pre-eclampsia is an important and serious condition affecting 2-8% of pregnancies 
worldwide and carries with it significant associated risk of morbidity and mortality for 
both mother and child. It is characterised by new onset hypertension after the 20
th
 week of 
gestation with accompanying proteinuria. Resolution of symptoms should occur following 
delivery. 
 
Several pathophysiological mechanisms are common to both pre-eclampsia and 
cardiovascular disease, and the link between pre-eclampsia and cardiovascular disease later 
in life has been established. While the underlying pathophysiological mechanisms of pre-
eclampsia are complex, endothelial dysfunction is a key component. Increased arterial 
stiffness and hypertension have also been documented. Endothelial dysfunction has been 
shown to extend beyond childbirth, into the postpartum period. Studies evaluating 
endothelial dysfunction at even longer time-points following an affected pregnancy have 
produced conflicting results.  
 
Results from biomarker studies have supported the concept of endothelial dysfunction 
throughout pregnancy and the postpartum period, but as more time elapses between index 
pregnancy and biomarker sampling, these results also vary.  
 
Cardiac imaging and electrocardiographic studies have also contributed to knowledge 
about the normal physiology of pregnancy and changes which are associated with 
hypertensive disorders of pregnancy during pregnancy, the post-partum period and beyond.  
 
The main focus of this thesis was to investigate the possible mechanisms behind the link 
between pre-eclampsia and future cardiovascular disease. The aim was to investigate 
women who were free from cardiovascular disease for any evidence of subclinical vascular 
damage long-term following a pre-eclamptic pregnancy. Overall women recruited to this 
study would be older than women who participated in the majority of previously published 
studies on this theme.  
 
Before embarking on the investigation of subclinical vascular damage in women with a 
history of pre-eclampsia, a link was confirmed between a history of pre-eclampsia and 
cardiovascular disease up to 30 years from time of index pregnancy. This was 
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accomplished using record-linkage in a large Scottish cohort; the Generation Scotland 
Family Health Study (GS:SFHS). Following on from this, ECGs available in women with 
and without a remote history of pre-eclampsia in the GS:SFHS cohort were assessed for 
any obvious differences. There was a more leftward shift in the QRS-axis in these women 
and a trend towards a longer corrected QT interval (QTc) which approached statistical 
significance, but after adjusting for other co-variates, pre-eclampsia did not independently 
predict QTc.  
 
Investigations for subclinical vascular damage were carried out by means of non-invasive 
vascular function studies in women recruited from three different cohorts (blood pressure 
clinics, GS:SFHS and the previous Proteomics in Pre-eclampsia (PIP) study of women 
during pregnancy). Time since index pregnancy varied between 1-30 years. Flow-mediated 
dilatation (FMD) was performed to assess for endothelial dysfunction, pulse wave analysis 
(PWA) and pulse wave velocity (PWV) assessed arterial stiffness, and carotid ultrasound 
was performed to establish whether there was any evidence of atherosclerosis. After 
adjusting for other co-variates, I was able to demonstrate the presence of endothelial 
dysfunction many years after pregnancy in women with a history of pre-eclampsia in 
comparison with those who experienced a normotensive pregnancy. There was also a 
significantly higher presence of carotid plaque in women with a history of pre-eclampsia. 
 
To investigate whether the findings from the vascular study translated to findings in 
biomarker studies of women with a history of pre-eclampsia in comparison with controls, 
samples from the vascular studies cohort and from the wider GS:SFHS cohort were used. 
Markers of inflammation, angiogenesis, cardiac damage and collagen turnover were 
studied. A significantly higher vascular endothelial growth factor (VEGF) was detected in 
women with a history of pre-eclampsia.  
 
Pre-eclampsia is associated with an increased risk of cardiovascular disease, and 
endothelial dysfunction is evident later on in life. Larger studies are required to further 
investigate the vascular and biomarker results, and studies including more thorough cardiac 
assessment (such as echocardiography) in this population should also be considered.  
 
The studies described found no evidence of one single component to explain the 
relationship between pre-eclampsia and cardiovascular disease later in life. This is not 
unexpected as pre-eclampsia is a complex condition with multiple contributing factors and 
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it is likely that the increased cardiovascular risk later in life is likewise multifactorial in 
origin.  
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RAAS  Renin-angiotensin aldosterone system 
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TIA  Transient ischaemic attack 
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1. Introduction 
 
 Introduction 1.1
 
Pre-eclampsia affects 2-8% of all pregnancies and is a leading cause of both maternal  (1)  
and fetal (2) morbidity and mortality with up to 40,000 women world-wide dying from the 
condition annually (3;4).  Nearly 40% of births which are delivered before 35 weeks of 
gestation are due to pre-eclampsia (5).  
 
A relationship between pre-eclampsia and future maternal cardiovascular risk has been 
widely established (6), however the underlying mechanisms of this relationship remain 
unclear. In an attempt to unravel possible contributing factors to the risk of cardiovascular 
disease years after a pregnancy complicated by pre-eclampsia, this chapter will first 
consider the changes the cardiovascular system experiences during pregnancy. It is then 
important to explore what is different in pre-eclampsia, and the pathophysiology of pre-
eclampsia. Following on from this one must consider what is currently known about the 
nature of the cardiovascular risk in women with a history of pre-eclampsia before finally 
examining the possible methods by which this could be further investigated, from the 
cellular and molecular level through to the clinical and vascular level.  
 
 The cardiovascular system in pregnancy 1.1.1
 
In normal human pregnancy there is vasodilation of the systemic vasculature which begins 
very early at around 5 weeks gestation (7). There is a decrease in peripheral vascular 
resistance which starts during the first trimester and continues into the second trimester. It 
then increases towards the end of pregnancy. In the post-partum period systemic vascular 
resistance has increased such that a few weeks after delivery the body has adjusted back to 
its pre-pregnant state (7;8). Blood volume increases throughout pregnancy (7) and red cell 
production is also increased but not proportionally as high as plasma volume therefore 
haemoglobin levels drop overall, causing the physiological anaemia of pregnancy.  
 
Cardiac output increases reaching its peak between the second trimester and term (9). It is 
15 % higher in twin pregnancy than singleton pregnancy (7). Heart rate increases (9) and 
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stroke volume increases until the end of the second trimester when it may stay constant or 
decrease (7). Pregnancy is associated with cardiac hypertrophy which is physiological and 
generally returns to normal by 1 year (9).  
 
Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure 
(MAP) all decrease during pregnancy, dropping to their lowest point mid-trimester (7;10). 
Blood pressure then rises again until delivery. One possible reason for this mid-trimester 
drop is thought to be the development of the utero-placental system, which is a low-
resistance system (11).  
 
A recent study by Nama et al challenged the concept of the mid-trimester drop in blood 
pressure in normal pregnancy (12). In a prospective study of 255 primigravid women who 
were normotensive at booking and had blood pressure measured at four time-points during 
gestation, SBP was found to increase throughout pregnancy. DBP also increased after an 
initial dip at 22 weeks gestation. Another study performed shortly after by Grindheim et al 
(11) with 57 normotensive women measured heart rate and blood pressure at 4 time points 
during pregnancy and at 6 months post-partum. There was a significant mid-trimester 
decrease in SBP, DBP and MAP confirming the findings of previous studies (13;14).  
 
 Hypertensive disorders of pregnancy 1.1.2
 
 Diagnostic criteria 1.1.2.1
 
Throughout the period of research resulting in the studies described in this thesis there 
have been updates both in the International Society for the Study of Hypertension in 
Pregnancy (ISSHP) guidelines (15;16) and in the guidelines from the American College of 
Obstetricians and Gynaecologists (17). A breakdown of criteria from ISSHP 
recommendations in 2000 (left column) and how they have been updated (right column) is 
provided in Table 1.1. There are several hypertensive disorders of pregnancy and it is also 
relevant to take into consideration the presence of any pre-pregnancy hypertension or 
proteinuria. Specific classifications of these disorders are given in Table 1.1. 
 
Chronic hypertension is classified as hypertension with onset before pregnancy. Pre-
eclampsia superimposed on chronic hypertension is defined as the appearance of de novo 
proteinuria starting after 20 weeks gestation in pregnant women with a prior diagnosis of 
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chronic hypertension. The diagnosis of white coat hypertension is confirmed by normal BP 
on 24hr ambulatory BP monitoring (ABPM) in the first half of pregnancy. If white coat 
hypertension is confirmed, up to 50% of these women can develop gestational 
hypertension or pre-eclampsia (15). 
 
Gestational hypertension is defined as de novo arterial hypertension (systolic BP ≥ 140 
mmHg and / or diastolic BP ≥ 90 mmHg on 2 occasions > 6 hours apart) occurring after 
gestational week 20, which returns to normal post-partum. Pre-eclampsia is often defined 
as gestational hypertension with proteinuria. Proteinuria is defined as in Table 1.1. 
Definitions for pre-eclampsia are continuing to change, and for the purposes of this thesis 
the definition of pre-eclampsia included proteinuria.  
 
Pre-eclampsia can be further defined depending on time of onset or severity of symptoms. 
The term “early” onset is used to describe pre-eclampsia which is diagnosed before 34 
weeks’ gestation. Classification of pre-eclampsia by level of severity is also possible 
however there are several factors which might contribute to severity and lack of 
consistency across studies. Examples of severity indicators include small for gestational 
age babies, or preterm birth at <37weeks gestation. When cohorts are separated based on 
level of severity of pre-eclampsia, there should be a clear description of this definition on 
an individual study basis. In an attempt to define severe pre-eclampsia better, the ISSHP  
circulated a questionnaire to the International Committee of the ISSHP and it was 
generally agreed that a pre-eclampsia should be defined as “severe” when blood pressure 
was >160 mmHg systolic, or 110 mmHg diastolic or if haemolysis, elevated liver enzymes 
and thrombocytopenia (HELLP) syndrome was present (18). Early-onset pre-eclampsia 
was generally agreed to be diagnosis at less than 34 weeks gestation.     
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Table 1.1 ISSHP Classification of the Hypertensive Disorders of Pregnancy*  
 
RECOMMENDATIONS 2000 RECOMMENDATIONS 2014 update 
Classification: 
1) Pre-eclampsia - eclampsia 
2) Gestational hypertension 
3) Chronic hypertension (essential and 
secondary) 
4) Pre-eclampsia superimposed on chronic 
hypertension 
Classification: 
1) Chronic hypertension 
2) Gestational hypertension 
3) Pre-eclampsia – de novo or 
superimposed on chronic hypertension 
4) White coat hypertension 
Pre-eclampsia definition: 
De novo hypertension after gestational week 20, 
and new onset of one or more of the following: 
 Proteinuria (as ≥300 mg/day or a spot 
urine protein/creatinine ratio ≥ 
30mg/mmol) 
 Renal insufficiency (creatinine 
≥90umol/L or oliguria) 
 Liver involvement (↑ transaminases 
and/or severe right upper quadrant or 
epigastric pain) 
 Neurological complications: eclampsia, 
hyperreflexia with clonus, severe 
headaches with hyperreflexia, persistent 
visual disturbances (scotomata) 
 Haematological disturbances: 
thrombocytopenia, DIC
#
, haemolysis 
 Foetal growth restriction 
 
Normalisation of blood pressure within 3 
months postpartum required for definition. 
 
Research definition for pre-eclampsia: 
De novo hypertension after 20 weeks gestation, 
returning to normal postpartum AND properly 
documented proteinuria 
Pre-eclampsia definition: 
Hypertension developing after 20 wks gestation 
and the coexistence of one or more of the 
following new onset conditions (15): 
1) Proteinuria (spot urine 
protein/creatinine ≥ 30mg/mmol or ≥ 
300mg/day or at least 1g/L [‘2+’] on 
dipstick testing) 
2) Other maternal organ dysfunction: 
 Renal insufficiency (creatinine 
≥90umol/L) 
 Liver involvement (↑ transaminases 
and/or severe right upper quadrant or 
epigastric pain) 
 Neurological complications (e.g. 
eclampsia, altered mental status, 
blindness, stroke, hyperreflexia when 
accompanied by clonus, severe 
headaches when accompanied by 
hyperreflexia, persistent visual 
scotomata) 
 Haematological complications 
(thrombocytopenia, DIC
#
, haemolysis) 
3) Uteroplacental dysfunction 
 Fetal growth restriction 
 
* Definition of hypertension in pregnancy: 
A systolic blood pressure (BP) ≥ 140mmHg and/or a diastolic BP ≥ 90mmHg on 2 separate occasions. If 
BP is severely elevated at >160/>110 mmHg, BP should be measured again every 15 minutes, then at 30 
minute intervals during initial assessment (18) according to ISSHP recommendations for severe and 
early-onset pre-eclampsia.   
#
DIC = disseminated intravascular coagulation   
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 Pre-eclampsia 1.2
 
 Pathophysiology of pre-eclampsia 1.2.1
 
While the underlying cause of pre-eclampsia is complex and remains poorly understood, 
most schools of thought support the “two phase” hypothesis which suggests that there is a 
first phase of the disease, the “placental” phase (with abnormal placentation), followed by 
a second phase, the “maternal” response (with systemic vascular inflammation). Pre-
eclampsia occurs only when a placenta is present, even if there is no fetus (e.g. 
hydatidiform mole) and usually resolves upon delivery of the placenta (19). 
 
 Placental phase 1.2.1.1
 
As part of the normal process of placentation, cytotrophoblasts cells invade the uterine 
wall. Cytotrophoblasts are then found in the maternal decidual arteries in the smooth 
muscle and endothelial layers. Maternal vessels are remodelled from low-flow, high 
resistance vessels into high-flow, low resistance vessels which supply the placenta and 
fetus with oxygen and nutrients. A study by Zhou et al found that in order to facilitate this 
process the phenotype of the cytotrophoblasts changes, and that they express adhesion 
molecules which are usually found on the surface of endothelial cells (20;21). 
 
An important factor in the pathogenesis of pre-eclampsia is thought to be an impairment of 
the normal remodelling process of the spiral arteries (22). Cytotrophoblasts do not fully 
invade and remain present only in superficial layers of the decidua (21). Thus there is 
failure of the remodelling process of the spiral arteries and this results in high resistance, 
narrower vessels. The cytotrophoblasts responsible for more shallow invasion in pre-
eclampsia have been found by Zhou et al not to exhibit the endothelial adhesion phenotype 
(23).  
 
When remodelling has failed there is poor quality uteroplacental perfusion caused by 
higher pressure and lower flow. This leads to an increase in the oxidative stress in the 
placenta from suboptimal utero-placental flow (24). Over time chorionic villi are injured in 
a form of ischaemia-reperfusion injury (25). Various factors are released which lead to the 
maternal syndrome some months later. These include syncytiotrophoblastic membrane 
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microparticles, factors involved in angiogenesis such as sFlt-1 and soluble endoglin and 
other factors which lead ultimately to endothelial dysfunction and the features of pre-
eclampsia (Figure 1.1).    
 
 
 
 
Figure 1.1. Abnormal Placentation in Preeclampsia   
1a) In normal pregnancy, cytotrophoblasts differentiate from an epithelial phenotype to an endothelial 
phenotype. 1b) In pre-eclampsia cytotrophoblasts do not have the invasive endothelial phenotype. This 
results in shallow spiral artery invasion. Figure from Karumanchi et al with permission (26) 
 
 Maternal phase 1.2.1.2
 
Maternal endothelial damage and systemic inflammation cause the features of pre-
eclampsia such as hypertension, proteinuria and oedema, seen in the second phase (25) 
(Figure 1.2). There is leucocyte and complement activation, an acute phase response, 
coagulation function is disturbed and there is also evidence of hyperlipidaemia and insulin 
resistance (27).  
 
a) 
b) 
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Figure 1.2. Maternal response and the evolution of pre-eclampsia. From Parikh et al with permission 
(28) 
 
The shape of the placenta in pre-eclampsia may differ from that of normal pregnancy (29). 
A Finnish study by Kajantie et al examining a large series of placental measurements from 
1934-1944 (30) found that the placenta in pre-eclampsia was more oblong-shaped. A 
circular shape is more usual in normal pregnancy. One hypothesis for the abnormal 
placental shape, proposed by Burton et al, suggests that normally as part of the 
trophoblastic invasion process, invasion is strongest at the centre of the placenta and is 
reduced moving towards the periphery (31). In peripheral areas where invasion is reduced, 
villi are damaged, partly as a result of excess oxidative stress and partly as a result of 
mechanical effects (29;31).  A circular placenta, with surrounding chorion laevae is formed 
from the resulting villus necrosis (29).  When there is more shallow invasion in pre-
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eclampsia, there is more generalized reduced plugging, and the regression of the placenta 
is not uniform or circumferential with unusual shapes resulting (29).  
 
 Animal models of pre-eclampsia 1.2.2
 
There is no perfect animal model for pre-eclampsia which exactly mimics all the human 
manifestations of the condition. In order to replicate the human experience of pre-
eclampsia as closely as possible, a desirable model would have impaired invasion of the 
trophoblast in the first trimester, develop pregnancy-specific hypertension and proteinuria, 
and exhibit an imbalance of angiogenic factors and endothelial dysfunction (32). 
Nevertheless, several animal models have been developed based on the proposed 
pathophysiological mechanisms of the disease and cover several possible mechanisms of 
the condition, from reduced uterine perfusion pressure and uteroplacental ischaemia to 
antagonism of angiogenesis, vasoconstriction, inflammatory models, metabolic models and 
transgenic and chronic hypertension models to name a few (33).  While such models have 
enhanced our understanding of the condition and can serve as a useful means of testing 
potential pharmacological interventions (32), cautious interpretation of the results of such 
studies would be required, especially considering the limitations of these models.  
 
 Risk factors for pre-eclampsia 1.2.3
 
Several risk factors for pre-eclampsia have been identified over the years and remain 
important. As with many other conditions, some of these risk factors are modifiable, others 
are not. Some risk factors are common to both pre-eclampsia and cardiovascular disease 
such as diabetes, pre-existing hypertension and renal disease.  
 
Insulin resistance, obesity and systemic inflammation and maternal age greater than 40yrs 
are all important risk factors (20;34-36). In a recent meta-analysis of the association 
between body mass index and pre-eclampsia, excess body mass was found to be 
significantly associated with an increased risk of pre-eclampsia (37). The risk for late-onset 
pre-eclampsia and gestational hypertension increases by 4% for every year over the age of 
32 years and by 10% for every 1 kg/m
2 
above a BMI of 24 kg/m
2 
(38). 
 
Regarding the pregnancy itself, risk of pre-eclampsia is increased with multiple gestation, 
with increased placental mass thought to play some role (20;34). In a systematic review of 
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risk factors, twin pregnancy was found to approximately triple the risk of pre-eclampsia 
(34). Limited recent exposure to the paternal antigen is also as predisposing risk factor as 
indicated by increased risk of pre-eclampsia with change in paternity with the latest 
pregnancy (20;39), use of barrier contraception (40), and assisted conception (41). There 
are conflicting reports regarding which components of assisted conception are responsible 
for the increased risk of pre-eclampsia. Ovulation induction, but not in vitro fertilisation 
was associated with an increase in early pre-eclampsia risk in a study by Poon et al (38). A 
proposed mechanism for this is that ovulation medications decrease the maternal serum 
concentration of pregnancy-associated plasma protein-A (PAPP-A), and low serum PAPP-
A has been associated with early onset pre-eclampsia (42).   
 
Nulliparity nearly triples the risk of pre-eclampsia (34) and women with a history of pre-
eclampsia have an increased risk of developing pre-eclampsia again in a subsequent 
pregnancy (43;44). The risk of recurrence varies depending on other factors such as 
maternal pre-existing medical disorders, gestational age at time of pre-eclamptic pregnancy 
and severity of pre-eclampsia (43;45). Longer inter-pregnancy intervals are associated with 
older maternal age, reduced fertility and the possibility of a change of partner (43). A 
meta-analysis by Cormick et al found that, when compared with inter-pregnancy intervals 
of 2-4 years, risk of recurrent pre-eclampsia was increased with longer inter-pregnancy 
intervals, but shorter intervals were not associated with an increased risk (43).    
 
Regarding family history of pre-eclampsia, a study by Poon et al revealed that independent 
prediction of pre-eclampsia applied to a history of pre-eclampsia in the mother but not the 
sister of affected women (38). This study also revealed a nine-fold increased risk of early 
pre-eclampsia, but there was not an increased risk for late pre-eclampsia, in women with 
chronic hypertension (38).   
 
Genetic factors play a role in pre-eclampsia, as discussed later in this chapter, but the most 
obvious evidence of this is that maternal and paternal family history of the disease have 
been shown to be predisposing factors (46). Ethnicity may also play a role. Black women 
have been shown to have an increased risk of early-onset pre-eclampsia, and Black and 
South Asian women an increased risk for late-onset pre-eclampsia, as reported by Poon et 
al (38). 
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Smoking during pregnancy has been shown to be protective against pre-eclampsia on 
systematic review (47). Similar protective findings relating to smoking have also been 
found in ulcerative colitis (48;49), Parkinson’s disease (50) and endometrial cancer in 
postmenopausal women (51). A potential explanation for this may be the vasoprotective 
properties of carbon monoxide (CO). In vitro culture experiments have shown that CO and 
CO-releasing molecules lower levels of sFlt-1 and soluble endoglin (49). In a Swedish 
study of tobacco use in pregnancy and pre-eclampsia risk (52), the effects of cigarette 
smoking and Swedish snuff on the risk of pre-eclampsia were compared. Cigarette 
smoking, but not snuff use during pregnancy, was found to decrease the risk of developing 
pre-eclampsia and gestational hypertension. Nicotine is the common ingredient in snuff 
and cigarette smoke, so this study lends weight to the concept that protective effects of 
cigarette smoking are likely mediated by an ingredient in combustion such as carbon 
monoxide. Nevertheless, the negative impact of smoking on pregnancy in general must not 
be underestimated. Its benefits in pre-eclampsia are by far outweighed by the damaging 
effects of smoking on overall health and perinatal outcomes (53). 
 
 Prediction of pre-eclampsia 1.2.4
 
There is ongoing research into the role of biomarkers in the prediction of pre-eclampsia, 
and individual biomarker advances such as sFlt-1/PlGF ratio are mentioned in the 
biomarker section 1.7.   
 
Some of the more interesting recent advances in this area include the findings of the 
“Screening for Pregnancy Endpoints (SCOPE)” study, which combined uterine artery 
Doppler at 19-21 weeks gestation with clinical risk factors and 11 biomarkers measured at 
14-16 weeks gestation to predict pre-eclampsia in low-risk nulliparous women (54). The 
final model for pre-eclampsia prediction included mean arterial pressure, body mass index 
at 14-16 weeks gestation, the consumption of ≥ 3 pieces of fruit per day, placental growth 
factor and mean uterine artery resistance index. In training and validation cohorts the 
performance of this model reported as area under the receiver operator curve (AUC) and 
95% confidence interval was AUC 0.73 (0.70 to 0.77) and 0.68 (0.63 to 0.74) respectively 
(54). A model for early-onset pre-eclampsia which included mean arterial pressure, any 
pregnancy loss at <10 weeks, angiogenin/placental growth factor ratio and mean uterine 
artery resistance index revealed AUC 0.89 (0.78 to 1.0) and 0.78 (0.58 to 0.99) in training 
and validation cohorts respectively. These models, especially in the prediction of term pre-
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eclampsia showed only modest prediction and further validation in larger cohorts is 
desirable. 
 
A metabolomics study evaluating 14 metabolites sampled at 15 weeks gestation in the 
prediction of pre-eclampsia has also yielded interesting results (55). The 14 metabolites 
gave an odds ratio of developing pre-eclampsia of 36 (95% CI: 12 to 108) with AUC 0.94. 
Validation of these findings in a separate cohort gave an odds ratio of 23 (95% CI: 7 to 73) 
for the 14 metabolites and AUC 0.92. These findings are, not only the first step in 
exploring the potential of metabolomics in prediction of pre-eclampsia, but also in the 
discovery of a potential early predictor of pre-eclampsia, measured at just 15 weeks 
gestation. Such a discovery could have huge implications for the application of clinical 
resources in a timely fashion, and subsequent improved maternal and fetal outcomes. 
Further validation work is awaited.  
 
Following on from these advances in research into the prediction of pre-eclampsia is the 
“Improved Pregnancy Outcomes via Early Detection (IMPROvED)” study (56) which is a 
multicentre study assessing a proteomic platform and a metabolomic platform in low risk 
primiparous women. Blood sampling occurs at 15 and 20 weeks gestation with the option 
of sampling at 11 and 34 weeks. Sampling across all trimesters will also allow gestational 
age at time of risk assessment to be evaluated.  At time of writing this study is still 
recruiting and the resulting biobank will provide a useful resource for this and future 
studies.  
 
In women with a diagnosis of pre-eclampsia, predicting serious complications and 
maternal mortality would be extremely useful. A study by von Dadelszen et al (57) devised 
a prediction model for adverse maternal outcomes within 48 hours; the fullPIERS (Pre-
eclampsia Integrated, Estimate of RiSk) model. Included were features such as chest pain, 
dyspnoea, oxygen saturation, creatinine and aspartate transaminase concentrations, platelet 
count and gestational age. The model performed well (AUC ROC 0.88, 95% CI: 0.84 to 
0.92). This model is being further validated and also refined for use in lower income 
settings where resources may otherwise preclude its use.  
 
In conclusion, further validation of prediction models is required (58), however, avenues of 
current research are exploring the potential of a predictive test, in a timely manner, which 
is ideally high throughput and cost-effective.  
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 Prevention of pre-eclampsia 1.2.5
 
There is evidence (59;60) that aspirin is useful in the prevention of pre-eclampsia and it is 
the drug of choice. The NICE guidelines “Hypertension in pregnancy: diagnosis and 
management” 2010 (2) recommends the use of 75mg aspirin daily from 12 weeks gestation 
until birth for women at high risk of pre-eclampsia and for women with more than one 
moderate risk factor for pre-eclampsia. In 2014 the US Preventive Service Task Force 
recommended the use of aspirin for pre-eclampsia prevention and a recent study by 
Tolcher et al, to evaluate the incidence of recurrent pre-eclampsia, revealed a decrease of 
30% since the 2014 recommendation (60). In a recent multicentre, randomized, placebo-
controlled, double-blind trial to investigate low dose aspirin to prevent preterm pre-
eclampsia in women at high risk, Rolnik et al (59) found that there was a lower incidence 
of preterm pre-eclampsia with aspirin vs placebo.   
 
Low molecular weight heparin (LMWH) is also useful in women at increased risk of pre-
eclampsia, however, many studies have been too small to draw reliable conclusions 
(58;61). A meta-analysis by Rodger et al (62) compared LMWH vs no LMWH for 
prevention of recurrent placenta-mediated pregnancy complications and 18.7% of women 
given LMWH had recurrent complications vs 42.9% on no LMWH (relative risk reduction 
0.52; 95% CI: 0.32 to 0.86). Further research into LMWH would therefore be useful. 
 
In women with low dietary calcium intake, high dose supplementation has been shown to 
reduce pre-eclampsia (63;64). Dietary supplementation of vitamins C and E and 
magnesium have not been proven to reduce the risk of pre-eclampsia (58;65;66). 
According to a Cochrane review (67), vitamin D supplementation requires further 
assessment (58) as there were only a limited number of high quality trials. In a systematic 
review of the literature, supplementation with L-arginine in pregnant women with 
hypertension or who were at risk of pre-eclampsia found a significant reduction in the risk 
of pre-eclampsia, however the sample size for the outcome was limited and further 
research is also required (68).  
 
A meta-analysis of dietary and lifestyle interventions in pregnancy (69) revealed that 
weight management was associated with an overall reduction in pre-eclampsia of 26% (RR 
0.74, 0.60 to 0.92, p=0.006) and dietary interventions led to a 33% reduction in the risk of 
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pre-eclampsia (RR 0.67, 0.53 to 0.85, P<0.001). However, the studies had limited 
information on duration of intervention, intensity of intervention and method of providing 
the service, therefore implementation of these interventions could be difficult to provide 
and maintain, and there may be issues of patient compliance. 
 
In summary, there is evidence for the use of aspirin to prevent pre-eclampsia, however, all 
other interventions mentioned require further assessment.  
 
 Management of pre-eclampsia 1.2.6
 
Pre-conception counselling in women who have risk factors for developing pre-eclampsia 
would be the ideal scenario, however global data for 2012 suggest that approximately 40% 
of all pregnancies worldwide are unplanned (70).  The number of women who have 
chronic hypertension when they become pregnant is also increasing (71;72) as is the 
frequency of women developing gestational hypertension during pregnancy (73). It is 
likely that increasing age at first pregnancy and higher BMI has contributed to these trends.  
 
The NICE guidelines for hypertension in pregnancy, published in 2010 and updated in 
2011, outline management of pre-eclampsia (2). They are currently under further review as 
of 2017.  Women with mild (BP 140-149/90-99 mmHg), moderate (BP 150-159/100-109 
mmHg) severe (BP ≥160/110 mmHg) hypertension with pre-eclampsia should be admitted 
to hospital. Treatment is suggested for those pre-eclamptic women with moderate and 
severe hypertension, aiming to keep systolic blood pressure <150mmHg and diastolic 
blood pressure 80-100 mmHg. Oral labetolol is suggested as first-line treatment, with 
methyldopa and nifedipine offered as potential alternatives depending on the woman’s 
side-effect profile. Blood pressure should be measured four times a day at least in mild to 
moderate cases and more frequently in severe cases. The guideline does not suggest repeat 
quantification of proteinuria. Blood tests for kidney function, electrolytes, full blood count, 
bilirubin and transaminases are suggested twice a week in mild pre-eclampsia and three 
times a week in moderate and severe cases (2).  
 
Regarding the timing of delivery, women should be managed conservatively until 34 
weeks and senior obstetric staff should document a plan of criteria for elective birth prior 
to this time. A plan for antenatal fetal monitoring during birth should also be documented. 
In cases of pre-eclampsia with severe hypertension after 34 weeks gestation, birth is 
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recommended once a course of corticosteroids is completed (if required) and blood 
pressure is controlled. Women with mild to moderate hypertension and pre-eclampsia 
should be offered delivery between 34
+0
 – 36+6 weeks as appropriate depending on the 
condition of mother and fetus and the availability of neonatal intensive care. For women at 
37
+0 
weeks gestation or beyond who have mild to moderate hypertension with pre-
eclampsia, birth is recommended within 1-2 days. Blood pressure should be followed-up 
along with monitoring of haematological and biochemical parameters.  
 
For women in a critical care setting with severe pre-eclampsia or severe hypertension, 
intravenous magnesium sulphate should be given if they have or previously had an 
eclamptic fit. Anti-hypertensives suggested are labetolol, hydralazine or nifedipine and 
response to treatment must be monitored with the aim to keep systolic blood pressure <150 
mmHg and diastolic blood pressure 80-100 mmHg. If birth is considered to be likely 
within 1 week, betamethasone is administered to aid maturation of the fetal lung. 
 
Regarding follow-up after delivery, in women with gestational hypertension or pre-
eclampsia, they should be informed that they are at increased risk of developing 
hypertension and its sequelae later in life. This information should also be forwarded to the 
primary care team (2). The guidelines also state that women with pre-eclampsia should be 
informed that they have a recurrence risk of pre-eclampsia of 1 in 6 in a future pregnancy, 
however this risk is increased to 1 in 4 if they had severe pre-eclampsia, eclampsia or 
HELLP syndrome with birth at <34 weeks gestation. In births at <28weeks, the risk 
increases again to 55%. Inter-pregnancy interval of <10 years does not confer any 
additional risk of pre-eclampsia (2).  
 
Topical issues in the management of women with hypertensive disorders of pregnancy and 
pre-eclampsia pertain to the optimum blood pressure to aim for in these women and the 
optimum timing of delivery. There has been concern over excessive blood pressure 
reduction in pregnancy and the concept that it might further reduce utero-placental 
perfusion causing lower birth weight. (74). A meta-regression analysis by von Dadelszen et 
al reported that a 10 mm Hg fall in maternal mean arterial pressure was associated with a 
176g decrease in birth weight (74).  
 
In order to further investigate the effect of blood pressure control on perinatal and maternal 
outcomes an international multicentre randomised controlled trial, “the Control of 
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Hypertension in Pregnancy Study (CHIPS)” was set up (75). There has been concern about 
the potential of lowering blood pressure to be harmful and the possibility of it impacting 
not only on fetal growth but also on perinatal morbidity and mortality. The CHIPS trial 
sought to investigate women with non-proteinuric, non-severe pre-existing hypertension or 
gestational hypertension, women with live singleton fetus at 14weeks to 33weeks 6 days 
gestation, and a diastolic blood pressure of 90-105mmHg if on no antihypertensive therapy 
or 85-105mmHg if they were on antihypertensive therapy. Women were randomly 
assigned to either less-tight control (target DBP 100 mmHg) or tight control (target DBP 
85 mmHg). In both groups just over 50% of the women were taking antihypertensive 
medication at enrolment. Labetolol was the antihypertensive medication suggested in the 
study protocol, however only two thirds of women on antihypertensive medication were on 
this agent. While women in the less-tight control group had a higher rate of severe 
maternal hypertension, there were no significant differences in risk of adverse perinatal 
outcomes or overall serious maternal complications. Secondary analysis of the CHIPS data 
(76) revealed that after adjusting for pre-eclampsia, severe hypertension was a significant 
risk factor for adverse perinatal and maternal outcomes. The CHIPS trial had a total study 
population of less than 1000 participants. Further studies would assist in further 
clarification regarding optimum blood pressure targets and their potential benefits.  
 
Regarding timing of delivery, this has been investigated in the first HYPITAT study (77), 
which was a multicentre randomised controlled trial investigating induction of labour in 
women with a singleton pregnancy complicated by gestational hypertension or mild pre-
eclampsia at 36-41 weeks gestation. It found that adverse maternal outcomes were reduced 
with delivery after 37 weeks gestation, and neonatal outcomes were not significantly 
different. The HYPITAT-II trial investigated delivery in women with hypertensive 
disorders of pregnancy between 34 and 37 weeks gestation and found that while the small 
risk of adverse maternal outcomes was reduced, there was a significant risk of neonatal 
respiratory distress syndrome (78). Risks to fetus must be weighed up in addition to 
maternal risks in considering delivery at 34-37 weeks gestation.  
 
 Cardiovascular risk after pre-eclampsia 1.3
 
Women with a history of hypertensive complications in pregnancy are known to be at an 
increased risk of vascular and metabolic diseases later on in life (79). One of the first 
suggestions of a link between pre-eclampsia and future cardiovascular disease was 
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reported ~55 years ago (80). Since then more and more evidence has accumulated in 
favour of postpartum cardiovascular risk in women with a history of pre-eclampsia (81-
85). In a recent study by Behrens et al (86), in comparison with women with normotensive 
pregnancies, women who had a hypertensive disorder of pregnancy in their first pregnancy 
were found to have an increased risk of developing hypertension during the following 10 
years of 14-32% depending on age at time of pregnancy. Recurrent pre-eclampsia is 
associated with greater risk of cardiovascular disease, and women who had pre-eclampsia 
associated with fetal growth restriction or developed pre-eclampsia before 34 weeks 
gestation have four to eight times the risk of cardiovascular death in comparison with 
women who had a normal pregnancy (87;88). The impact of pre-eclampsia on future 
cardiovascular health has now been acknowledged by the American Heart Association, 
which recognises pre-eclampsia as a risk factor for cardiovascular disease (89) and stroke 
(90) in its latest guidelines regarding cardiovascular risk in women. 
 
 
 
Figure 1.3 Increased vascular risk with complicated pregnancy 
Women with a history of complicated pregnancy e.g. pre-eclampsia (red line) have greater 
risk of developing vascular and metabolic disease than women with healthy pregnancies (blue 
line). Figure from Sattar et al with permission (79).  
 
Shared risk factors for pre-eclampsia and cardiovascular disease include obesity, insulin 
resistance and lipid abnormalities. Endothelial dysfunction is a key component of both. In 
normal pregnancy there is upregulation of inflammatory markers, an increase in 
coagulation factors, a degree of insulin resistance and hyperlipidaemia (91). In pre-
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eclampsia these normal adaptive mechanisms are enhanced (92). Oxidative stress also 
contributes to endothelial dysfunction in atherosclerosis and in pre-eclampsia. 
 
 
 Epidemiological studies 1.3.1
 
Many epidemiological studies in various populations comprising various ethnicities have 
reported the associations between pre-eclampsia and cardiovascular disease (93), and these 
studies are getting larger and larger. A large study of 1.03 million women in Ontario 
Canada, the CHAMPS study, found that women with pre-eclampsia, who did not have any 
evidence of cardiovascular disease at the beginning of pregnancy were found to have a 
hazard ratio of 2.1 of developing future cardiovascular disease in comparison with women 
who did not have a history of pre-eclampsia (83). Another large study in Taiwan 
demonstrated that women with a history of pre-eclampsia/eclampsia had an increased risk 
of major cardiac events up to 3 years post-partum (94). 
 
Various studies in other parts of the world have drawn similar conclusions; USA (95;96), 
Nordic countries (81;97;98), UK (99) and Scotland (85;100). One of the Scottish studies 
by Smith et al (85) used routine discharge data to link all singleton first births from 1981-
1985 with the mothers’ subsequent admissions and deaths for a 15-19yr follow-up period. 
Delivering a baby in the lowest birthweight quintile for gestational age gave an adjusted 
hazard ratio 1.9 [95% CI 1.5-2.4] of developing maternal ischaemic heart disease or death. 
Preterm delivery, and pre-eclampsia gave adjusted hazard ratios [95% CI] of 1.8 [1.3-2.5] 
and 2.0 [1.5-2.5] respectively. Women with all three characteristics had a risk of IHD 
admission or death seven times greater than the reference category. Bellamy et al (6) 
performed a systematic review of the literature and meta-analysis and reported on the 
relationship between pre-eclampsia, cardiovascular diseases and cancer. Women with a 
history of pre-eclampsia had relative risk of 3.70 (2.70 to 5.05) of developing 
hypertension, 2.16 (1.86 to 2.52) of developing ischaemic heart disease and 1.81 (1.45 to 
2.27) of developing stroke in comparison with women who had normal pregnancies. They 
were followed up for 14yrs, 11yrs and 10yrs respectively and there were no differences in 
rates of cancer in general or breast cancer between groups. Another systematic review and 
meta-analysis, by McDonald et al (101), also reported that in women with a history of pre-
eclampsia there was approximately a 2-fold increase in risk of stroke, ischaemic heart 
disease and cardiovascular death in women with a previous history of pre-eclampsia. In a 
systematic review and meta-analysis of cardiovascular disease in women with pre-
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eclampsia by Brown et al, a significant increase in odds of fatal or diagnosed 
cardiovascular disease, hypertension and cerebrovascular disease was found (102). The 
odds of having such an event was also estimated as being double that of women without 
pre-eclampsia.  
 
Regarding hypertensive disorders of pregnancy without proteinuria, a recent large Finnish 
study (82) has suggested that in patients with any hypertensive disorder of pregnancy, there 
was an increase in cardiovascular disease risk including myocardial infarction (MI), MI 
death, ischaemic heart disease, stroke and heart failure.  
 
 Causes of cardiovascular risk after pre-eclampsia  1.3.2
 
There is debate as to whether pre-eclampsia itself causes cardiovascular disease or whether 
pregnancy reveals a woman’s underlying and pre-existing risk of cardiovascular disease 
(Figure 1.3).  
 
New evidence for the direct effect of pre-eclampsia itself on cardiovascular risk has 
recently emerged from animal studies. In a study by Pruthi et al (88) after exposure to a 
mouse model of sFlt-1 induced pre-eclampsia, a mouse carotid injury model was used, to 
test the hypothesis that there is an enhanced vascular response to future vessel injury with  
prior exposure to pre-eclampsia. Mice exposed to pre-eclampsia did exhibit an enhanced 
responsiveness to the carotid injury model in comparison with mice not exposed to pre-
eclampsia (88). These findings support the concept of pre-eclampsia itself changing the 
response to future vascular insult.  
 
However, evidence in support of the hypothesis that there may be pre-pregnancy risk 
factors common to both pre-eclampsia and cardiovascular diseases has been provided by 
the Norwegian population-based Nord-Trondelag Health Study (HUNT) (103) where 
longitudinal data from two different time-points were linked with Medical Birth Registry 
of Norway data.  Data available from HUNT 1 (1984-1986), and HUNT 2 (1995-1997) 
included measurement of height, weight, blood pressure and lifestyle factors such as 
socioeconomic status and smoking history. Non-fasting serum lipid measurements had also 
been made at the time of HUNT 2. Women with a history of pre-eclampsia or gestational 
hypertension had higher systolic and diastolic blood pressure measurements, higher BMI 
and unfavourable lipid profiles. On adjustment for pre-pregnancy measurements, there was 
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attenuation of the difference in BMI, blood pressure, triglycerides and HDL cholesterol. 
The results suggest there were risk factors for later cardiovascular disease present before 
the pregnancies themselves. They do not, however, completely exclude the possible role of 
a hypertensive or pre-eclamptic pregnancy on later cardiovascular disease. Further 
longitudinal studies may help to further clarify the role of pre-pregnancy status on risk of 
cardiovascular disease after hypertensive disorders of pregnancy. 
 
There are a vast spectrum of study types which tackle various aspects of the 
pathophysiology and management of disease in pre-eclampsia, cardiovascular disease itself 
and cardiovascular disease in women with a more remote history of pre-eclampsia. Various 
investigative approaches are common to all three of these study areas (see Fig 1.4). In 
order to clarify outstanding questions in the pathophysiology of pre-eclampsia and 
underlying mechanisms of future cardiovascular disease risk after pre-eclampsia further 
research is required.  
 
 
 
 
 
 
Figure 1.4 Types of studies investigating pre-eclampsia, cardiovascular disease and 
the relationship between them 
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Rather than separating the link between pre-eclampsia and cardiovascular disease as being  
from the metabolic disturbance and endothelial damage initiated by the onset of pre-
eclampsia itself or by pre-existing and pre-pregnancy susceptibility to pre-eclampsia and 
later cardiovascular disease, it is more likely that a combination of these two concepts 
underlies the overall cardiovascular disease susceptibility.   
 
 Cardiovascular risk in offspring of women with pre-eclampsia 1.3.3
 
While pregnancy is now being viewed as a critical period of time in which to assess a 
woman’s future cardiovascular risk, a window to her cardiovascular future, it is also 
important to offspring cardiovascular risk (104).  
 
A systematic review by Davis et al (105) of traditional cardiovascular risk factors in 
offspring of pre-eclamptic pregnancies vs controls revealed that during childhood and 
young adulthood, systolic blood pressure was 2.39 mmHg (95% CI: 1.75-3.05, P<0.0001) 
higher and diastolic blood pressure 1.35 mmHg (95% CI: 0.90-1.80, P<0.00001) higher. 
BMI was also higher in children exposed to a pre-eclamptic in-utero environment 
compared with controls (0.62kg/m
2
, P<0.00001). 
 
A UK-based study of children aged 9-12 years (106) found evidence of 2.04 mmHg (95% 
CI:1.33,2.76) higher systolic blood pressure and 1.10 mmHg (95% CI: 0.47, 1.73) diastolic 
blood pressure in children who were offspring of pre-eclamptic pregnancies, after adjusting 
for maternal and offspring confounders such as BMI.   
 
One explanation for these findings would be Barker’s hypothesis that an increased risk of 
hypertension and cardiovascular disease may result from exposure of the developing fetus 
to an adverse in-utero environment during a critical period of development (107).   
 
However, contradictory to this hypothesis is a recent study by Alsnes et al (108) which 
found that while offspring born to mothers with hypertensive disorders of pregnancy 
exhibited greater cardiovascular risk in adulthood than offspring of normotensive 
pregnancies, the cardiovascular risk to siblings born to the same mother but following a 
normotensive pregnancy were the same. The findings of this study were in favour of a 
genetic or lifestyle influence being stronger in determining offspring cardiovascular risk 
than maternal blood pressure in pregnancy. This has implications for future risk assessment 
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for cardiovascular disease after hypertensive pregnancy. It promotes the concept that 
offspring should also be followed up regarding their own cardiovascular risk, regardless of 
whether their mother experienced hypertension specifically in her pregnancy with them, 
but rather if she experienced hypertension in any pregnancy.  
 
 Vascular function in pre-eclampsia 1.4
 
 Endothelial function 1.4.1
 
Whilst there are several non-invasive methods for measuring endothelial function in 
research, flow-mediated dilatation (FMD) has been one of the most widely used, especially 
in the evaluation of women with a history of pre-eclampsia. However, endothelial function 
can also be assessed by means of peripheral arterial tonometry (PAT) and laser doppler 
imaging (and iontophoresis) which have also been used to investigate women with a 
history of pre-eclampsia, and both of which are less operator dependent than FMD. All 
three of these modalities will be addressed in this section.  
 
 Flow-mediated dilatation 1.4.1.1
 
In flow-mediated dilatation the change in artery diameter in response to reactive 
hyperaemia is measured (109). Specialised ion channels in the endothelial cell membrane 
open in response to shear stress (110) and calcium entry is increased. The calcium activates 
the enzyme endothelial nitric oxide synthase (eNOS), and the generation of nitric oxide 
which subsequently occurs results in flow-mediated dilatation. FMD was first proposed as 
a tool for assessment of endothelial function in 1992 and since then there have been further 
technological and methodological advances in protocols (110-114). The limitations of 
FMD are widely acknowledged (109;115) and while as a tool it has great merit in the 
research setting, its use in the clinical arena is precluded at the present time. While FMD is 
known to be highly operator dependent, several studies have assessed reproducibility with 
reassuring results and suggest that its use in clinical studies is acceptable (116-119). While 
in most studies FMD is performed at the brachial artery, it can also be performed at the 
radial or femoral arteries (109). During a normal FMD protocol, duplex ultrasound is used 
to measure baseline artery diameter and velocity of blood flow.  
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Figure 1.5 Flow-mediated dilatation. A) The FMD protocol typically involves at least 
1 minute of baseline measurement, 5 minutes of distal cuff occlusion, and up to 5 
minutes of data collection following release of the cuff. From Weissgerber TL et al 
(112), B) Analysis software showing region of interest box. From Charakida M et al 
(113), C) Edge detection software generated output. From Charakida M et al with 
permission (113).   
 
The occlusion cuff is inflated to suprasystolic pressure for 5 minutes. When it is released, 
the reduction in downstream resistance (caused by dilatation of the distal vessels in 
response to the ischaemia in tissue distal to the cuff) results in increased blood flow to the 
arm. The resulting increase in shear stress causes the endothelium to release vasodilators 
which in turn normally cause dilatation in healthy vessels. Dilatation is reduced or absent 
in patients with vascular dysfunction (112). FMD is calculated as the percentage change in 
artery diameter.  Maximum dilatation tends to occur at ~45-60 seconds post-release in 
young healthy individuals (109;112), however there can be marked variability between 
individuals and peak diameter can occur later in individuals with disease or older 
individuals (120). The procedure is outlined in Figure 1.5. 
 
Previous studies, including a meta-analysis, have shown that brachial FMD can predict 
incident cardiovascular events in middle-age to older adults (121;122) and in patients with 
obstructive coronary artery disease, it has been shown to be predictive of future adverse 
events (123). 
 
A 
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Endothelium-dependent FMD can be used to assess vascular function in women with pre-
eclampsia (109;112). In most studies in women with pre-eclampsia, FMD is reduced in 
women with pre-eclampsia in comparison with women who were normotensive during 
pregnancy (112;124-131). There were some studies which did not report a difference 
between women with pre-eclampsia and normotensive women (112;132-134). However, in 
a recent systematic review and meta-analysis of FMD before, during and for 3 years after 
pre-eclampsia, 37 studies were eligible for meta-analysis. The findings indicated that 
women with a history of pre-eclampsia had lower FMD before the development of pre-
eclampsia, at the time of pre-eclampsia and for 3 years post-partum, in comparison with 
women who did not have pre-eclampsia (135). On further investigation of FMD after pre-
eclamptic pregnancy, some studies suggest that in the initial 4-6 weeks post-partum period, 
FMD is actually increased in women with pre-eclampsia (128;132) suggesting an initial 
reversal of the endothelial dysfunction. Studies investigating the post-partum period up to 
3 years tend to suggest FMD will remain lower in women with a history of pre-eclampsia 
(127;134;136-140) in comparison with normotensive women. Some studies suggest the 
timing and severity of pre-eclampsia may have an impact on FMD with early-onset or pre-
term pre-eclampsia having lower FMD measurements (112;127;141). FMD has also been 
found to be lower in women with recurrent pre-eclampsia in comparison with women who 
had one pre-eclamptic pregnancy (136).  
 
By 10 or more years post-partum, two studies have shown that vascular dysfunction no 
longer persists and there is normalisation of FMD. For example, a study by Ostlund et al 
reports that women who had pre-eclampsia and were evaluated at 1 year post-partum were 
found at that time to have reduced FMD, but when they were evaluated again at 11 years 
post-partum they were found to have FMD values similar to women with normotensive 
pregnancies (142). However, the women with pre-eclampsia, at this later time point, had 
evidence of impaired glucose tolerance and higher blood pressures than their normotensive 
counterparts (142). The other study, assessing endothelial function in women 10 years after 
a pre-eclamptic first pregnancy (89 women) vs first pregnancies without pre-eclampsia (69 
women) also concluded that pre-eclampsia was not associated with impaired FMD 10 
years after pregnancy in previously healthy women, however in this study pre-eclampsia 
was associated with changes in circulating markers representative of possible early 
endothelial dysfunction (143).  
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 Peripheral arterial tonometry (PAT) 1.4.1.2
 
This non-invasive method uses fingertip pulse amplitude tonometry to evaluate endothelial 
dysfunction by measuring the changes in digital pulse volume throughout reactive 
hyperaemia (144;145). It is measured with an endothelial Peripheral Arterial Tonometry 
(EndoPAT) device. First a blood pressure cuff is applied to the dominant arm. Pneumatic 
finger probes are then applied to the index finger of each hand and a recording of the PAT 
signal is commenced for 5-10 minutes baseline recording (depending on study protocol) 
(144;145). Occlusion of the brachial artery is achieved by inflation of the blood pressure 
cuff to suprasystolic pressures for 5 minutes. The other arm acts as a control. On release of 
the blood pressure cuff, PAT recording continues for another 5 minutes. The reactive 
hyperaemia index (RHI) is calculated by dividing the average amplitude of the PAT signal 
over a specified time-period after cuff deflation, with the average amplitude over a 
specified time before the cuff inflation. The control arm is used to correct for other factors 
such as room temperature, and the RHI is calculated by EndoPAT software. The EndoPAT 
device is also capable of recording augmentation index, a measure of arterial stiffness.  
 
A previous study has shown that an impaired hyperaemic response is associated with 
endothelial dysfunction of the coronary arteries (144;146), and RHI has also been 
associated with several traditional and metabolic risk factors in the Framingham Heart 
Study (147-149).  
 
In a study of endothelial function in pregnancy, using EndoPAT (145), pregnant women 
who had risk factors for developing pre-eclampsia were examined at gestational weeks 16 
and 28 and again between 6-9 months postnatally. In women who had developed pre-
eclampsia or pregnancy-induced hypertension, the postnatal baseline pulse amplitude was 
lower than in normotensive controls. However, during pregnancy there had been no 
difference between cases and controls at either 16 weeks or 28 weeks, therefore EndoPAT 
had not been able to predict pre-eclampsia. Both groups had shown a higher baseline pulse 
amplitude at week 28, but it was not until the postnatal period that any differences in pulse 
amplitude emerged between groups. RHI was not significantly different between groups at 
any time point.  
 
Two more recent studies have assessed women with pre-eclampsia during pregnancy (150) 
and between 6 months and 4 years after delivery (151). Both showed evidence of 
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endothelial dysfunction with statistically significantly reduced RHI and both showed an 
increase in arterial stiffness as measured by augmentation index with the EndoPAT device. 
These findings are consistent with a previous study by Yinon et al (152) which 
demonstrated evidence of endothelial dysfunction in pregnant women with pre-eclampsia 
in comparison with normotensive controls.  
 
 Laser Doppler imaging and iontophoresis 1.4.1.3
 
In laser Doppler imaging, a monochromatic laser is scanned across the skin surface and 
light is backscattered from moving erythrocytes. The light undergoes a shift in frequency 
which is proportional to the velocity of the erythrocytes (153;154). The resulting image is 
colour-coded and represents the skin blood flow over the area which is being scanned. 
Each image is processed using software which calculates the laser Doppler flux 
measurement given in flow units.  Drugs are administered via iontophoresis which follows 
the principle that charged molecules of a drug solution will migrate across the skin under 
the influence of a current which is applied (154;155). Acetylcholine which vasodilates in 
an endothelium-dependent manner and sodium nitroprusside which vasodilates in an 
endothelium-independent manner are the more commonly used drugs in this procedure.   
 
In a recent study microvascular function was evaluated in women in the third trimester of 
uncomplicated pregnancies, and was re-evaluated at 6 weeks and 6 months postpartum 
(156). This study found that acetylcholine-mediated vasodilation was increased in normal 
pregnancy and returned to pre-pregnant levels by 6 months postpartum, however, in 
women with pre-eclampsia levels did not decrease in the postpartum period but remained 
high. The findings of increased microvascular responses in women with pre-eclampsia are 
mostly consistent with other studies (153;155-157), the only difference being that Khan et 
al (153), who examined women by laser Doppler imaging at 22 weeks, 26 weeks, 34 weeks 
gestation and 6 weeks postpartum did not find differences between pre-eclamptic and 
normotensive pregnancies in the postpartum period. Microvascular responses during 
pregnancy had been higher in pre-eclamptic than normotensive women.  
 
Overall, these results contradict the findings of larger vessels such as the brachial artery, 
where during the same time periods, FMD shows a decreased response in relation to pre-
eclampsia. One hypothesis for this disparity is that endothelial dysfunction is expressed 
differently between macro- and microvessels (153) during pregnancy and the post-partum 
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period. In a study of women with a much more remote history of pre-eclampsia, 15-25 
years after pregnancy (158) there was a decrease in acetylcholine response which it 
concluded was indicative of impaired endothelial function. The interpretation of these 
findings as impaired endothelial function in this context is similar to other studies which 
found reduced response to acetylcholine and sodium nitroprusside in coronary heart 
disease risk (159) and type 1 diabetes (160).  
 
 Vascular stiffness 1.4.2
 
 Pulse wave velocity 1.4.2.1
 
Pulse wave velocity (PWV) is related to the intrinsic elasticity of the arterial wall and its 
anatomic dimensions (161;162). The speed of the reflected arterial wave increases as 
arteriolar constriction occurs or arterial stiffness increases (162). PWV increases from 4-5 
m/s in the ascending aorta to 8-9 m/s in the iliac and femoral arteries (162). Disease and 
aging can reduce the elastic component of the arterial wall, therefore arterial stiffness tends 
to increase with age (163). Endothelial function can affect wall stiffness, by altering the 
integrity of the extracellular matrix or smooth muscle tone (163). Pulse wave velocity itself 
is calculated from the distance between two recording sites, and the time delay between 
corresponding points of the pressure wave (164). The main benefits of this method of 
assessment are that it is reproducible, non-invasive and simple to perform. 
 
In 2015 the American Heart Association issued recommendations for improving research 
on arterial stiffness (163). Recommendations for devices used to measure PWV are that 
arterial stiffness should be determined noninvasively by measurement of carotid-femoral 
PWV (cfPWV) (163;165;166). The measurement of PWV in other areas such as carotid-
radial was not recommended as there was no evidence that it predicted outcomes 
(163;167). Carotid-femoral PWV was also thought to inform risk stratification above that 
provided by traditional cardiac risk factors in people who are at intermediate risk of 
cardiovascular disease (163;165).  
 
In the 2007 European Society of Hypertension/European Society of Cardiology 
(ESH/ESC) guidelines for the management of hypertension (168) a fixed cut-off for 
cfPWV of 12m/s to indicate subclinical organ damage was suggested. However, a more 
recent consensus statement proposed the use of 10m/s as the cut-off, as this took into 
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consideration a new distance calculation method (169). The 2015 AHA recommendations 
warn of the hazards of using a fixed threshold e.g. the effects of age on PWV (163).  
 
In a very small study of pregnant women, comprising 10 normotensive, 8 hypertensive and 
8 pre-eclamptic pregnancies, cfPWV was higher in the 16 hypertensive pregnant women 
than the 10 normotensive (p-value <0.001) (170). In a systematic review and meta-analysis 
published in 2012, the association between pre-eclampsia and arterial stiffness was 
examined and 23 studies were included (171). Women with pre-eclamptic pregnancies had 
a significant increase in cfPWV and augmentation index (discussed below in the section on 
pulse wave analysis) in comparison with women who had normotensive pregnancies (171). 
This increase in arterial stiffness was noted prior to, during and in the months following 
pre-eclamptic pregnancy. The difference between pre-eclamptic cases and normotensive 
controls was larger in early-onset and severe pre-eclampsia.  
 
This study concluded that arterial stiffness measurements may be useful in predicting the 
onset of pre-eclampsia, and arterial stiffness may have a role in the increased risk of 
cardiovascular disease later in life (171).    
 
 Pulse wave analysis  1.4.2.2
 
Pulse wave analysis (PWA) recordings are generated from pulse pressure waveforms 
obtained with applanation tonometry. Applanation tonometry is simple to perform, non-
invasive, reproducible and is validated  (172). It is a technique which allows assessment of 
the various components of the pulse wave. The central aortic pressure wave comprises a 
forward-travelling wave, which is initiated by left ventricular ejection, and a later wave 
which is reflected from the periphery (173;174) (Figure 1.6). Different arterial sites give 
rise to different pulse waveforms. Also, as arterial stiffness increases, the velocity of the 
forward and reflected waves increases, and the reflected wave arrives earlier and augments 
the pressure in late systole. Augmentation pressure is defined as the difference between the 
second and first systolic peak, and augmentation index (AIx) is the augmentation pressure 
divided by the pulse pressure expressed as a percentage (174). Central aortic waveforms 
are derived from the radial artery waveform using a generalised transfer function. Heart 
rate is known to influence AIx (175), therefore it is normalised to a heart rate of 75 beats 
per minute (AIx@75).  
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Figure 1.6  The pulse wave and derived functions 
The augmentation pressure (AP)  is the pressure difference between the maximal 
systolic peak and the inflection point. Augmentation index is calculated as AP divided 
by pulse pressure (PP). From Stoner et al with permission (176). 
 
 
A study by Weber et al reported that non-invasively measured AIx and augmentation 
pressure were independent risk markers for coronary artery disease (174). 
 
In women with a history of pre-eclampsia, AIx is increased in comparison with women 
who have other hypertensive disorders of pregnancy without proteinuria (177). Another 
study examining women a few years postnatally found no difference in augmentation index 
between women who had pre-eclampsia and those who had normal pregnancies (178). 
However, a recent meta-analysis of markers of vascular dysfunction after hypertensive 
disorders of pregnancy (179) found that women with a history of hypertensive disorders of 
pregnancy had a higher AIx than women with normotensive pregnancies.    
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 Carotid ultrasonography 1.4.3
 
Carotid ultrasound is a non-invasive safe method of measuring carotid intima-media 
thickness (IMT) and detecting carotid plaques. It has been validated for use in assessing 
the presence of pre-clinical atherosclerosis and the procedure is reproducible and simple to 
perform with several protocol guidelines in existence (180-182). Carotid intima-media 
thickness is measured as the distance between the luminal-intima and media-adventitial 
interfaces according to the original paper by Pignoli et al (183).  
 
Over the past decade guidelines have varied in their recommendations. In 2010, the 
American Heart Association/American College of Cardiology (AHA/ACC) guideline 
recommended that in intermediate risk asymptomatic adults, carotid IMT measurement 
could be used for assessment of cardiovascular disease risk (115). This was a class IIa 
recommendation. In 2013 however, the AHA/ACC guidelines recommended against the 
use of carotid IMT in predicting individual risk in clinical practice (184). The European 
Society of Hypertension/European Society of Cardiology recommend carotid ultrasound 
for the detection of atherosclerosis or vascular hypertrophy as a class IIa recommendation 
with level of evidence B (185), and a Mannheim Consensus update regarding carotid 
intima-media thickness and plaques recommended measurement of carotid IMT and plaque 
presence for detection of cardiovascular risk in individuals who were asymptomatic but at 
intermediate risk or if risk factors were present (182).  
 
In the past, studies have shown that there is not any significant prognostic value found in 
combining carotid IMT with classic risk factor scores, such as the Framingham Risk Score 
(186-189). Despite this, there have been many studies which have shown an association 
between carotid IMT and the risk of cardiovascular events in the future (190-193). To 
further complicate matters, the findings of two meta-analyses on the subject, by Lorenz et 
al and Den Ruijter et al were inconsistent (194;195). Lorenz et al found the risk of 
cardiovascular events increased with increasing carotid IMT (195), but Den Ruijter found  
that when carotid IMT was added to traditional cardiovascular risk models the added value 
was small and not thought to be of clinical importance (194).   
 
There have been contradictory results not only regarding the value of carotid ultrasound in 
cardiovascular risk prediction, but also in assessing cardiovascular risk in women with pre-
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eclampsia. This may be partly due to problems such as varying study sizes and varying 
carotid ultrasound protocols. There can be differing results depending on which segments 
of the carotid artery are imaged and whether carotid plaque assessment is included (186). 
Carotid plaque presence has been found to have a stronger effect on improving 
cardiovascular risk prediction in women rather than men (196). 
 
A recent systematic review and meta-analysis by Milic et al (197) found that women who 
had pre-eclampsia had a higher carotid IMT than normotensive women at time of diagnosis 
and within the first decade postpartum. This is during the period of time when the majority 
of women are still pre-menopausal. The onset of menopause is also associated with an 
increase in cardiovascular risk factors, as mentioned in a study by Johnson et al (198). In 
this study, among healthy women undergoing repeated carotid IMT measurement over a 3 
year period, a higher rate of preclinical cardiovascular disease progression was noted in 
women with a more rapid menopausal transition (198). In order to assess carotid IMT and 
subclinical atherosclerosis in women with more remote histories of pre-eclampsia, at ten or 
more years since pre-eclamptic pregnancy, Garovic et al performed a meta-analysis of 
these studies and presented the data which included their own most recent study (199). In 
their own study of women at approximately 30 years since pre-eclampsia, carotid IMT was 
increased in women with a history of pre-eclampsia in comparison with normotensive 
pregnancies, and this association was independent of other cardiovascular risk factors 
(199). The meta-analysis of women with pre-eclampsia 10-40 years ago showed a similar 
difference; women with a history of pre-eclampsia had higher carotid IMT measurements 
than those with normotensive pregnancies (199).   
 
 Cardiological findings in pre-eclampsia  1.5
 
It has long been acknowledged that pregnancy may act as an early “stress test” and identify 
women at higher risk of cardiovascular disease later in life (79). An imbalance between 
pro-angiogenic vascular endothelial growth factor (VEGF) and placental growth factor 
(PlGF) and anti-angiogenic soluble Fms-like tyrosine kinase 1 (sFlt-1) contributes to pre-
eclampsia as discussed further in section 1.7.1. The fact that PlGF is expressed in cardiac 
and lung tissue as well as the placenta may be important in the evolution of cardiac 
problems in pre-eclampsia (200), and cardiac findings in relation to pre-eclampsia are 
further explored in this section.  
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 Echocardiography 1.5.1
 
One in three women with a history of pre-eclampsia will develop hypertension within 12 
years of delivery (201). Evidence is mounting that women with pre-eclampsia can develop 
abnormal left ventricular geometry and decreased diastolic function which may persist 
(202;203). Normally in pregnancy there is an increase in left ventricular (LV) mass and its 
dimensions also increase. It is an eccentric hypertrophy which is a physiological process 
and reverses within a few weeks post-partum (203). It is a more concentric hypertrophy 
which develops in pre-eclampsia and this is as a consequence of the increase in LV 
workload caused by the higher blood pressure (204). It is possible that excessive cardiac 
remodelling does not revert back to normal after delivery (201).  
 
A recent study by Melchiorre et al (202) found that at 1 year post-partum, asymptomatic 
left ventricular moderate-severe dysfunction/hypertrophy was significantly higher in 
women who had experienced pre-term pre-eclampsia in comparison with term pre-
eclampsia or matched controls. This study also found that the risk of developing essential 
hypertension within 2 years post-partum was significantly higher in pre-term pre-eclamptic 
women and women with persistent LV moderate /severe abnormal function (202). In a 
large multi-centre echocardiographic study by Scantlebury et al (205), a history of 
hypertensive pregnancy was associated with left ventricular hypertrophy after adjusting for 
traditional risk factors.  
 
In a study focusing on whether women with persistent cardiac dysfunction after pre-
eclampsia were at risk of recurrent pre-eclampsia (206), Valensise et al found that women 
with recurrent pre-eclampsia compared with controls and non-recurrent pre-eclampsia had 
lower stroke volume, lower cardiac output and higher total vascular resistance. In both the 
recurrent and non-recurrent pre-eclampsia groups left ventricular mass index was higher 
than in the control group. There was also progressive impairment of diastolic function in 
women with a history of pre-eclampsia, and those with recurrent pre-eclampsia were 
affected worse than those with non-recurrent pre-eclampsia (206). Echocardiography could 
therefore be a useful tool in evaluating cardiovascular risk after pre-eclampsia, and merits 
further consideration.   
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 The Electrocardiogram 1.5.2
 
American Heart Association Electrocardiography and Arrhythmia Committee made 
recommendations in 2009 for the interpretation of the electrocardiogram including the ST 
segment, T and U waves and the QT interval (207). The QT interval is defined as the 
interval from the onset of the QRS complex to the end of the T wave and should be 
measured in the lead showing the longest QT interval (207) which tends to be V2 or V3 
(see Figure 1.7). The QT interval varies depending on heart rate, with a shorter QT interval 
with a faster heart rate and a longer QT interval with a slower heart rate (208). Several 
different methods of “correcting” the QT interval have been devised and they work out the 
expected value, the corrected QT (QTc) interval, if the heart rate was 60 beats per minute. 
The most popular methods of QT correction are Bazett’s, Fridericia, Framingham and 
Hodges (208). Both Bazett and Fridericia formulas are nonlinear and Framingham and 
Hodges are linear functions. While Bazett’s correction is the most commonly used method, 
the results of a study by Luo et al (208) revealed that it did not perform as well as other 
methods. For example, the study analysed 10,303 ECGs and found that 30% of apparently 
normal ECGs would be reported by Bazett’s as having abnormal QT intervals for a 440ms 
threshold, and 10% if a 460ms threshold was used. The other formulae would have been 
incorrect in <2% of the ECGs (208). The study concluded that Hodges QTc formula 
performed the best. 
 
 
 
Figure 1.7 Method for measurement of the QT interval. A tangent is drawn to the steepest 
slope of the last limb of the T wave. The end of the T wave is the intersection of the tangent 
with the baseline.  From Postema et al (209) with permission. 
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Minnesota code classifications are widely used in clinical studies to describe features of 
the electrocardiogram. These codes provide a standardised, objective method of ECG 
analysis and have proven to be extremely useful (210).  
 
Little is known about the ECG during pregnancy and the post-partum period. The best 
method of QT interval correction has not been ascertained and accurate measurement is 
particularly important concerning the increased risk of arrhythmia and death associated 
with a prolonged QT interval. Also there are limited studies investigating the ECG both 
during pregnancy and the post-partum period. Pre-eclampsia may be a risk factor not only 
for future cardiovascular disease, but also for arrhythmia (200).   
 
Normal adaptations to pregnancy include increase in heart rate, which reaches a peak in the 
third trimester. Gestational age impacts on the QRS complex and T waves by promoting a 
leftward axis shift as pregnancy progresses. In the majority of women there is a leftward 
QRS axis shift during the second and third trimesters which changes to rightward before 
delivery (211). There is evidence that hypertensive disorders of pregnancy are associated 
with changes in P-wave morphology and QT interval. Isezuo and Ekele showed that 
eclampsia was associated with prolonged ventricular repolarisation (212). Raffaelli et al 
more recently published a study looking at 76 women affected by pre-eclampsia and a 
control group of pregnant women without cardiovascular disease or gestational 
hypertension (213). All participants had a 12-lead ECG performed prior to delivery. Pre-
eclamptic women had a lower heart rate, a longer P-wave duration, a longer mean 
corrected QT interval (QTc) and a higher QT dispersion. QT dispersion is defined as the 
difference between the maximum and minimum QT interval measured in each ECG lead. 
Prolongation of QT dispersion is correlated with an increased incidence of ventricular 
arrhythmias and is a known predictor of all-cause mortality (214). It has also been found 
that non-specific changes in the ECG can predict morbidity and mortality due to 
cardiovascular disease in the future and it is used in risk estimation and screening in the 
hypertensive population (215;216). 
 
In a controlled cross-sectional study the ECGs of 64 women with pre-eclampsia were 
compared with 32 healthy women with uncomplicated pregnancies in the third trimester. 
QT parameters, the interval between the peak and end of the T wave  (Tp-e) , and Tp-e/QT 
ratio were compared and Tp-e interval and Tp-e/QT ratio were significantly higher in pre-
eclampsia (200).  
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In normal pregnancy the heart rate increases and peaks during the third trimester (211). 
There is generally reported to be a leftward shift in the QRS-axis as pregnancy progresses 
and in particular during the 2
nd
 and 3rd trimesters. Before delivery there is a rightward axis 
shift in most women. However some previous studies have shown conflicting results. The 
QTc interval was thought not to be significantly altered in normal pregnancy (211), 
however two recent studies have found significantly different QTc intervals in pregnant 
women vs non-pregnant women, with a longer QTc interval noted in pregnancy (although 
still within the normal range).     
 
In a large retrospective cohort study by Ray et al, women with maternal placental 
syndromes including pre-eclampsia were found to be at a higher risk of premature heart 
failure and dysrhythmias, starting one year after delivery (217). Monitoring of these 
women to facilitate early intervention and avoid serious consequences is important to 
consider.   
 
 Renal consequences of pre-eclampsia 1.6
 
In normal pregnancy the kidneys can increase in size by up to 30%, with 1-1.5cm increase 
in length (218).  Renal function itself changes in response to hormonal variations during 
the menstrual cycle and the mean arterial pressure and systemic vascular resistance are 
lower in the mid-luteal phase than the mid-follicular phase. This results in an increase in 
cardiac output, renal plasma flow (RPF) and glomerular filtration rate (GFR) (218). These 
changes continue in pregnancy and at term GFR has been found to be 40% higher in 
comparison with non-pregnant women, but returns to normal 1 month after delivery (219).   
 
Pre-eclampsia, HELLP syndrome, eclampsia and acute fatty liver of pregnancy (AFLP) 
have considerable overlap in presentation and may all share a similar pathophysiology.  
Pre-eclampsia, eclampsia or HELLP syndrome can develop from mild to severe 
microangiopathy affecting the placenta, liver, kidneys and brain. A decline in renal 
function develops and in the developed world, severe pre-eclampsia accounts for ~40% of 
pregnancy-related acute kidney injury (218).   
 
Microalbuminuria is itself a risk factor for cardiovascular events (220). An association 
between end stage renal disease (ESRD) after pre-eclampsia has also been shown in a 
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Norwegian study of 570,433 women (221). The study population consisted of women who 
had a first singleton birth between 1967 and 1991. Pre-eclampsia during the first pregnancy 
was associated with a relative risk of ESRD of 4.7 (95% confidence interval [CI], 3.6 to 
6.1). In women with two or more pregnancies, pre-eclampsia during the first pregnancy 
was associated with a relative risk of ESRD of 3.2 (95% CI, 2.2 to 4.9), during the second 
pregnancy with a relative risk of 6.7 (95% CI, 4.3 to 10.6), and during both pregnancies 
with a relative risk of 6.4 (95% CI, 3.0 to 13.5). Among women who had been pregnant 
three or more times, pre-eclampsia during two or three pregnancies was associated with a 
relative risk of 15.5 (221). It is clear, from this and other studies, that ESRD has 
associations with pre-eclampsia (221-223). However the precise mechanism of this 
increased risk of renal disease is not well understood (224). 
 
A further complication to consider regarding the renal system is renal conditions which 
may worsen during pregnancy and which may mimic pre-eclampsia. For example, pre-
eclampsia and chronic kidney disease may both present during pregnancy with worsening 
hypertension and proteinuria (224). Women with lupus nephritis during pregnancy may 
also present with proteinuria, hypertension and increased creatinine (224). In order to 
better differentiate between these renal diseases and pre-eclampsia, the role of biomarkers 
as a potential tool has been studied. In one such study (225) maternal serum levels of sFlt-1 
were much higher and PlGF levels much lower in women with pre-eclampsia in 
comparison with chronic kidney disease patients or women with normotensive 
pregnancies. In a small study investigating systemic lupus erythematosus (SLE) and pre-
eclampsia, women with both pre-eclampsia and SLE had a significantly higher serum sFlt1 
concentration than women with SLE but no pre-eclampsia (226). 
 
 Biomarkers in pre-eclampsia 1.7
 
There are a number of circulating biomarkers which are associated with pre-eclampsia and 
this section further describes them and their role in cardiovascular disease.  
 
 Markers of angiogenesis 1.7.1
 
Markers described in this section are involved in angiogenesis, vasculogenesis and play a 
crucial role in normal placental development. Two pro-angiogenic growth factors, vascular 
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endothelial growth factor (VEGF) and placental growth factor (PlGF) are important in 
trophoblast proliferation and the normal process of implantation (227). 
 
In normal pregnancy levels of pro-angiogenic placental growth factor (PlGF) peaks at 
around 30 weeks (228), decreasing towards term (229). In pre-eclampsia levels of 
circulating PlGF are reduced, particularly in cases of early-onset pre-eclampsia (230;231). 
In pre-eclampsia, levels of VEGF are lower than in normal pregnancy and VEGF 
antagonists which are used in patients with cancer can produce glomerular endothelial 
damage, hypertension and reversible posterior leucoencephalopathy, which are similar to 
findings in pre-eclampsia and eclampsia (232;233).     
 
A splice variant of the vascular endothelial growth factor receptor Flt-1 (sFlt-1) is a 
circulating anti-angiogenic protein. It inhibits the pro-angiogenic VEGF and PlGF (19). 
sFlt-1 is made in the placenta in the syncytiotrophoblast layer before being secreted into 
the maternal circulation (19). In normal pregnancy maternal concentrations of the anti-
angiogenic protein soluble fms-like tyrosine kinase-1 (sFlt-1) do not change throughout the 
first two trimesters, increasing throughout the third trimester (229). Even though the 
placenta is the main source of sFlt-1, the major site of its production is thought to be 
syncytial knots which are degenerating syncytiotrophoblast tissue (234) and this is 
increased in pre-eclampsia.  
 
In pre-eclampsia there is an increased level of sFlt-1 in the second and third trimesters 
(228). The levels increase before onset of clinical symptoms (229;235). As sFlt-1 levels 
increase, PlGF and VEGF decrease. In mouse models of pre-eclampsia, the phenotype can 
be improved by antagonising sFlt-1 (236).  
 
Soluble endoglin (sEng) is also anti-angiogenic by disrupting transforming growth factor-β 
(TGFβ) signalling in vasculature (237). Endoglin is a glycoprotein which is expressed on 
endothelial cells and placental syncytiotrophoblasts (228). It may also play a role in the 
pathophysiology of pre-eclampsia (19). As levels of sFlt-1 and sEng increase and PlGF 
decreases in women with pre-eclampsia, they correlate with disease severity and with 
gestational age (229;238-240). When sFlt-1 and sEng are administered to pregnant rats, a 
pre-eclampsia-like phenotype is produced with glomerular endotheliosis, proteinuria, 
hypertension and fetal growth restriction and thrombocytopenia (241).  
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The potential for angiogenic markers to be used in the prediction of pre-eclampsia is an 
ongoing area of research. For example in a prospective multicentre observational study 
Zeisler et al sought to derive and validate a cut-off value for the sFlt-1/PlGF ratio for 
which levels at or below the cut-off would predict the absence of pre-eclampsia one week 
after the visit, and levels higher than the cut-off would predict pre-eclampsia developing 
within 4 weeks (242). A cut-off value of 38 was found to have important predictive value 
in separate development and validation cohorts. The utility of such a test, in accurately 
predicting the absence of disease early on, would assist greatly with management decisions 
in pregnant women (e.g. home vs hospital in women with possible pre-eclampsia).   
 
With regard to the role of markers of angiogenesis in cardiovascular disease there is 
considerable evidence in the literature. In patients with acute coronary syndrome, PlGF has 
been found to be upregulated in atherosclerotic lesions (243). It is thought to have an 
inflammatory role in atherosclerotic plaque instability. Increased circulating levels of PlGF 
may be representative of a greater risk for cardiovascular events and mortality in patients 
with heart disease. PlGF levels have also been found to positively correlate with C-reactive 
protein (CRP) and it is hypothesised that the source of increased PlGF is inflamed 
endothelium (243). VEGF and sFlt-1 have also been associated with cardiovascular disease 
(244;245). VEGF is known to be increased in patients with cardiovascular risk factors such 
as hypertension, atherosclerosis and hyperlipidaemia (244;246;247). sFlt-1 correlates with 
severity of cardiovascular disease (248) and is independent of other risk factors. sEng has 
been implicated in hypercholesterolaemia and endothelial dysfunction (249). 
 
In women with a history of hypertensive disorder of pregnancy, studies of angiogenic 
markers have been evaluated in two recent systematic review and meta-analyses (179;250). 
Visser et al (250) reported higher median VEGF levels in women with a history of 
hypertensive pregnancy, however, only two studies had reported VEGF levels (251;252). 
One of these studies reported a higher mean sFlt-1 level (252) and the other, a higher 
median sFlt-1 (251). PlGF and sEng were not evaluated in this paper. The other meta-
analysis by Grand’Maison et al (179) also evaluated VEGF and sFlt-1. It found that on 
pooled analysis, there was no significant difference in levels of VEGF between women 
with a history of hypertensive disorder of pregnancy and those with normotensive 
pregnancies. Mean levels of sFlt-1 were higher in women with a history of hypertensive 
disorder of pregnancy.  
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 Markers of inflammation 1.7.2
 
 Cytokines 1.7.2.1
 
Some of the more commonly researched cytokines with regard to pre-eclampsia are 
interleukin-6 (IL-6), interleukin-10 (IL-10) and tumour necrosis factor-alpha (TNF-α). IL-
10 is an anti-inflammatory product of the T-helper 2 (Th2) cells (253), IL-6 is produced by 
the placenta, vascular endothelial cells and leucocytes and is a multifunctional cytokine 
(254) and TNF-α is mainly activated by macrophages and monocytes and stimulates the 
release of other cytokines (254).  
 
The maternal systemic inflammatory response is considered to be enhanced in pre-
eclampsia (254). Plasma levels of TNF-α and IL-6 have been found to be raised in pre-
eclampsia (254-257).  IL-10 levels have also been found to be higher in pre-eclampsia 
(258).  
 
IL-6 has been implicated in cardiovascular diseases including unstable angina and heart 
failure (259-263). IL-10 has also been implicated in cardiovascular disease with several 
studies showing contradictory findings (264-268). In addition, studies of TNF-α have 
reported conflicting roles such as beneficial effects in myocarditis, pressure overload and 
cardioprotection against ischaemia but possible adverse effects from atherosclerosis and 
reperfusion injury to heart failure and hypertrophy (269). 
   
In women with a history of hypertensive pregnancy, studies have revealed both higher and 
lower TNF-α levels (250;256;270;271) and a study by Girouard et al (270) reported higher 
IL-6 levels in women with a history of hypertensive disorders of pregnancy. Freeman et al 
reported higher IL-6/IL-10 ratio in women with a history of pre-eclampsia (256).    
 
  Adhesion Molecules 1.7.2.2
 
Cell adhesion molecules promote attachment of leucocytes to the endothelium, to sites of 
inflammation and facilitate their movement in arterial walls (272). An increase in soluble 
vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 
(ICAM-1) is thought to be indicative of endothelial cell activation (273). An increase in 
soluble P-selectin in thought to represent platelet activation and an increase in soluble E-
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selectin is thought to be a marker of endothelial cell activation or dysfunction. Differences 
in soluble L-selectin are thought to represent leucocyte activation (273). In pre-eclampsia 
plasma levels of E-selectin, P-selectin, ICAM-1 and VCAM-1 have been found to be 
increased, and levels of L-selectin decreased (273;274).  
 
In cardiovascular disease there is evidence that soluble cell adhesion molecules may play a 
role (272). For example, using “Atherosclerosis Risk In Communities (ARIC)” Study 
participants, Hwang  et al (275) found higher ICAM-1 and E-selectin levels in subjects 
with coronary heart disease and coronary artery atherosclerosis in comparison with control 
subjects however levels of VCAM-1 were not significantly different (275). Luc et al (276) 
investigated ICAM-1 and VCAM-1 in relation to myocardial infarction and coronary death 
or angina in a group of healthy men aged 50-59 years. ICAM-1 was found to be predictive 
of myocardial infarction or death and angina, however VCAM-1 was not associated with 
the occurrence of a first cardiovascular event (276). Nevertheless, a recent study by 
Kunutsor et al (272) has revealed some unexpected findings regarding VCAM-1 in 
comparison with previous literature. The study consisted of a large cohort of 2,638 
participants without any cardiovascular disease at baseline, from the “Prevention of Renal 
and Vascular End-stage Disease (PREVEND)” study. An inverse association between 
VCAM-1 and cardiovascular disease was found after adjusting for cardiovascular risk 
factors.  
 
In assessing adhesion molecules in women with a history of hypertensive pregnancy 
disorders, the meta-analysis by Visser et al (250) revealed that five studies found no 
difference in mean ICAM  levels and three studies showed no difference in mean VCAM 
levels between women with a history of hypertensive disorders of pregnancy and women 
with a normal pregnancy.  One study described higher median ICAM and VCAM levels 
(277). Another meta-analysis by Grand’Maison et al (179) revealed that on pooled 
analysis, neither ICAM nor VCAM levels were different between women with a history of 
pre-eclampsia and those with normotensive pregnancies.   
 
  CRP 1.7.2.3
 
C-reactive protein (CRP) is an acute phase protein produced in the liver in response to 
inflammatory stimuli (278). CRP has also been found in amniotic fluid (279). In a recent 
study by Parchim et al (280) the placenta was identified as a site of production of CRP. In 
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normal pregnancy an increased CRP level has been noted (281), however, in pre-eclampsia 
CRP levels are even higher. Previous studies have proposed that pre-eclampsia is related to 
CRP, and a meta-analysis (278) revealed a significant relationship however body mass 
index was found to be an important modifier.  
 
CRP has been linked with cardiovascular disease and has been implicated in endothelial 
damage by increasing foam cell formation, leading to atherosclerosis (280;282). It has been 
associated with renal dysfunction and CRP also correlates with kidney function decline in 
patients with chronic kidney disease (280). This is thought to be related to increased 
oxidative stress from the deposition of CRP in the glomeruli.   
 
In a study by Hubel et al (283), significantly elevated CRP levels have been found in 
women 30 years after pregnancy complicated by eclampsia after adjustment for age, 
smoking, body mass index and hormone replacement.  
 
 Renin-Angiotensin Aldosterone system 1.7.3
 
The renin-angiotensin-aldosterone system (RAAS) is involved in the regulation of renal 
cardiac and vascular physiology. It is implicated in many diseases including renal disease, 
hypertension and heart failure, and activation of RAAS can result in vasoconstriction, 
fibrosis, and vascular and cardiac hypertrophy (284).  
 
Renin is synthesized by the juxtaglomerular cells of the kidney and is secreted in response 
to lower than normal renal perfusion or low sodium concentration. Renin then cleaves 
angiotensinogen, which is made in the liver, to angiotensin I. This in turn is transformed 
into angiotensin II by angiotensin-converting enzyme (ACE), in the lung (284). 
Angiotensin II is a powerful vasoconstrictor and influences the release of aldosterone from 
the renal cortex. Aldosterone exerts its effect on blood volume and blood pressure by 
adjusting reabsorption of sodium and excretion of potassium in the kidney.  
 
In normal pregnancy generalised vasodilation may result in activation of the RAAS to 
enable sodium and water retention (285). In normotensive pregnancies this leads to 
increased levels of renin, angiotensin II and aldosterone (286). However, during pregnancy 
there are components of the RAAS which can be synthesized by the placenta (286). Higher 
than expected levels of aldosterone are found (286) and placental size and trophoblast 
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growth have been found to be positively correlated with the presence of aldosterone (287). 
Features of intrauterine growth restriction (IUGR) are present in animal models with 
reduced aldosterone secretion (288). Another interesting feature of the RAAS in normal 
pregnancy is that women do not appear to respond to the vasoconstrictor effect of 
angiotensin II and blood pressure remains low despite the observed increase in angiotensin 
II (286).  
 
One possibility for the increased expression of aldosterone in pregnancy is angiotensin II-
independent production of aldosterone (287). A recent study by Gennari-Moser et al 
revealed VEGF to be more powerful than angiotensin II in stimulating adrenal aldosterone 
(289). Aldosterone levels are lower in pre-eclamptic pregnancies than normotensive 
pregnancies (286). In a rat model, sFlt-1 (the VEGF inhibitor) resulted in a fall aldosterone 
concentration, and might explain the low levels of aldosterone in pre-eclampsia (286;289).  
 
Also of great relevance is the fact that a higher frequency of women with pre-eclampsia 
have been found to have loss-of-function mutations in the gene for aldosterone synthase 
(CYP11B2) (290). A lower frequency of gain-of-function mutations in this gene have been 
found in pre-eclampsia (291). Studies in women with a history of hypertensive disorders of 
pregnancy have revealed that these women have an increased sensitivity to angiotensin II 
(292) at ≥8 months post-partum, and an experimental rat model has revealed an increase in 
responsiveness to angiotensin II following pre-eclampsia (293). The animal model in 
particular supports the argument that pre-eclampsia itself may influence cardiovascular 
disease risk. 
 
Further research into the complexities of the RAAS in pregnancy, pre-eclampsia and its 
potential role in future cardiovascular risk after hypertensive disorders of pregnancy is 
warranted.   
 
 Uric acid 1.7.4
 
Hyperuricaemia may directly contribute to vascular damage and hypertension (294;295) 
and is therefore important in cardiovascular risk.  
 
In pre-eclampsia the elevation in uric acid tends to precede the onset of proteinuria and fall 
in GFR (26;296). The degree of uric acid elevation not only correlates with maternal 
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morbidity (297) and severity of proteinuria (298) and renal changes (299), but it has also 
been found to correlate with fetal mortality (300). The mechanism of uric acid elevation in 
pre-eclampsia is unresolved but may be due to decreased renal clearance or tissue 
injury/ischaemia (26). 
 
In women with hypertensive disorders of pregnancy, these higher uric acid concentrations 
have been found to persist even decades after the pregnancy. In a large study by 
Weissgerber et al of 2472 women from 1282 sibships (301) women who had a history of 
hypertensive disorders of pregnancy were more likely to have uric acid concentrations 
>5.5mg/dL than women with normotensive pregnancies. These differences persisted after 
correcting for traditional cardiovascular risk factors and co-morbidities. Family-based 
subgroup analysis which compared women with hypertensive pregnancies vs their parous 
normotensive sisters also revealed a significant difference in uric acid concentrations 
between the two groups. Therefore, uric acid concentrations were found to be higher 
decades after pregnancy, however familial pre-disposition did not explain these findings. 
Several smaller studies have suggested uric acid concentrations are increased or not 
different in women with a history of pre-eclampsia or other hypertensive disorders of 
pregnancy in comparison with normotensive pregnancies (137;143;302). These conflicting 
results merit further investigation, especially considering the role hyperuricaemia may play 
in cardiovascular disease. 
 
 Homocysteine 1.7.5
 
Homocysteine has primary atherogenic and pro-thrombotic properties and has been linked 
to coronary heart disease previously (93;303). It is a metabolite of the amino acid 
methionine and homocysteine levels are influenced by several different mechanisms 
ranging from intake of folate and cobalamin to genetic polymorphisms in the MTHFR gene 
(304) which are discussed more fully below. Homocysteine is associated with arterial wall 
inflammation and myocardial infarction and has been found to have an effect on 
cardiovascular risk above that of inflammatory markers and traditional cardiovascular risk 
factors (305). Vitamin B12, folate and vitamin B6 are necessary for homocysteine 
metabolism (306).  
 
The human MTHFR gene on chromosome 1p36.3 encodes methylenetetrahydrofolate 
reductase (MTHFR). This enzyme catalyses the reduction of 5, 10-
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methylenetetrahydrofolate to 5-methyltetrahydrofolate (307). Folate and total 
homocysteine (tHcy) levels can be influenced by the presence of C677T and A1298C 
mutations in the MTHFR gene (307). Women with these mutations have higher levels of 
plasma homocysteine in comparison with women who have a normal genotype. For 
example, the C677T substitution causes abnormalities of folate binding and reduced 
MTHFR enzyme activity (307). There is an increased folic acid requirement in order to 
sustain usual homocysteine remethylation to methionine. Overall the MTHFR C677T 
mutation is associated with a slightly increased plasma tHcy concentration and a lower 
folate level in red blood cells, serum and plasma (307).      
 
Levels of homocysteine have been found to be elevated in women with a history of 
hypertensive disorders of pregnancy (250;304). More specifically, pre-eclampsia has been 
associated with hyperhomocysteinaemia (308;309). It is possible that the pathophysiology 
of pre-eclampsia may involve the MTHFR C677T mutation. Previous studies have been 
contradictory and results from a meta-analysis by Wu et al (307) revealed that MTHFR 
C677T was associated with risk of pre-eclampsia, especially in Caucasians and Asians, but 
MTHFR A1298C was not (307).    
 
A systematic review and meta-analysis by Visser et al (250) found that homocysteine 
levels were higher in women with disorders of hypertensive pregnancies in comparison 
with women with normotensive pregnancy. A study by Vollset et al investigated the 
relationship between pre-eclampsia and plasma homocysteine levels (310). The adjusted 
risk for pre-eclampsia was 32% higher in women with plasma homocysteine levels in the 
upper quartile in comparison with women with plasma homocysteine levels in the lower 
quartile. However, a later study by Timmermans et al revealed no effect of folic acid on the 
occurrence of gestational hypertension or pre-eclampsia (311). When homocysteine was 
included as part of an early prediction model in a study by Masoura et al (306) it was found 
that in the first trimester of pregnancy, elevated levels of homocysteine combined with 
higher values of other biomarkers could predict hypertensive disorders of pregnancy at a 
later gestation. 
 
A study by Wang et al (312) found that folic acid supplementation and higher dietary 
folate intake during pregnancy reduced the risk of pre-eclampsia and that the risk reduction 
may vary depending on severity of pre-eclampsia. A prospective cohort study by Wen et al 
(313) assessed the effect of folic acid supplementation in pregnancy on the risk of pre-
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eclampsia and found that the rate of pre-eclampsia was lower in women on folic acid 
supplementation, and the difference was statistically significant in women with a high risk 
of pre-eclampsia. High risk pregnancy was classified as previous history of pre-eclampsia, 
chronic hypertension, diabetes, multiple pregnancy and body mass index ≥35kg/m2. A 
Cochrane review of homocysteine-lowering interventions for preventing cardiovascular 
events (314) did not find any differences between supplements of vitamins B6, B9 or B12 
(given in combination or alone) and placebo in myocardial infarction, death from any 
cause or adverse events.  
 
Further studies are required to clarify the part homocysteine plays in the pathophysiology 
of pre-eclampsia and the possible role of folic acid in future management of pre-eclampsia. 
 
 Lipids 1.7.6
 
High serum lipid levels are known to contribute to atherosclerosis (315;316). In particular 
low-density lipoprotein (LDL) cholesterol has been implicated (316). High-density 
lipoprotein (HDL) cholesterol is thought to be inversely related to cardiovascular risk 
(317). This decrease in risk is thought to be due to the role of HDL in removing excess 
cholesterol from the peripheral tissues and transporting it to the liver to be excreted in bile 
(318). HDL cholesterol has other cardio-protective properties such as the inhibition of 
inflammation and it has anti-thrombotic properties and can promote endothelial repair 
(318). 
 
In normal pregnancy cholesterol is necessary for the synthesis of placental steroid. Levels 
of total cholesterol, HDL cholesterol, triglycerides and LDL cholesterol increase (319). 
During the first two trimesters maternal fat stores accumulate as a source of calories for 
later in pregnancy and the post-partum period (319;320). Anabolic metabolism and 
hyperphagia aid the increase in maternal adipose tissue stores (321). In the third trimester, 
maternal metabolism becomes catabolic, and by late pregnancy there is peripheral adipose 
tissue lipolysis and increasing maternal insulin resistance (321). Maternal free fatty acids 
and lipoprotein triglyceride content are increased (321). 
 
In pre-eclampsia there is increased maternal lipid oxidation (321) and this process may be 
implicated in the placental vascular dysfunction and endothelial dysfunction which 
characterises the condition. In the placenta lipid-filled foam cells have been found to 
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accumulate in the spiral arteries as part of a process of acute atherosis (322). This process 
is not pathognomonic of pre-eclampsia and can be seen in other conditions such as 
diabetes, thrombotic conditions and intrauterine growth restriction (322).  
 
A recent meta-analysis of studies investigating the relationship between pre-eclampsia and 
maternal serum triglycerides revealed higher triglyceride levels in women with a history of 
pre-eclampsia in comparison with normotensive women (319;323). In a systematic review 
and meta-analysis examining pregnancy levels of total cholesterol, LDL cholesterol, high-
density lipoprotein (HDL) cholesterol, non-HDL cholesterol (e.g. very low density 
lipoproteins (VLDL)), and triglycerides and subsequent pre-eclampsia risk, maternal serum 
total cholesterol, non-HDL cholesterol and triglycerides were higher during all trimesters 
in women who developed pre-eclampsia (319). There were also increased levels of LDL 
cholesterol in all trimesters in women who developed pre-eclampsia in comparison with 
normotensive controls but the results were of borderline significance (319). HDL 
cholesterol was lower during the third trimester in women with pre-eclampsia in 
comparison with controls (319). Increased triglyceride in cells is associated with reduced 
prostacyclin release, and raised triglycerides have also been linked to alterations in LDL 
particle size, with a shift to smaller more atherogenic subtypes (318). 
 
New insights into the potential role of obesity in the risk of pre-eclampsia have recently 
been described by Huda et al (324). This group hypothesised that adipocyte release of pro-
inflammatory adipokines is exaggerated under basal and stressed conditions in pre-
eclampsia in comparison with controls. They also hypothesized that adipose tissue 
macrophage infiltration is increased in women with pre-eclampsia, and that this response 
might be more obvious in a particular type of adipose tissue e.g. visceral in comparison 
with subcutaneous. Macrophages are important mediators of inflammation in adipose 
tissue and promote insulin resistance in white adipose tissue (324). sFlt-1 has been shown 
to be secreted by adipocytes in the non-pregnant state, and sFlt-1 production by adipocytes 
in pre-eclampsia had not previously been investigated (324). They found that visceral 
adipose tissue in pre-eclampsia had higher activated macrophage content and higher 
expression of TNFα than controls. They also found that adipocytes from visceral adipose 
tissue in pre-eclampsia was more responsive to lipopolysaccharide stimulation in that they 
released higher levels of IL-6 and TNFα (324). In pre-eclamptic cases there was no 
significant evidence of sFlt-1 release from adipocytes, which suggests adipocytes do not 
act as an additional source of sFlt-1 in pre-eclampsia (324).  
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The menopause transition brings with it changes in the lipoprotein subclass profile, but the 
postmenopausal increased risk of cardiovascular disease may also be caused by more 
vulnerable vessels due to adipose tissue re-distribution, decreased oestrogen and aging 
(325). Oestrogen has LDL-lowering effects, however this does not fully explain the pattern 
of cardiovascular risk in women (316). In the Framingham heart study, women with 
incident coronary heart disease had increased triglyceride levels and decreased HDL levels 
(326). When elevated triglyceride levels occur in conjunction with increased serum LDL, 
the risk of cardiovascular disease is increased above that of raised LDL without 
hypertriglyceridemia (316;327). Other actions of hypertriglyceridemia are an increase in 
glucose intolerance and insulin resistance, decreased HDL cholesterol, prothrombotic 
states and hypertension. These actions have a compound effect on cardiovascular risk 
(327).     
 
Studies of lipids in women with a remote history of pre-eclampsia have also provided some 
important insights. An Icelandic study of postmenopausal women after eclampsia found 
that in comparison with women who experienced normotensive pregnancies, a greater 
number were on hypertensive medication, and they had increased levels of apolipoprotein 
B, smaller-sized LDL particles and increased total cholesterol:HDL cholesterol ratio (328). 
Women who had eclampsia and had recurrent hypertension in pregnancy also had much 
smaller LDL sizes in comparison with women who had non-recurrence (328). A meta-
analysis has suggested that non-HDL cholesterol levels such as VLDL and apolipoprotein 
B-containing lipoproteins may be even better than LDL cholesterol levels at predicting 
cardiovascular disease (329). In a more recent large prospective cohort study (330), women 
who were 18 years postpartum with a past diagnosis of pre-eclampsia or gestational 
hypertension had higher triglycerides and lower HDL cholesterol levels than women with 
normotensive pregnancies.  
 
Statins have been avoided in pregnancy in the past, due to concerns regarding teratogenesis 
(321). Nevertheless, their actions on lipids and endothelial function and their anti-
inflammatory and anti-oxidant properties have made them an attractive prospect in the 
potential treatment of pre-eclampsia (321). Studies such as the “Statins to Ameliorate early 
onset Pre-eclampsia (StAmP)” are further evaluating their role (331;332).  
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 Proteomics 1.7.7
 
 
 
Figure 1.8 Capillary electrophoresis (CE) coupled to mass spectrometry (MS). Proteins and 
peptides are separated by capillary electrophoresis, ionised by electrospray ionization (ESI) 
and detected in a time-of-flight mass spectrometer (TOF-MS). Figure reproduced with 
permission from Raedler et al (333).    
 
Proteomics is the study of the proteome, which reflects the protein content of the genome 
(334). The proteome refers to the whole protein content of the cell, tissue, organism or 
different bodily fluids. Proteome profiles change depending on variations in gene 
expression, alternative splicing, and post-translational modifications (335).  
 
It is a rapidly advancing field, and with the development of high-throughput techniques it 
is hoped that this might facilitate the discovery of even more biomarkers implicated in the 
pathophysiology of disease and with the potential for therapeutic targeting. Specific protein 
biomarker panels for several different diseases have already been identified. 
 
Proteomic analysis can be performed on any type of human tissue, bodily fluid or cultured 
cells. Urinary proteins have been found to remain stable for several years without 
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significant alterations in the proteome, even at temperatures as low as -20
o
C (336), which 
is a desirable quality in research. Urine is available in large volumes and collection is non-
invasive. Also the simplicity of sampling make it convenient for collection in the research 
and clinic setting.  
 
There are several methods of proteomic analysis available including liquid 
chromatography coupled to mass spectrometry (LC-MS), surface-enhanced laser 
desorption/ionization coupled to mass spectrometry (SELDI-MS) and capillary 
electrophoresis coupled to mass spectrometry (CE-MS). Each has advantages and 
disadvantages. LC-MS is multidimensional and high sensitivity but is time-consuming 
with a restricted mass range (336). SELDI-MS is easy to use and requires a low sample 
volume but is restricted to selected proteins, has low information content and lack of 
comparability (336). CE-MS is high-sensitivity and fast, with low sample volumes and is 
low cost but is not suited to larger proteins (>20kD) (336).  
 
Capillary electrophoresis (CE) which was used for the proteomic analyses performed in 
this thesis separates proteins based on their migration through a buffer-filled capillary. 
Separated proteins are then delivered from the end of the capillary by nano-ion spray into a 
mass-spectrometer (MS) (Figure 1.8).  
 
A study by Buhimschi et al (337) sought to identify women with pre-eclampsia who would 
benefit from delivery based on urinary polypeptide profile of samples collected at 
diagnosis of the condition. This urinary polypeptide profile was able to distinguish 
between pre-eclampsia and other disorders causing proteinuria and other hypertensive 
disorders of pregnancy.  
 
Chen et al (338) found decreased levels of SERPINA 1 in the urine of women with 
gestational hypertension and increased levels in pre-eclampsia. This biomarker may 
therefore be able to specify between some of the hypertensive conditions of pregnancy. In 
another study by Lee et al (339) four protein peaks were able to determine which women 
had severe pre-eclampsia, mild pre-eclampsia or were controls. In a study using urine 
samples from various time-points during pregnancy, Carty et al (340) were able to 
discriminate between women who proceeded to develop pre-eclampsia and matched 
controls. The study described a model of 50 urinary peptides which was able to diagnose 
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women with pre-eclampsia at 28 weeks gestation. However, the predictive value of this 
panel of peptides could not be verified in an independent cohort at 20 weeks gestation.  
 
Proteomic studies require large numbers of samples in order to produce reliable results 
(341). Of utmost importance is the thorough phenotyping of subjects, to gain the maximum 
amount of information in gestational hypertensive disorders and the subtle differences 
between them.  
 
 Genetic factors 1.7.8
 
Some epidemiological studies have shown a strong familial predisposition to pre-
eclampsia. For example, women with first degree relatives who experienced pre-eclampsia  
have been reported as having five times the risk of developing the condition themselves, 
and women with second-degree relatives affected have twice the risk (5;342). However, 
evidence for the placental origin of early-onset pre-eclampsia comes from the fact that 
parous monozygotic twins have been found to be discordant for the development of pre-
eclampsia (343). An increase in risk of pre-eclampsia has also been found in women who 
have pregnancies with men who have a history of being involved with pregnancies 
complicated by pre-eclampsia in the past (5;344;345).  
 
For most of the population, pre-eclampsia represents a complex genetic disorder occurring 
as the result of many common variants at different loci. Individually they have small effect, 
but combined they contribute to an individual’s susceptibility to disease. Environmental 
contributions such as age and weight my also contribute to whether these variants of low 
penetrance may result in the disease manifesting itself (346).   
 
Candidate gene studies focus largely on maternal genotype. The choice of gene is made 
based on prior knowledge of the pathophysiology of pre-eclampsia and if the gene lies 
within a region identified by linkage studies then this choice is further strengthened (346). 
 
There have been a number of studies such as genome-wide scans performed to date to try 
to discover which genes might be involved in pre-eclampsia (347-354). Results have been 
limited however two susceptibility genes have been identified (ACVR2A and STOX1) 
(355;356). The ACVR2A gene codes for an Activin receptor type II which can bind Activin 
ligands. Activin A has a role in the placenta on both the maternal and fetal sides (356). The 
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STOX1 gene codes for a protein containing a winged helix domain and it acts as a 
transcription factor (356).  
 
The Genetics of Pre-eclampsia (GOPEC) consortium studied 28 SNPs (in 7 genes which 
had previously been reported as conferring pre-eclampsia susceptibility) in 657 women and 
their families. None of the SNPs achieved statistical significance (357). This study re-
iterated the importance of conducting studies of adequate size to provide precise genetic 
risks and to avoid over-reporting of false positive results (357). 
 
In 2014 a meta-analysis study of maternal genotype and severe pre-eclampsia in 57 studies 
evaluating 50 genotypes (358) showed that there was a higher risk of severe pre-eclampsia 
with coagulation Factor V gene (proaccelerin, labile factor) (F5) polymorphism rs6025, 
coagulation factor II (thrombin) gene (F2) mutation G20210A (rs1799963), leptin receptor 
gene (LEPR) polymorphism rs1137100 and the thrombophilic gene group. However the 
meta-analysis concluded that there was potential for bias from inconsistent definition of the 
phenotype and poor-quality genotyping (358).  
 
Large collaborations to ensure adequately powered studies will be an important 
consideration for the future. The complexities of the pathophysiology of pre-eclampsia, 
and the differing diagnostic criteria over time and in different countries is important to 
consider, especially in genetic studies where robust phenotyping will be important.  
 
 Aims of this thesis 1.8
 
The overall aim of this thesis is to explore the possible mechanisms for cardiovascular risk 
later in life in women with a history of pre-eclampsia.  
 
Firstly I will study the relationship between pre-eclamptic pregnancy and cardiovascular 
outcomes in Scottish women using the “Generation Scotland: Scottish Family Health 
Study” (GS:SFHS). I will seek to confirm whether the relationship between cardiovascular 
risk later in life and a history of pre-eclampsia is confirmed in this population of women.  
 
Secondly I aim to determine the effects of pregnancy on the ECG by examining the ECGs 
of women years after pregnancy (using GS:SFHS). Newly emerging evidence in this area 
suggests that women with a history of pre-eclampsia are at increased risk of cardiovascular 
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events and cardiovascular disease, not only through hypertension (as evidenced by a 
degree of ventricular hypertrophy on the ECG), but also by prolongation of the QT interval 
(increasing risk of arrhythmic events and sudden death).  
 
Thirdly I aim to find out whether middle-aged women without overt cardiovascular 
disease, with a history of pre-eclampsia, have different vascular structure and function later 
on in life in comparison with those who had normotensive pregnancies. 
 
Finally, I aim to determine whether levels of inflammatory markers, angiogenic markers, 
cytokines and other biomarkers are altered years after pre-eclampsia and may predispose to 
cardiovascular disease risk. Included are proteomic studies using previously validated 
panels for coronary artery disease and pre-eclampsia.
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Figure 1.9. Summary of thesis 
The overall aim of this thesis is to investigate the underlying mechanisms of the association between 
pre-eclampsia and cardiovascular disease as outlined in the flow diagram.  
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2 Materials and Methods 
 
 Introduction 2.1
 
Women with a history of pre-eclampsia are known to be at a greater risk of cardiovascular 
disease later in life (6), however the precise causal mechanisms of this relationship are not 
fully understood. The work undertaken in this thesis has aimed to address some of the key 
issues in further elucidating these causal mechanisms. By using a multifaceted approach of 
record linkage, clinical and laboratory studies, the aim was to further examine the 
relationship between pre-eclampsia and cardiovascular disease later in life.  
 
The main theme of this work was to study cardiovascular risk in women  1-30 years after 
pre-eclampsia. First I sought to establish whether, in a relatively large cohort of parous 
women, there was any evidence of a greater risk of cardiovascular events in those with a 
history of pre-eclampsia. I then investigated whether there was any evidence of subclinical 
vascular damage in previously pre-eclamptic women, to determine whether there were any 
specific findings which might explain any increased risk. Biomarker studies were also 
performed to establish whether there were any differences many years after pre-eclampsia 
which might be in keeping with the relationship with cardiovascular disease. Finally I 
examined ECG data in women many years after pregnancy to identify whether there was 
any evidence of cardiovascular disease after pre-eclampsia.  
 
In order to address these questions I took advantage of the Generation Scotland Scottish 
Family Health Study (GS:SFHS) resource. This was used for risk assessment, biomarker 
studies and ECG analysis. For the vascular studies I recruited my own cohort, the 
“Cardiovascular Consequences of Pre-eclampsia (COPS) vascular studies” cohort from 
women who had participated in GS:SFHS, the previous Proteomics in Pre-eclampsia study 
(PIP), and blood pressure clinics. This vascular study cohort was also used for additional 
biomarker studies.   
 
These studies all contributed to the overall “Cardiovascular Consequences of Pre-
eclampsia study” (COPS). A fuller description of individual study materials and methods 
are described in dedicated chapters; record-linkage study (chapter 3), ECG studies (chapter 
4), vascular studies (chapter 5) and biomarker studies (chapter 6). For all studies  
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included in this thesis, the diagnosis of pre-eclampsia was based on ISSHP 
recommendations and proteinuria of at least “2+” on dipstick was used.   
 
 Funding 2.2
 
The COPS study was funded by the Chief Scientist Office, Scotland. Grant Ref ETM/196. 
The author was also funded by the European Commission’s 7th Framework Programme 
Collaborative Project “EU-MASCARA”.  
 
 Ethical approval 2.3
 
The overall COPS study (record-linkage, vascular studies and biomarker studies) was 
approved by the West of Scotland REC (reference 12/WS/0306) and sponsored by NHS 
Greater Glasgow and Clyde Research and Development Service (reference GN11CA468). 
Paperwork is available in Appendices 1-13. The study was registered on the UK Clinical 
Research Network (Ref 13723).  
 
 The Generation Scotland Family Health Study (GS:SFHS) 2.4
 
The GS:SFHS is a rich resource consisting of questionnaire data, clinical data and 
biosamples of more than 20,000 members of the Scottish general population (359;360). 
Study participants were recruited in Aberdeen, Dundee, Edinburgh and Glasgow between 
2006 and 2011.   Women from this cohort were included in the record-linkage study 
described in chapter 3. Clinical and ECG data which were available through the record-
linkage study were further explored in chapter 4. Women who participated in GS:SFHS 
were also invited to attend for COPS vascular studies as outlined in chapter 5. Serum 
samples from the wider GS:SFHS cohort of women, stored at time of recruitment to 
GS:SFHS, were available from pre-eclampsia cases and controls which had been identified 
in chapter 3. Samples were available from 329 women with a history of pre-eclampsia and 
658 normotensive controls matched for year of birth, BMI, systolic blood pressure and 
smoking status. Biomarker studies were performed in a subset of these women (55 cases 
and 110 matched controls) as described in chapter 6.  
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 Generation Scotland ethical approval and other approvals 2.4.1
 
Ethical approval had been granted for the GS:SFHS (REC reference number 05/S1401/89) 
and women who had taken part in GS:SFHS had agreed to be contacted to participate in 
future studies and had given consent at time of recruitment for the use of their blood and 
urine samples in other related studies. Access to Generation Scotland data and samples was 
applied for and granted by the Generation Scotland access committee (reference number 
GS11088).  
 
For the record linkage study, additional approval was required. The anonymity of study 
subjects was maintained as outlined in a Privacy Advisory Committee (PAC) application 
which was filed by the COPS study team and had been approved (Appendix 13). 
 
 The COPS vascular study  2.5
 
 Recruitment 2.5.1
 
The COPS vascular studies took place at the British Heart Foundation Glasgow 
Cardiovascular Research Centre (BHF GCRC) and recruited 86 women with a history of 
pre-eclampsia and 80 controls. They were recruited from multiple sources: GS:SFHS, the 
Proteomics in Pre-eclampsia (PIP) study cohort, blood pressure clinics and some friends 
and colleagues of participants who contacted us because they had heard about the study 
and were interested in participating. These women were recruited to the blood pressure 
group as this group best reflected their age.  
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Figure 2.1 COPS vascular study recruitment groups. 
 
 Ethical approvals relating to the COPS vascular study 2.5.2
 
The COPS vascular study was approved as part of the overall COPS study as mentioned in 
section 2.3. All participants who had previously been recruited to GS:SFHS and PIP had 
given written informed consent at the time of those studies. GS:SFHS approval is 
described in section 2.4.1 and PIP REC approval reference 07/S0709/79.   
New recruitment of women to the COPS vascular study was carried out according to the 
Declaration of Helsinki and written informed consent was given (forms in Appendices 1-
13)  
 
 Study protocol  2.5.3
 
Inclusion criteria were women who had a pregnancy 1-30 years ago and women were 
excluded if they were >60 years old, already had established cardiovascular disease or if 
they were unable to give informed consent. There were deviations from the study protocol 
only on age of recruitment of women for the purposes of age-matching and these were 
discussed with R&D and appropriate file note documented in the site file as advised.  
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 Study visit 2.5.4
 
All clinical vascular studies were carried out at the BHF GCRC. Study participants were 
asked to refrain from smoking or caffeine intake for 6 hours before the appointment and 
wore loose fitting clothing. Time of last meal, time of last cigarette and time of study visit 
were all noted. All studies were carried out in quiet dedicated temperature-controlled 
rooms between 21-23
o
C.  
 
 Study questionnaire 2.5.5
 
The study questionnaire consisted of obstetric history, past medical history, drug history, 
smoking history and family history (Appendix 10). 
 
 Anthropometric measurements 2.5.6
 
Height was measured to the nearest millimetre with shoes removed. Weight was measured 
using routinely calibrated Seca weighing scales. The same equipment was used for all 
study visits. Body mass index (BMI) kg/m
2
 was calculated as:  weight (kg)/height (m)
2
. 
 
 Blood pressure 2.5.7
 
Participants rested in a sitting position for 5 minutes. The Omron 705-IT device (Omron 
Corporation, Shimogyo-ku, Kyoto, Japan) was used to take three readings and the average 
of the 2
nd
 and 3
rd
 blood pressure readings was used for subsequent analysis. Any 
significant abnormalities were reported to the subject’s general practitioner.  
 
 Blood and urine samples 2.5.8
 
Blood samples were taken from the antecubital fossa using a standard tourniquet and 
Vacutainer system. One of the gold topped serum separator (SST) tubes was delivered to 
NHS Greater Glasgow and Clyde, Western Infirmary biochemistry laboratory for lipid 
studies. Any significant abnormalities were reported to the patient and the patient’s general 
practitioner. The other samples were placed on ice and centrifuged at 2500 rpm in the 
laboratory at 4
o
C for 15 minutes. They were then frozen at -80
o
C as indicated in Figure 
2.2. A mid-stream specimen of urine was collected in a universal container and aliquoted 
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in the laboratory into 3 separate 1ml aliquots. These were frozen at -80
o
C. Unique study 
IDs were given to samples from each participant, starting with the letter “C” for the 
“COPS” study, then a 5 digit space for sequential numbering beginning at number “00001” 
for the first patient, and a final letter indicating which recruitment cohort the participant 
came from e.g “G” for Generation Scotland, “P” for the PIP study and “C” for the blood 
pressure clinic group. The first patient was given code “C-00001-P” indicating they were 
from the PIP cohort.  
 
 
Figure 2.2 Blood and urine sample processing for the COPS vascular study.  
6 blood samples were taken as follows: 1x lithium heparin, 2x EDTA, 1x tempus RNA tube, 2x gold 
SST. EDTA= ethylenediamine tetraacetic acid, SST=serum separator tube, DNA= deoxyribonucleic 
acid, RNA= ribonucleic acid  
 
 Electrocardiogram 2.5.9
 
A standard 12-lead resting electrocardiogram (ECG) was carried out in the supine position. 
Any significant abnormalities were reported to the participant’s general practitioner. It was 
important to perform ECG prior to commencement of pulse wave analysis and pulse wave 
velocity as these tests cannot be performed in patients who are not in sinus rhythm. 
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 Statistical analysis 2.6
 
Statistical analyses were performed using Minitab v17 (Minitab Inc, State College, PA, 
USA) and SPSS v22 (IBM Corp, Armonk, New York, USA). The Kolmogorov-Smirnov 
test was used to assess normality of data distribution and histograms and plots were 
manually examined. Independent samples t-test was used for comparison of continuous 
variables unless data were matched, in which case paired samples t-test was used. If data 
were not normally distributed, they were transformed. Any continuous variables which 
remained non-parametric were analysed using the Mann-Whitney U test for comparison of 
independent samples and Wilcoxon signed rank test if paired. All variables are described 
as mean ± standard deviation or median (interquartile range) as appropriate unless 
otherwise stated. Chi-squared test and Fisher’s exact test were used to compare categorical 
variables. Pearson’s or Spearman’s correlation coefficient were used as appropriate and 
multiple linear regression to investigate relationships between variables. A p-value of 
<0.05 was considered significant.  
 
This is a general description of statistics, and any specific methods will be described in the 
relevant results chapters.  
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3 The Cardiovascular Consequences of Pre-eclampsia Record 
Linkage Study 
 
  Introduction 3.1
 
Women with a history of pre-eclampsia are known to be at an increased risk of 
cardiovascular disease later in life. One of the first descriptions of this was by Adams and 
MacGillivray et al over 50 years ago (80). Over the past decades, supportive evidence has 
been compiled to such an extent that, in the American Heart Association’s latest guidelines 
regarding cardiovascular risk in women, pre-eclampsia has been recognised as a risk factor 
for cardiovascular disease and stroke (89;90).  
 
Many epidemiological studies have addressed risk of death from cardiovascular disease 
following hypertensive pregnancy disorders (6;81;101;361-363). Risk of cardiovascular 
diseases in general such as hypertension, cerebrovascular disease and ischaemic heart 
disease, following hypertensive disorders of pregnancy (6;80;81;83;85;95;97-101;364) 
have also been addressed.  
 
The effects of parity on future risk of cardiovascular disease must also be considered. 
There has been conflicting evidence in the literature regarding the influence of parity, 
especially nulliparity on future cardiovascular disease (365-371). A recent meta-analysis of 
cardiovascular disease mortality and parity by Lv et al (372) reported a borderline 
reduction in cardiovascular mortality in ever parous women vs nulliparous. It argued that 
higher fertility could reflect healthier women at baseline, who would therefore be at a 
lower risk of cardiovascular mortality. In contrast, one of the most recent studies in this 
field (370) in the pan-European (EPIC)-CVD study, a case-cohort nested study from the 
EPIC prospective study, found that in 12,319 women with data on parity and incident 
coronary heart disease, hazard ratio in parous vs nulliparous women was 1.27 (95% CI 
1.09-1.47) and after adjusting for potential confounders this was attenuated to 1.19 (95% 
CI 1.01-1.41). Hazard ratio appeared to increase as parity increased up to 5 or more 
children. Childbearing women who had ever breastfed were at a lower risk of coronary 
heart disease than those who had never breastfed.  
 
Preterm birth in women with pre-eclampsia is also an important risk factor for later 
cardiovascular event and mortality as evidenced by a large register-based Norwegian study 
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of incident coronary heart disease after pre-eclampsia (373). Women who gave birth 
between 1980-2002 were followed for incident major coronary event and mortality. When 
women with pre-eclampsia were compared to those without pre-eclampsia, the hazard ratio 
for major coronary event was 2.1 (95% CI 1.73-2.65) for pre-eclampsia, 3.3 (2.37-4.57) for 
pre-eclampsia combined with babies small for gestational age, and 5.4 (3.74-7.74) for pre-
eclampsia in combination with preterm delivery (373).  
 
The study described in this chapter sought to investigate the effect of pre-eclampsia on 
future cardiovascular event risk in women who had been enrolled in the Generation 
Scotland Scottish Family Health Study (GS:SFHS) as a representative sample of the 
Scottish population, by record linkage using data held by the Information Services 
Division (ISD). Its aims were: 
 
1) to examine the relationship between nulliparous and parous women and cardiovascular 
disease. 
2) to investigate whether women with a history of pre-eclampsia were at an increased risk 
of cardiovascular disease later in life. 
3) to perform survival analysis to further evaluate the relationship between cardiovascular 
events and pre-eclampsia.  
 
 Methods 3.2
 
 Ethical approval 3.2.1
 
This study was approved by the West of Scotland Research Ethics Committee (reference 
12/WS/0306). Approval for data linkage was obtained from the Privacy Advisory 
Committee (PAC) of NHS National Services Scotland. The study adhered to the principles 
of the Declaration of Helsinki and all participants had provided written informed consent 
for access to their health records. Ethical approval for the Generation Scotland study itself 
is outlined in Chapter 2. 
 
 Generation Scotland and Record Linkage 3.2.2
 
The Generation Scotland: Scottish Family Health Study (GS:SFHS) was used. This 
resource has a large amount of data available from questionnaires and clinical 
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examinations. Blood and urine samples were also taken, processed and stored at the time of 
recruitment. More than 20,000 participants have been recruited to this study from the 
Scottish population (359;360). Recruitment between 2006 and 2011 was based in 
Aberdeen, Dundee, Glasgow and Edinburgh.  
 
Record linkage (as outlined in Figure 3.1) was performed to enable cardiovascular 
outcomes to be linked with the study participant and also obstetric history (which was not 
part of the GS:SFHS study questionnaire). Requirements for anonymity of study subjects 
(as agreed with the Privacy Advisory Committee) was maintained and facilitated by the 
GS:SFHS team in Edinburgh (Archie Campbell) working with the Information Services 
Division (ISD NHS Scotland) and Health Informatics Centre (HIC). A new identification 
number was allocated for each participant, which for the purposes of this study was 
labelled the ‘ISD’ number (number from the Information Services Division). For the 
purposes of data analysis, through the ISD number it was possible to link the SMR01 and 
SMR02 data, which was sent via the secure NHS server. A description of the process used 
to link SMR01 and SMR02 data is found in the Statistical analysis section 3.2.4. 
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Figure 3.1 Outline of application process and acquisition of data for record linkage study. 
 
The Information Services Division have assessed the quality of SMR01 and SMR02 data 
(374;375)  and data collection has been >99% complete since the ICD-9 classifications 
would have started at the end of the 1970s (376).  
Once the relevant SMR01 and SMR02 data had been collated by ISD it was forwarded in a 
format which facilitated merging of datasets, with a unique ISD number linking the 
information between SMR01 and SMR02. The data remained fully anonymised without 
possibility of access to CHI numbers or other patient personal identifiers. The data 
obtained was stored on secure servers at the University of Glasgow.  
 
 
 
Linked anonymised data forwarded to 
COPS team for analysis 
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 International Classification of Disease (ICD) 3.2.3
 
The International Classification of Disease (ICD) is a coding system which was developed 
to promote uniformity of disease diagnoses in published literature by the World Health 
Organization that provides an internationally recognised method of coding diseases in 
order to categorise mortality and morbidity statistics. The tenth and most recent revision 
(ICD-10) was introduced in 1999. Revisions are currently underway for new ICD-11 
classifications and a final version for approval at the World Health Organisation World 
Health Assembly is expected in 2018. For the purposes of this study ICD-9 classifications 
were also used as these were introduced in 1979-1998. I excluded pregnancies classified as 
pre-eclampsia by earlier ICD-8 classification as these diagnoses were judged to be less 
reliable considering the changing diagnostic criteria for hypertensive disorders of 
pregnancy over the past 40years.  
 
  Hospital admission SMR01 data 3.2.3.1
 
Cardiovascular events were only included if they were listed as the main condition for the 
hospital admission. SMR01 data were coded as follows: Rheumatic heart diseases (ICD-9 
390-398, ICD-10 I00-09), hypertensive diseases (ICD-9 401-405, ICD-10 I10-15), 
ischaemic heart diseases (ICD-9 410-414, ICD-10 I20-I25), pulmonary heart diseases 
(ICD-9 415-417, ICD-10 I26-28), other forms of heart disease (ICD-9 420-429, ICD-10 
I30-I52), cerebrovascular diseases (ICD-9 430-438, ICD-10 I60-69), diseases of the 
arteries, arterioles and capillaries (ICD-9 440-448, ICD-10 I70-79) and other circulatory 
diseases (ICD-9 459, ICD-10 I95-99) . Any disorders of the venous system e.g. ICD-9 
codes 451-458 and ICD-10 codes I80-89 were excluded. The full breakdown of number of 
entries for each code is given in Table 3.9. 
 
 Maternity SMR02 data 3.2.3.2
 
As previously mentioned, for the purposes of this study pregnancies dating as far back as 
1980 were included. Regarding SMR02 data, women to be classified as a ‘case’ of pre-
eclampsia had ICD-9 codes 642-4, 642-5, 642-6 and 642-7 or ICD-10 codes O11, O14-0, 
O14-1, O14-2, O14-9, O15-0, O15-1, O15-2 and O15-9. Women with hypertensive 
disorders of pregnancy but not pre-eclampsia were excluded and had ICD-9 codes 642-0, 
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642-1, 642-2, 642-3, 642-9, 646-2, 648-0, 648-8 and ICD-10 codes O10, O12, O13, O16, 
O24. A full description of the individual codes is given in Tables 3.1 and 3.2.  
 
 Generation Scotland data 3.2.3.3
 
Information available from the Generation Scotland recruitment visit as analysed in this 
chapter was made up of several different components: The age at time of visit, 
anthropometric measurements, clinical measurements (blood pressure and heart rate), 
biochemistry and self-reporting of clinical diagnoses (hypertension and diabetes) and 
smoking history. 
 
 Statistical analysis 3.2.4
 
Initial preparation of the dataset using R (http://R-project.org) was performed by Mr Scott 
Robinson. This consisted of identification and removal of duplicate records, merging of 
SMR01 and SMR02 tables, homogenisation of ICD codes with the use of regular 
expressions and calculation of data used directly for analysis for example survival times 
and the categorisation of participants. Following this, biochemistry and other phenotype 
data were then merged with this table using a custom visual basic script run in Microsoft 
Excel.  
 
Statistical analysis was then performed by the author using IBM SPSS Statistics for 
Windows (Version 22.0, Armonk, NY: IBM Corp, 2013). For comparison of continuous 
variables independent samples t-test or Mann-Whitney U test were used depending on the 
distribution of the data. Categorical variables were compared using Chi-squared test. 
Continuous variables were summarised using mean ± standard deviation or medians and 
inter-quartile range, depending on data distribution. Birth weight was adjusted for 
gestational age using z-scores (standard deviation scores). Z-score calculations were 
performed using the 2003 Fenton growth chart (377)  This particular chart was used in 
preference to more modern gender-specific growth charts because information on gender 
of baby was not available to us in the extracted SMR02 data. However, the 2003 Fenton 
chart is based on data from population studies with large sample sizes. Time–to-event 
analysis was performed using Kaplan-Meier survival curves and Cox proportional hazards 
model was used to evaluate the hazard ratio and its confidence intervals.  
 
Chapter 3  88 
 
8
8
 
 
 
 Results 3.3
 
 Identification of women with a history of pre-eclampsia in the 3.3.1
GS:SFHS  
 
The index pregnancy was defined as the first pregnancy in normotensive women and the 
first pre-eclamptic pregnancy in those with pre-eclampsia (according to ICD-9 and ICD-10 
classification). See Tables 3.1 and 3.2 for inclusion and exclusion classifications for pre-
eclampsia; also included is the number of times each code was entered for SMR02 data. 
None of the pregnancies had gestations of <20weeks; if they had been present they would 
have been excluded. 
 
The flow diagram in Figure 3.2 demonstrates the identification of pre-eclampsia cases and 
normotensive controls within the Generation Scotland cohort. There were 9,732 women 
with SMR01 and SMR02 data available. Of them 3,693 were never pregnant and 6,039 
women had 11,170 pregnancies. Thirteen women experienced a cardiovascular event 
before their first pregnancy and were therefore excluded, as cardiovascular event was the 
endpoint of interest. This left a total of 6,026 women with 11,146 pregnancies. A further 
496 women (with 1,004 pregnancies) were excluded as they had experienced other 
hypertensive disorders of pregnancy. Of the remaining 5,530 women with 10,142 
pregnancies, another 277 women (with 559 pregnancies) were excluded because they had 
less reliable ICD-8 coding for pre-eclampsia and no ICD-9 or ICD-10 code. Their 
classification as a “case” would not necessarily have been correct, neither could they 
reasonably be used as a “control”. A total of 5,253 women with 9,583 pregnancies 
remained. Of these, 4,922 women had 8,880 normotensive pregnancies and 331 women 
with 703 pregnancies were in the pre-eclampsia group. Out of the 331 women, there were 
359 actual pre-eclamptic pregnancies. Pre-eclampsia occurred in the first pregnancy in 
237/331 (71.6%) women, the second pregnancy in 76/331 (23%) women and the third 
pregnancy in 18/331 (5.4%) women. A total of 303/331 (91.5%) women experienced pre-
eclampsia in only one pregnancy, and 28/331 (8.5%) experienced pre-eclampsia in two 
pregnancies. 
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Figure 3.2 Identification of women with pre-eclampsia in GS:SFHS 
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Table 3.1  Breakdown of pre-eclampsia ICD codes in 331 women for inclusion 
ICD-9 codes Description Number of PE entries in SMR02 data 
642-4 Mild or unspecified pre-eclampsia 259 
642-5 Severe pre-eclampsia 45 
642-6 Eclampsia 4 
642-7 Pre-eclampsia or eclampsia superimposed on pre-existing hypertension 1 
ICD-10 codes   
O11 Pre-existing hypertension with superimposed proteinuria 1 
O14-0 Mild to moderate pre-eclampsia  8 
O14-1 Severe pre-eclampsia 7 
O14-2 HELLP syndrome  0 
O14-9 Unspecified pre-eclampsia 39 
O15-0 Eclampsia in pregnancy 1 
O15-1 Eclampsia in labour 0 
O15-2 Eclampsia in the puerperium 1 
O15-9 Eclampsia unspecified as to time period 0 
   
 TOTAL number of PE codes for 331 women with 703 pregnancies 366
† 
 
 PE = pre-eclampsia, HELLP = haemolysis, elevated liver enzymes, low platelets, ICD = International Classification of Diseases, SMR= Scottish Morbidity Records. 
 † 
N.B. Some pre-eclamptic pregnancies were given 2 different “pre-eclampsia category” codes for one admission. This data reflects the fact that there were 366 pre-
 eclampsia codes entered in total for 331 women during the course of their 703 pregnancies. 
9,732 women with SMR01 and SMR02 linked data available 
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 Table 3.2  Breakdown of ICD codes in 496 women with other hypertensive disorders of pregnancy, excluded from further analysis 
ICD-9 codes Description Number of entries in SMR02 data 
642-0 Benign essential hypertension 5 
642-1 Hypertension secondary to renal disease 1 
642-2 Other pre-existing hypertension 1 
642-3 Transient hypertension 16 
642-9 Unspecified hypertension 326 
646-2 Unspecified renal disease without hypertension 14 
648-0 Diabetes mellitus 7 
648-8 Abnormal glucose tolerance 22 
ICD-10 codes   
O-10 Pre-existing hypertension 15 
O-12 Gestational oedema and proteinuria without hypertension 35 
O-13 Gestational hypertension without proteinuria 82 
O-16 Unspecified  maternal hypertension 32 
O-24 Diabetes mellitus in pregnancy 22 
   
 TOTAL number of coding entries for the  
496 women (1,004 pregnancies) excluded 
578* 
 
 PE = pre-eclampsia, ICD = International Classification of Diseases, SMR= Scottish Morbidity Records. 
 * N.B. Some pregnancies were different codes in the table during a single pregnancy. This table reflects the number of times each individual code was used for the 
 1,004 pregnancies in 496 women. 
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 Descriptive statistics for Generation Scotland data 3.3.2
 Descriptive statistics for nulliparous women vs pregnant women 3.3.2.1
It is important to clarify that for the purposes of describing the work presented in this 
chapter, the word “nulliparous” has been used to describe women who have not given 
birth. Some studies describe pregnant women as “nulliparous” if they are experiencing 
their first pregnancy, i.e. they have never been parous before but are currently pregnant.  
This thesis describes such women as “primigravida” (pregnant for the first time) and 
“primiparity” as having given birth to their first child. The word “parous” is used to mean 
women who have given birth. 
The following table shows the differences between baseline characteristics of nulliparous 
and parous women at time of recruitment to the Generation Scotland study. Of note is the 
fact that nulliparous women had a significantly higher body mass index (BMI), systolic 
blood pressure (SBP) and diastolic blood pressure (DBP). There were also significant 
differences in most biochemical parameters, with a higher total cholesterol in women who 
had given birth. On Chi-squared test there was a significant difference in current diagnoses 
of hypertension and diabetes between the two groups, with women who had never been 
pregnant having a higher proportion of cases of hypertension and diabetes. There was also 
a significant difference in smoking between the two groups with parous women being 
more likely to smoke (Table 3.3). 
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Table 3.3 Comparison of clinical and biochemical measurements taken at time of 
recruitment to the Generation Scotland study in the remaining 8,946 women 
following exclusions 
 
SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, HDL = high density 
lipoprotein, BMI = body mass index 
* In order to demonstrate the direction of difference, data are displayed as mean ± standard deviation. 
Proportions are given for categorical data, with the denominator reflecting the number of data entries 
available for that parameter. 
† p-value is for independent samples t-test if continuous data normally distributed, and Mann-Whitney 
U test if continuous data not normally distributed. Chi-squared test results are given for categorical 
data. 
Measurement Nulliparous* 
(N=3,693) 
Pregnant ever* 
(N=5,253) 
p-value† Age-
adjusted p-
value 
Age (yrs) 49.4 ± 18.1 46.5 ± 10.9 <0.001 N/A 
Height (cm) 161.9 ± 6.8  162.6 ± 6.3 <0.001 0.032 
Weight (kg) 70.2 ± 15.4 69.7 ±  14.7 0.182 0.139 
BMI (kg/m
2
) 26.8 ± 5.8 26.3 ± 5.4 0.001 0.015 
Mean SBP (mmHg) 130.9 ± 19.3 125.6 ± 17.1 <0.001 <0.001 
Mean DBP (mmHg) 78.5 ± 10.1 77.8 ± 10.0 0.004 0.608 
Mean HR (bpm) 71.0 ± 11.1 70.4 ± 10.7 0.009 0.001 
Glucose (mmol/L) 4.8 ± 1.0 4.7 ± 1.0 <0.001 0.007 
Total cholesterol 
(mmol/L) 
5.1 ± 1.1 5.2 ± 1.1 <0.001 <0.001 
HDL cholesterol 
(mmol/L) 
1.583 ± 0.414 1.582 ± 0.410 0.890 0.175 
Sodium (mmol/L) 139.6 ± 2.5 139.8 ± 2.3 0.003 <0.001 
Potassium (mmol/L) 4.17 ± 0.46 4.13 ± 0.41 <0.001 <0.001 
Urea (mmol/L) 5.0 ± 1.6 4.8 ± 1.2 <0.001 <0.001 
Creatinine (μmol/L) 67.9 ± 12.3 66.4 ± 10.4 <0.001 <0.001 
     
Current 
Hypertension 
606/3637 (16.7%) 492/5143 (9.6%) <0.001  
Current Diabetes 123/3637 (3.4%) 72/5143 (1.4%) <0.001  
Current smoker 563/3583 (15.7%) 933/5100 (18.3%) 0.002  
Chapter 3  94 
 
9
4
 
 
 
 Descriptive statistics for women with pre-eclampsia vs normotensive 3.3.2.2
pregnancies 
 
Women with a history of pre-eclampsia had significantly higher weight and BMI at time of 
recruitment to the Generation Scotland study than women with normotensive pregnancies. 
They also had significantly higher BMI, SBP, DBP and heart rate and significant 
differences in current diagnosis of hypertension and diabetes, with a greater proportion of 
women having these conditions in the pre-eclampsia group (Table 3.4). 
 
Comparison of birth characteristics of the index pregnancies (as used for survival analysis, 
described further in section 3.3.4) revealed that there was no difference in age at index 
pregnancy and women with pre-eclampsia gave birth to lower birth weight babies and gave 
birth at an earlier gestation. However, on adjusting birth weight for gestational age using z-
scores, there was no statistically significant difference between groups. Chi-squared test  
revealed that women with a history of pre-eclampsia were more likely to have had a C-
section at delivery, and to have had a multiple gestation pregnancy (Table 3.5). For twin 
pregnancies, the mean of two birth weights was used in statistical analysis. 
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Table 3.4  Comparison of clinical and biochemical measurements taken at time of 
recruitment to the Generation Scotland study in 5,253 women with pregnancies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, HDL = high density 
lipoprotein, BMI = body mass index. * Data are displayed as mean ± standard deviation to 
demonstrate the direction of difference. Proportions are given for categorical data, with the 
denominator reflecting the number of data entries available for that parameter. 
† p-value is for independent samples t-test if continuous data normally distributed, and Mann-Whitney 
U test if continuous data not normally distributed. Chi-squared test results are given for categorical 
data. 
 
Measurement Normotensive 
pregnancy* 
(N=4,922) 
Pre-eclampsia* 
(N=331) 
p-value† Age-
adjusted 
p-value 
Age (yrs) 46.4 ± 11.0 48.3 ± 8.5 0.006 N/A 
Height (cm) 162.7 ± 6.3 162.0 ± 6.0 0.066 0.192 
Weight (kg) 69.4 ± 14.5 73.2 ± 16.8 <0.001 <0.001 
BMI (kg/m
2
) 26.2 ± 5.3 27.9 ± 6.2 <0.001 <0.001 
Mean SBP (mmHg) 125.1 ±17.0 132.7 ± 16.5 <0.001 <0.001 
Mean DBP (mmHg) 77.5 ± 9.9 83.0 ± 9.3 <0.001 <0.001 
Mean HR (bpm) 70.3 ± 10.7 72.4 ± 11.1 0.001 <0.001 
Glucose (mmol/L) 4.7 ± 1.0 4.8 ± 1.1 0.002 0.017 
Total cholesterol 
(mmol/L) 
5.2 ± 1.1 5.3 ± 1.1 0.503 0.525 
HDL cholesterol 
(mmol/L) 
1.58 ± 0.41 1.57 ± 0.38 0.587 0.188 
Sodium (mmol/L) 139.8 ± 2.3 140.0 ± 2.2 0.202 0.282 
Potassium (mmol/L) 4.13 ± 0.41 4.11 ± 0.38  0.619 0.332 
Urea (mmol/L) 4.8 ± 1.2 4.9 (1.3) 0.137 0.503 
Creatinine (μmol/L) 66.3 ± 10.4 67.4 ± 10.4 0.05 0.095 
     
Current Hypertension 398/4818 (8.3%) 94/325 (28.9%) <0.001  
Current Diabetes 59/4818 (1.2%) 13/325 (4.0%) <0.001  
Current smoker 886/4777 (18.5%) 47/323 (14.6%) 0.072  
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Table 3.5 Comparison of birth data in women with pre-eclampsia vs women with 
normotensive pregnancy 
Measurement Normotensive 
pregnancy 
(N=4,922) 
Pre-eclampsia 
(N=331) 
p-value 
Age at index pregnancy (yrs)* 27 ± 5 27 ± 5  0.389 
Birth weight at index pregnancy (g)* 3384 ± 548 3216 ± 699 <0.001 
Gestation at index pregnancy birth 
(weeks)* 
39.6 ± 1.9 38.7 ± 2.4 <0.001 
Z-score for birth weight -0.1612 ±  0.86  -0.1861 ± 0.89 0.456 
Number of multiple gestation 
pregnancies† 
66/4922 (1.3%) 11/331 (3.3%) 0.004 
C-section required at delivery† 791/4922 (16.1%) 92/331 (27.8%) <0.001 
 
* Data described as mean ± standard deviation for the purposes of this table. Continuous data were 
compared using parametric or non-parametric methods depending on distribution.    
†Chi-test was used to compare data for categorical outcomes. 
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Table 3.6 Table of descriptive results for pre-eclampsia cases and normotensive controls in 5,253 women by cardiovascular events vs no 
cardiovascular events 
 Cardiovascular event (N=218) No cardiovascular event (N=5,035) 
Measurement Normotensive 
pregnancy (N=193) 
Pre-eclampsia 
(N=25) 
p-value Normotensive 
pregnancy (N=4,729) 
Pre-eclampsia 
(N=306) 
p-value 
Age (yrs) 54 (10) 53 (9) 0.578 47 (17) 49 (12) 0.010 
Height (cm) 161.2 ± 6.0 160.0 ± 6.5 0.326 163.0 (8.2) 162.0 (9.9) 0.135 
Weight (kg) 70.7 (23.5) 76.4 (26.0) 0.858 66.7 (17.1) 69.3 (19.7) <0.001 
BMI (kg/m
2
) 27.2 (9.7) 27.0 (10.5) 0.645 25.2 (6.4) 26.6 (7.1) <0.001 
Mean SBP (mmHg) 132 (30) 135 (22) 0.445 122 (21) 130 (23) <0.001 
Mean DBP (mmHg) 79 (15) 81 (12) 0.283 77 (12) 82 (12) <0.001 
Mean HR (bpm) 70 (12) 73 (11) 0.225 69 (14) 72 (14) <0.001 
Glucose (mmol/L) 4.7 (0.7) 4.8 (1.8) 0.243 4.6 (0.5) 4.6 (0.7) 0.007 
Total cholesterol (mmol/L) 5.2 ± 1.2 5.1 ± 1.1 0.694 5.1 (1.4) 5.2 (1.3) 0.425 
HDL cholesterol (mmol/L) 1.5 ± 0.4 1.5 ± 0.4 0.675 1.5 (0.5) 1.5 (0.5) 0.564 
Sodium (mmol/L) 140 (4) 140 (2) 0.317 140 (3) 140 (2) 0.109 
Potassium (mmol/L) 4.1 (0.5) 4.1 (0.6) 0.465 4.1 (0.4) 4.1 (0.4) 0.692 
Urea (mmol/L) 5.1 (1.7) 5.1 (1.2) 0.932 4.6 (1.6) 4.8 (1.5) 0.204 
Creatinine (μmol/L) 65 (12) 73 (23) 0.018 65 (13) 66 (12) 0.188 
       
Current Hypertension 47/187 (25.1%) 13/25 (52%) 0.005 351/4631 (7.6%) 81/300 (27%) <0.001 
Current Diabetes 10/187 (5.3%) 5/25 (20%) 0.007 49/4631 (1.1%) 8/300 (2.7%) 0.012 
Current smoker 46/186 (24.7%) 7/25 (28%) 0.723 840/4591 (18.3%) 40/298 (13.4%) 0.034 
 
BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, HDL = high density lipoprotein. 
† p-value is for independent samples t-test if continuous data normally distributed, and Mann-Whitney U test if continuous data not normally distributed. Chi-
squared test or Fisher’s exact test results are given for categorical data. 
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Table 3.7 Table of descriptive results for cardiovascular events vs no cardiovascular events by pre-eclampsia vs normotensive 
pregnancy in 5,253 women 
 Pre-eclampsia (N=331) No pre-eclampsia (N=4,922) 
Measurement No CV event (N=306) CV event (N=25) p-value No CV event (N=4,729) CV event 
(N=193) 
p-value 
Age (yrs) 49 (12) 53 (9) 0.008 47 (17) 54 (10) <0.001 
Height (cm) 162.0 (9.9) 161.0 (8.7) 0.088 163.0 (8.2) 161.0 (8.0) 0.003 
Weight (kg) 69.3 (19.6) 76.4 (26.0) 0.683 66.7 (17.1) 70.7 (23.5) 0.001 
BMI (kg/m
2
) 26.6 (7.1) 27.0 (10.5) 0.331 25.2 (6.4) 27.2 (9.7) <0.001 
Mean SBP (mmHg) 130 (23) 135 (22) 0.449 122 (21) 132 (30) <0.001 
Mean DBP (mmHg) 83 ± 9 81 ± 9 0.300 77 (12) 79 (15) 0.009 
Mean HR (bpm) 73 ± 11 73 ± 11 0.863 69 (14) 70 (17) 0.458 
Glucose (mmol/L) 4.6 (0.7) 4.8 (1.8) 0.076 4.6 (0.5) 4.7 (0.7) <0.001 
Total cholesterol (mmol/L) 5.3 ± 1.1 5.1 ± 1.1 0.347 5.1 (1.4) 5.1 (1.3) 0.264 
HDL cholesterol (mmol/L) 1.5 (0.5) 1.5 (0.4) 0.818 1.5 (0.5) 1.5 (0.6) 0.015 
Sodium (mmol/L) 140 (2) 140 (2) 0.190 140 (3) 140 (4) 0.347 
Potassium (mmol/L) 4.1 (0.4) 4.1 (0.6) 0.922 4.1 (0.4) 4.1 (0.5) 0.028 
Urea (mmol/L) 4.8  (1.5) 5.1 (1.2) 0.143 4.6 (1.6) 5.1 (1.7) <0.001 
Creatinine (μmol/L) 66.8 ± 9.4 75.2 ± 17.0 0.028 65 (13) 65 (12) 0.416 
       
Current Hypertension 81/300 (27%) 13/25 (52%) 0.008 351/4631 (7.6%) 47/187 (25.1%) <0.001 
Current Diabetes 8/300 (2.7%) 5/25 (20%) <0.001 49/4631 (1.1%) 10/187 (5.3%) <0.001 
Current smoker 40/298 (13.4%) 7/25 (28%) 0.047 840/4591 (18.3%) 46/186 (24.7%) 0.027 
 
 
BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, HDL = high density lipoprotein. 
† p-value is for independent samples t-test if continuous data normally distributed, and Mann-Whitney U test if continuous data not normally distributed. Chi-
squared test or Fisher’s exact test results are given for categorical data. 
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Further analysis of parous women revealed that amongst the 218 women with 
cardiovascular events (see Table 3.6), there were generally no significant differences in 
anthropometric or biochemical measurements in those with pre-eclampsia vs those with 
normotensive pregnancy, except for a significantly higher creatinine in women with pre-
eclampsia. On Chi-squared analysis, those with a history of pre-eclampsia had a 
significantly higher proportion with a current diagnosis of hypertension or diabetes. In 
women who had not experienced any cardiovascular events (N=5,035) women with pre-
eclampsia had a significantly higher BMI, SBP, DBP and heart rate later in life. Chi-
squared analysis also revealed a higher proportion of currently hypertensive and diabetic 
women in the pre-eclampsia group. There were a significantly higher proportion of current 
smokers in the normotensive group in comparison with the pre-eclampsia group (Table 
3.6). 
When grouping the 5,253 parous women differently and dividing them up by pre-
eclampsia status (pre-eclampsia N=331 vs normotensive N=4,922) it was then possible to 
analyse differences between those with cardiovascular events vs no cardiovascular events 
(Table 3.7). In the pre-eclampsia group N=331, there was a significantly higher creatinine 
in women with a cardiovascular event and women with a cardiovascular event also had a 
significantly higher proportion of current diagnosis of hypertension and diabetes and 
significantly more were current smokers in comparison with pre-eclamptic women who 
had not experienced a cardiovascular event since pregnancy. However, women in the 
cardiovascular event group were statistically significantly older at time of recruitment to 
Generation Scotland than those who did not experience a cardiovascular event. 
In the group of women who did not experience pre-eclampsia (N=4,922) the age at time of 
recruitment to Generation Scotland was also statistically significantly different, with 
women in the cardiovascular event group (N=193) being older at time of recruitment. 
These women had significantly higher BMI, SBP and DBP than women without any 
cardiovascular events and they also had a higher glucose. Higher proportions of women in 
the cardiovascular event group had current diagnosis of hypertension, diabetes and were 
more likely to be current smokers (Table 3.7), a similar pattern to the pre-eclampsia group 
described above.  
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 Summary of cardiovascular event data 3.3.3
 
The number of entries for each individual cardiovascular diagnosis is presented in Table 
3.9. A cardiovascular event code denotes the main cardiovascular diagnosis for that 
specific hospital admission. Some people had more than one hospital admission with a 
cardiovascular event. In the 333 nulliparous women with cardiovascular events there were 
909 separate cardiovascular admissions. Of the 218 parous women with cardiovascular 
events there were 634 separate hospital admissions, and in the 25 women with 
cardiovascular event after a pregnancy complicated by pre-eclampsia, there were 57 
hospital admissions. 
 
As Table 3.9 shows, there were cardiovascular events in 9% of women who never had a 
pregnancy, 4.2% of women with pregnancies, and in 7.6% of women with a history of pre-
eclampsia in pregnancy. A Chi-squared test confirms a statistically significant difference in 
cardiovascular events between nulliparous women and women with at least one pregnancy, 
with test statistic 88.87 and p-value <0.001 (see Table 3.8).  
 
Table 3.8 Comparison of cardiovascular events in nulliparous vs parous women 
 
 Never pregnant Pregnant 
Cardiovascular event ever 333 218 
No cardiovascular event ever 3,360 5,035 
Total 3,693 5,253 
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Table 3.9 Summary of SMR01 data: Cardiovascular events described by ICD-9 and ICD-10 category 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CV = cardiovascular.  * This describes the main cardiovascular diagnosis per cardiovascular event entry in the SMR01 data and each time one code was used equates to a 
cardiovascular admission. The total cardiovascular events in the totals column is therefore the total number of separate cardiovascular admissions to hospital for that 
column.    
Description of CV event* 
 
ICD 9 
codes 
ICD 10 
codes 
Breakdown of CV 
events in the 
333/3,693 (9%) of 
never pregnant 
women who had CV 
events 
Breakdown of CV 
events in the 
218/5,253 (4.2%) of 
all pregnant women 
who had CV events 
Breakdown of CV 
events in the 25/331 
(7.6%) of women with 
pre-eclampsia who had 
CV events 
Rheumatic heart disease 390-398 I00-09 4 4 0 
Hypertensive diseases 401-405 I10-15 25 22 8 
Ischaemic heart disease 410-414 I20-25 434 195 11 
Pulmonary heart diseases 415-417 I26-28 31 32 2 
Other forms of heart disease 420-429 I30-52 212 132 21 
Cerebrovascular diseases 430-438 I60-69 76 84 10 
Diseases of arteries, arterioles 
and capillaries 
440-448 I70-79 116 160 5 
Other and unspecified 
circulatory disorders  
459 I95-99 11 5 0 
  Total CV 
events by 
code 
909 634 57 
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Graphical presentation of individual cardiovascular events in the pregnancy group revealed similar 
patterns for all cardiovascular events and first cardiovascular event (see Figures 3.3-3.6).  
Comparison of these pie charts of first cardiovascular event reveals that generally the types of 
cardiovascular diagnoses were ischaemic heart disease, other forms of heart disease, 
cerebrovascular disease and diseases of the arteries, arterioles and capillaries. In the 25 women 
with cardiovascular event after pre-eclampsia, hypertensive diseases also featured in the 
commonest first cardiovascular events documented.  
Chi-squared test (see Table 3.10) revealed a statistically significant difference in cardiovascular 
events between women with pre-eclampsia and those with a normotensive pregnancy, chi-test 
statistic 10.283, p-value 0.0013. 
 
Table 3.10 Comparison of cardiovascular events in women with pre-eclampsia vs 
normotensive pregnancy 
 No pre-eclampsia Pre-eclampsia 
Cardiovascular event ever 193 25 
No cardiovascular event ever 4,729 306 
Total 4,922 331 
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 Figure 3.3 Summary of all 634 cardiovascular events in the 218 women with 
 cardiovascular events after pregnancy  
 
 
 Figure 3.4 Summary of all 57 cardiovascular events in the 25 women with 
 cardiovascular events after pre-eclampsia  
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disease
Cerebrovascular disease
Diseases of the arteries &
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 Figure 3.5 First cardiovascular event in the 218 women with cardiovascular 
 events after pregnancy  
 
 Figure 3.6 First cardiovascular event in the 25 women with cardiovascular 
 events after pre-eclampsia 
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 Survival analysis 3.3.4
For survival analysis, as before, index pregnancy was defined as either first pregnancy in 
normotensive controls, and first pre-eclamptic pregnancy (by ICD-9 or ICD-10 definition) 
in cases. Admission to hospital with first cardiovascular event (as defined by ICD-9 and 
ICD-10 coding in Table 3.9) was the endpoint of interest. In subjects who did not 
experience the endpoint of interest, censoring occurred either when the end of the study 
was reached (1
st
 July 2013) or if they experienced death from a non-cardiovascular 
admission diagnosis. There were two deaths from cancer during the follow-up period, both 
in the normotensive group, and they were censored accordingly.  
Out of a total of 5,253 women, there were 25 cardiovascular events in 331 women with 
pre-eclampsia (306 women were censored). There were 193 cardiovascular events in 4,922 
women with normotensive pregnancies (4,729 were censored). There was a statistically 
significant difference between women with a history of pre-eclampsia and those with 
normotensive pregnancy on Kaplan-Meier survival analysis, with log rank Mantel-Cox p-
value <0.001. (Figure 3.7).  
 
Figure 3.7 Kaplan-Meier curve for time to cardiovascular event in pre-eclampsia vs 
normotensive pregnancies 
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Further survival analysis was performed after correction for possible confounders: multiple 
pregnancies, low birth weight (<2,500g), birth at gestation <37weeks. Data were prepared 
by removal of the following numbers of subjects; 277 with low birth weight (<2500g), then 
107 with pre-term delivery (<37weeks gestation) then 35 with multiple gestation 
pregnancies. This left a total of 4,834 women (270 with pre-eclampsia and 4,564 with 
normotensive pregnancies). A total of 169 cardiovascular events occurred in the 
normotensive group, and 4,395 subjects were censored. In the pre-eclampsia group there 
were 20 cardiovascular events and 250 subjects were censored. Repeat survival analysis 
revealed the same significant results (p=0.001). Kaplan-Meier curve is seen in figure 3.8. 
  
Figure 3.8 Kaplan-Meier curve for time to cardiovascular event in pre-eclampsia 
cases and normotensive controls in women following exclusion of possible 
confounders 
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 Cox Proportional Hazards  3.3.5
 
In order to further investigate the effects of traditional cardiovascular risk factors on 
cardiovascular events, it was possible to incorporate such data, already linked through 
Generation Scotland. Using a Cox Proportional Hazards model, smoking, diabetes and 
BMI at time of recruitment to the Generation Scotland study were all found to be 
significantly associated with an increased risk of cardiovascular event, as was pre-
eclampsia itself (see Table 3.11 for individual hazard ratios and 95% confidence intervals). 
 
  
Table 3.11 Cox proportional hazards model for cardiovascular risk factors 
 Hazard ratio (95% CI) P-value 
Pre-eclampsia 2.051 (1.335, 3.152) 0.001 
Age (yrs) 1.004 (0.983, 1.025) 0.707 
BMI (kg/m
2
) 1.034 (1.011, 1.058) 0.003 
SBP (mmHg) 1.004 (0.995, 1.012) 0.378 
Diabetes 3.078 (1.749, 5.416) <0.001 
Current smoking 1.683 (1.220, 2.320) 0.001 
 
On comparison of birth characteristics pre-eclampsia was found to have a two-fold 
increased risk of cardiovascular event (p=0.001).  (Table 3.12).  
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Table 3.12 Cox proportional hazards model for birth characteristics 
 
 Hazard ratio (95% CI) P-value 
Pre-eclampsia 2.001 (1.305, 3.069) 0.001 
Age at index pregnancy 
(yrs) 
1.018 (0.989, 1.048) 0.223 
Birth weight at index 
pregnancy 
1.000 (0.999, 1.000) 0.044 
Gestation at delivery index 
pregnancy   
1.004 (0.926, 1.089) 0.925 
C-section 1.383 (0.967, 1.977) 0.076 
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 Discussion 3.4
 
 Findings 3.4.1
 
The main findings of this study were: 1) nulliparous women had a higher blood pressure 
and greater risk of cardiovascular event than parous women, 2) women with a history of 
pre-eclampsia had a higher blood pressure and greater risk of cardiovascular events later in 
life than women with normotensive pregnancies, 3) women with a history of pre-eclampsia 
experienced earlier gestational age at delivery and were more likely to have a caesarean 
section birth, and 4) on survival analysis, women with a history of pre-eclampsia were 
more likely to have a cardiovascular event later in life than women with normotensive 
deliveries. Women with a history of pre-eclampsia were found to have a lower birth weight 
than those with a normotensive pregnancy, however, on adjusting birth weight for 
gestational age the difference in birth weight was no longer significant. 
 
 Strengths 3.4.2
 
An important strength of this study is the use of ICD classification (which is standardised 
and used by most other studies in this field) and SMR01 and SMR02 data as opposed to 
questionnaires for information regarding cardiovascular and maternity diagnoses. This 
study does not depend on recall of participants many years after the event and is therefore 
not subject to this form of bias. Furthermore, the Scottish Information Services Division 
data undergo quality assessment and are therefore more likely to be reliable for 
retrospective studies than individual maternity record check. In addition, depending on 
which health board the maternity data relates to, searching through case notes of 
pregnancies >25 years ago can prove problematic as some records may have been 
destroyed.   
 
For the purposes of this study only pre-eclamptic pregnancies were included as cases, not 
general hypertensive disorders of pregnancy, because they potentially differ in precise 
pathophysiology. Thus, rigorous exclusion of any pregnancy which was not deemed to 
qualify in ICD classification as pre-eclampsia was pursued. Rigorous exclusion of any 
“non-normotensive” pregnancy was also applied to the control group to make sure it did 
not incorporate any pregnancy which had any element of hypertensive disorder, mild, 
transient or otherwise. Other studies in this area have not consistently gone to such lengths 
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to exclude these milder conditions, whilst others have combined pre-eclampsia/eclampsia 
with other hypertensive disorders of gestation.  
 
Another strength of this study was the ability to evaluate cardiovascular events in 
nulliparous women in addition to those with pre-eclampsia and normotensive pregnancies. 
Previous studies investigating parity and risk of cardiovascular disease and mortality later 
in life have provided inconsistent results (99;365;368;370-372;378-381). In the COPS 
record-linkage study nulliparous women had a higher risk of cardiovascular event than 
parous women. A recent meta-analysis of cohort studies (372) investigated parity and 
cardiovascular disease mortality included ten prospective studies with a total of 994,810 
participants and 16,601 cardiovascular events. This study found a borderline significant 
reduction in risk of cardiovascular disease mortality in ever parity vs nulliparous women 
(RR=0.79, 95% CI: 0.60-1.06). While higher fertility may be representative of generally 
healthier women, and other lifestyle factors must also be taken into consideration when 
comparing nulliparous women with parous such as anxiety or fear of having children 
which might also contribute to the increased cardiovascular mortality risk in the 
nulliparous group (372).  
 
Other important considerations at the outset of this work were whether to investigate data 
on mortality or cardiovascular events themselves. The decision to use cardiovascular 
events as the primary endpoint of interest extends current knowledge as to the different 
types of cardiovascular disease women with a history of pre-eclampsia are more likely to 
experience. In order to best direct future research and management strategies for 
cardiovascular disease prevention in women with a history of pre-eclampsia, and to be 
more vigilant as to what type of cardiovascular disease these women will be at greater risk 
of, it is important to appreciate which cardiovascular diseases these women are more likely 
to experience. Blood pressure was found to be higher later in life in women with a history 
of pre-eclampsia in comparison with normotensive women, however this information alone 
is not as advantageous as the additional information of which diseases of the 
cardiovascular system they are more likely to develop.   
 
 Limitations  3.4.3
 
This study only included women who had lived long enough to enrol in the Generation 
Scotland study, while women who exhibited cardiovascular events earlier in their lives and 
suffered a cardiovascular-related mortality are now dead. This is a form of bias. Also, these 
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women were participants in the Generation Scotland study. They may naturally have been 
healthier women or be more interested than average in their own health and general fitness 
and wellbeing since they actively sought to enrol in GS:SFHS.  
 
Due to size of study it was not possible to assess the effects of recurrent pre-eclampsia, nor 
was it possible to separate women with only one pregnancy from women with multiple 
pregnancies. A recent study (382) assessed recurrent pre-eclampsia in one of the largest 
cohorts studied to date, with 606,820 women with two or more deliveries and 501,761 
women with one delivery. Similar to the study described in this chapter, their study 
included both liveborn and stillborn deliveries, and only included pregnancies extending 
past 20 weeks (as pre-eclampsia can only be diagnosed after this time). Recurrent pre-
eclampsia was associated with a higher risk of future hospitalisation with cardiovascular 
event and also with significantly shorter time to first event. It also found that pre-eclamptic 
women with only one delivery were at almost the same risk of cardiovascular hospital 
admission as those with recurrent pre-eclampsia.   
 
Miscarriage has been found in the literature to itself carry a risk of cardiovascular events 
later in life (383). Similarly stillbirth, which has been counted as first delivery in other 
large studies (83) may also carry additional risk of cardiovascular events and could thus 
potentially bias results (383). In this population-based prospective (EPIC) cohort study of 
11,518 women (in Heidelberg, Germany), mean follow-up was 10.8 years. With each 
miscarriage, the risk of myocardial infarction (MI) increased more than 40%. There was 
also a >3.5-fold increased risk of MI with a history of stillbirth.  
  
The COPS linkage study would have been underpowered to examine the effects of 
different types of pre-eclampsia e.g. classification by gestational age (early onset vs late 
onset). However, it is important to consider how to combine studies (which have this 
information available) in the future, to add more power to studies investigating the 
possibility of different pathophysiological mechanisms of cardiovascular risk for the 
different classifications of pre-eclampsia which are emerging.  
 
 Conclusions 3.4.4
 
The findings of this study support an association between pre-eclampsia and later 
cardiovascular disease. Pre-eclampsia, along with other traditional cardiovascular risk 
factors such as smoking and diabetes, was found to increase the risk of future 
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cardiovascular disease significantly. Even in the absence of other cardiovascular risk 
factors, if a woman has a personal history of pre-eclampsia, she may benefit from early 
cardiovascular disease screening.  
 
There is little guidance on when screening for cardiovascular disease should begin in 
women with a history of pre-eclampsia, or the nature of what this screening should be. 
Future longitudinal studies monitoring blood pressure and other non-invasive 
cardiovascular assessment methods may inform the likeliest age of onset of early 
cardiovascular disease in these women. Otherwise, it is difficult to confirm the exact length 
of time after pre-eclamptic pregnancy that women start to exhibit features of their 
increased cardiovascular risk. Obviously, having identified that these women are at 
increased cardiovascular risk, prevention of cardiovascular endpoints is of the utmost 
importance. Monitoring of the intermediate cardiovascular phenotype will be important, in 
order to facilitate timely intervention and prevent serious disease.  
 
It remains clear that there is lack of consistency between epidemiological studies and their 
methods, therefore improved standardisation of approach would be better for future large 
studies and the possible integration of existing datasets.
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4 The ECG in women with a history of pre-eclampsia 
 
 Introduction 4.1
 
The increased risk of cardiovascular disease later in life in women with a history of pre-
eclampsia has several proposed mechanisms. One important finding, confirmed in the 
studies presented in this thesis, is that women with a history of pre-eclampsia are more 
likely to have a higher blood pressure later in life. In a recent study by Behrens et al (86), 
the risk of hypertension following hypertensive pregnancy disorders was found to be 
higher than in women with normotensive pregnancies in the immediate post-partum period 
and this difference remained and was still present at 20 years post-partum. Hypertension in 
pregnancy is a risk factor for adverse cardiac remodelling and in a study of women later in 
life (mean age 56 years), 427 women with a history of hypertensive pregnancy were 
compared with 2210 women with normotensive pregnancy. Those with a history of 
hypertensive pregnancy were found to have evidence of left ventricular hypertrophy after 
adjusting for age, ethnicity, BMI, hypertension, diabetes, parity and education (205). 
However, after the length of time of hypertension was considered, the relationship was no 
longer significant.  
 
Previously held beliefs that the immediate effects of hypertensive pregnancy on the heart 
regressed postpartum have been challenged (202;205). In addition a study by Ray et al 
found evidence that at 8 years post-partum, women with a history of maternal placental 
syndromes (including pre-eclampsia) at index pregnancy were at an increased risk of 
developing heart failure and dysrhythmias than women without maternal placental 
syndromes (217).  
 
Taking into consideration the above findings, possible mechanisms for left ventricular 
hypertrophy (LVH) following hypertensive pregnancy include longer exposure to 
hypertension in general in these women, or possibly the persistence of cardiac changes 
themselves following hypertensive pregnancy, which go unnoticed due to blood pressure 
settling in the immediate post-partum period.  
 
Hypertension after pre-eclampsia has been found to be preceded by changes in cardiac 
structure and function in a study by Ghossein-Doha et al (201). Formerly pre-eclamptic 
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women who were initially normotensive but developed hypertension within the 12 years 
following the pregnancy were found to have had an increased left ventricular mass index  
and decreased diastolic dysfunction when they were screened during the post-partum 
screening period in comparison with normotensive formerly pre-eclamptic women.  
 
The electrocardiogram (ECG) is a routinely used tool which can be used to detect evidence 
of cardiovascular risk. It has previously been used in the risk prediction of hypertensive 
patients (215;216;384). A study by Raffaelli et al (213) revealed that pregnant women with 
pre-eclampsia had a lower heart rate and significantly longer P wave duration, QT interval 
and QTc interval in comparison with a control group of women with normotensive 
pregnancies. They also had a higher QT dispersion (QTd). On further subgroup analysis, 
dividing pre-eclampsia into early-onset vs late-onset, there were no significant differences 
in any of the ECG parameters. In an earlier study by Hoogsteder et al (385), firstly, 658 
women with a recent history of pre-eclampsia were screened with an ECG for any 
abnormalities and 23 were found to have clinically relevant findings, with 13 having 
evidence of ischaemic heart disease. The group then went on to evaluate whether 
primiparous women with early-onset pre-eclampsia, who went on to develop recurrent pre-
eclampsia in a subsequent pregnancy, were different from women who had a normal 
second pregnancy. These women were found to have statistically significantly more 
leftward deviation of P-axis and R-axis and a longer QTc on ECG in comparison with 
women who had a normal subsequent pregnancy.  
 
A prolonged QTc interval (generally considered to be >450ms in women) is of significance 
due to associated risks of arrhythmia and sudden cardiac death (386). Women, especially, 
are at an increased risk of life-threatening arrhythmias such as Torsades de Pointes when 
on medications which might prolong the QT interval (387). There are many medications 
which can prolong the QT interval such as antibiotics (e.g. moxifloxacin, erythromycin), 
antihistamines (e.g. terfenadine), antidepressants (e.g. amitriptyline) and antipsychotics 
(e.g. citalopram). Comprehensive lists of medications which can prolong the QT interval 
are available online on such websites as http://sads.org.uk/drugs-to-avoid/. Some of these 
websites are aimed at people with conditions such as congenital long QT syndrome, for 
whom the risks of adverse events are greater and who should check, before starting any 
medication, whether it has any effect on the QT interval. In the context of pre-eclampsia, 
one important medication which may prolong the QT interval is magnesium sulphate 
(211). This further complicates interpretation of QT interval findings in studies of QT 
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interval at time of delivery in women with pre-eclampsia and is mentioned as a limitation 
in the interpretation of data in the study by Raffaelli et al (213).  
 
LVH itself is considered to be evidence of target organ damage in arterial hypertension and 
has been found to alter conduction and repolarization of the ventricle (388). In the 
“Losartan Intervention for Endpoint Reduction in Hypertension (LIFE)” study, in a 
hypertensive risk population with left ventricular hypertrophy, mortality risk was further 
stratified by increased QRS duration and maximum QTapex interval (388). In considering 
determinants of QRS axis, there is evidence that as BMI increases, QRS axis shifts from 
rightward to leftward, and BMI should be noted when performing assessment for left 
ventricular hypertrophy (389). 
 
A relatively small study by Murphy et al (390) sought to determine the effect of normal 
pregnancy on late trimester and postpartum ECG parameters and effects of pre-eclampsia 
on postpartum ECG parameters. P-wave and QRS duration were not affected by 
uncomplicated pregnancy, however, 20 women with a history of pre-eclampsia exhibited 
significantly longer P-wave and QRS duration in comparison with 15 never pregnant and 
20 normotensive pregnant controls in the postpartum period (390). A persistently increased 
blood pressure, prolonged P-wave and QRS duration were noted at 5-10 weeks and 6-8 
months after pre-eclampsia, however, after adjusting for blood pressure the differences in 
P-wave duration resolved. The significant QRS conduction delay at 6-8 months postpartum 
in women with a history of pre-eclampsia predisposes to an increased risk of cardiac 
arrhythmia in these women. 
 
To date, on review of the literature by the author, no studies appear to have investigated 
ECG parameters in nulliparous vs parous women later in life. In Chapter 3, nulliparous 
women were found to be at greater risk of cardiovascular events later in life than parous 
women in the Generation Scotland cohort. The literature in general yields varying results 
regarding parity and risk of cardiovascular disease later in life. This area warrants further 
attention. Reasons for nulliparity vary considerably, and it is possible that different cohorts 
of nulliparous women in different studies are exposed to different confounders overall 
which are influencing the results and influencing their cardiovascular risk. It is not always 
possible to correct for all confounders on statistical analysis. Clinical and ECG parameters 
may serve to identify possible mechanisms for the increased risk identified in these 
women.  
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The aims of this study were to determine: 
 
1) whether there was any evidence on ECG for the increased risk of cardiovascular events 
which was identified in nulliparous vs parous women in the Generation Scotland cohort in 
chapter 3.  
 
2) whether women with a remote history of pre-eclamptic pregnancy had any evidence of 
LVH, atrial abnormality or increased risk of arrhythmia based on ECG parameters in 
comparison with women with a history of normotensive pregnancy. 
 
 Methods 4.2
 
Clinical information, maternity information and ECGs were available from Generation 
Scotland as part of the record linkage study described in chapter 3, with ethical approval as 
described in chapter 2. Here in chapter 4, the available data from the ECGs was explored 
further.  
 
During the Generation Scotland study visit a 12-lead resting ECG was recorded by the 
Atria 6100 system (Burdick, Cardiac Science Corporation, Bothell, WA, USA). Any 
serious abnormalities of the ECG were followed up as necessary according to Generation 
Scotland study protocols. Information from the Atria 6100 was analysed centrally at the 
ECG core lab, Glasgow Royal Infirmary using the “Glasgow ECG analysis program”. 
ECGs were confirmed and paper copies were sent back to the Generation Scotland co-
ordinating centre. Digital results data was sent in plain text format to the Robertson Centre 
for Biostatistics, University of Glasgow. Information on ECG parameters, Minnesota code 
classifications (210), left ventricular mass index (LVMI) and measures of LVH were 
reported.  
 
For the purposes of this study, heart rate, P-axis, QRS-axis, T-axis, P wave duration, QRS 
duration, PR interval, QT interval and QTc interval were analysed. Measures for left 
ventricular hypertrophy included LVMI Rautaharju (391), Cornell voltage (392), Cornell 
product (393) and Sokolow-Lyon criteria (394). These had already been calculated on the 
ECGs at the ECG core lab according to the following formulae: 
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LVMI Rautaharju (white women): 88.5 + 0.018(RV5) + 0.053(SV5) – 0.112(SI)  
    + 0.108(TposV1) + 1.70(TnegaVF) – 0.094(TposV6) 
 
Cornell voltage (female):  RaVL + SV3 > 2000 μV  
 
Cornell product:  (RaVL + SV3) x QRS duration >244 mV.ms 
 
Sokolow-Lyon criteria: SV1 + RV5 or V6 > 3500 μV  
 
RV5 = amplitude of R wave in lead V5, SV5 = amplitude of S wave in lead V5,       
TV1 = amplitude T wave in lead V1, TaVF = amplitude of T wave in lead aVF,      
TV6 = amplitude of T wave in lead V6, RaVL = amplitude of R wave in lead aVL, 
SV3 = amplitude of S wave in V3,  SV1 = amplitude of S wave in V1 
 
The QTc intervals available from the Generation Scotland data used Hodges correction 
method. Hodges = QT interval +1.75 (heart rate-60).  
 
 Statistical analysis 4.2.1
 
Statistical analyses were performed using Minitab v17 (Minitab Inc, State College, PA, 
USA) and SPSS v22 (IBM Corp, Armonk, New York, USA). Normality of distribution 
was assessed using the Kolmogorov-Smirnov test and visual inspection of histograms and 
plots. Data are expressed as mean ± standard deviation unless otherwise stated. Data which 
were not normally distributed were transformed and non-parametric tests were used if data 
did not normalise on transformation. Independent samples t-test was carried out on 
normally distributed data and the Mann-Whitney U test was used for non-parametric data. 
Comparison of categorical data was performed using Chi-squared test, or Fisher’s exact 
test as appropriate. Multiple linear regression was used to further investigate ECG 
parameters. A p-value of <0.05 was considered significant. 
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 Results 4.3
 
 Comparison of ECGs in all GS:SFHS women: nulliparous vs parous 4.3.1
 
There were 8820 women with ECGs available in Generation Scotland. Of them 3641 were 
nulliparous and 5179 had one or more children. Women who did not have children had a 
statistically significantly higher BMI, blood pressure and heart rate, however, numerically 
these differences were small (Table 4.1). They had a more leftward P-axis, QRS-axis and 
T-axis in comparison with parous women. P wave duration was longer and PR interval and 
corrected QT interval (Hodges) were also significantly longer (Table 4.2). 
 
Table 4.1 Comparison of clinical parameters in nulliparous vs parous women in 
Generation Scotland 
 Nulliparous (n=3641) Parous (n=5179) P-value 
Age (yrs) 49±18 47±11 <0.001 
BMI (kg/m
2
) 26.8±5.8 26.3±5.4 0.001 
SBP mmHg 131±19 126±17 <0.001 
DBP mmHg 78±10 78±10 <0.001 
HR bpm 65±10 64±10 0.001 
All measurements are given as mean ±SD. Comparison is by independent t-test for normally 
distributed data and Mann-Whitney U test for non-parametric data. BMI = body mass index, 
SBP= systolic blood pressure, DBP= diastolic blood pressure, BW= birth weight, HR= heart 
rate, LVMI= left ventricular mass index.  
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Table 4.2 Comparison of ECG parameters in nulliparous vs parous women in 
Generation Scotland 
 Nulliparous 
(n=3641) 
Parous  
(n=5179) 
P-value 
P-axis 39±28 41±26 <0.001 
QRS-axis 33±32 37±30 <0.001 
T-axis 36±23 36±20 0.007 
P duration (ms) 105±14 105±13 0.019 
QRS duration (ms) 87±11 87±10 0.974 
PR interval (ms) 160±25 159±23 0.046 
QT interval (ms) 408±32 408±30 0.908 
QTc Hodges (ms) 417±23 415±21 0.007 
 (n=1826) (n=2806)  
LVMI Rautaharju (g/m
2
) 89.4±30.2 89.5±28.9 0.248 
Cornell voltage (μV) 1550±479 1538±440 0.955 
Cornell product (mV.ms) 134.6±49.7 133.9±45.3 0.745 
Sokolow-Lyon (μV) 1989±589 1989±571 0.945 
All measurements are given as mean ±SD. Comparison is by independent t-test for normally 
distributed data and Mann-Whitney U test for non-parametric data. LVMI= left ventricular mass 
index.  
 
Table 4.3 Comparison of subjects meeting criteria for LVH and prolonged QTc in 
nulliparous vs parous women in Generation Scotland 
 Nulliparous  Parous  
 
P-value 
Number fulfilling Cornell 
voltage criteria for LVH 
(>2000 μV) 
272/1826 
(14.9%) 
372/2806 
(13.3%) 
0.115 
Number fulfilling Cornell 
product criteria for LVH 
(>244mV.ms) 
50/1825   
(2.7%) 
53/2803 
(1.9%) 
0.056 
Number fulfilling Sokolow-
Lyon criteria for LVH (>3500 
μV) 
27/1822 
(1.5%) 
35/2800 
(1.3%) 
0.503 
Number with QTc >450ms 309/3638 
(8.5%) 
341/5172 
(6.6%) 
0.001 
 
 
Chapter 4  120 
 
1
2
0
 
 
The number of women who fulfilled Cornell and Sokolow-Lyon criteria for left ventricular 
hypertrophy was greater in the nulliparous group but this was not statistically significantly 
different (Table 4.3). The number of women fulfilling criteria for longer QTc interval was 
significantly higher in the nulliparous group.  
 
 Minnesota classifications 4.3.1.1
 
There were significant differences between groups in Minnesota code classification for left 
bundle branch block (nulliparous 17/3439 (0.5%) vs parous 8/4893 (0.2%), p=0.007), right 
bundle branch block (nulliparous 20/3439 (0.6%) vs parous 9/4893 (0.2%), p=0.002) and 
atrial fibrillation (nulliparous 30/3439 (0.9%) vs parous 6/4893 (0.1%), p=<0.001). Other 
differences were not significant (Table 4.4). 
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Table 4.4 Minnesota code classifications in nulliparous vs parous women 
 
Minnesota code 
classification 
Nulliparous Parous P-value 
IHD 272/3439 (7.9%) 381/4893 (7.8%) 0.838 
LVH 28/3439 (0.8%) 24/4893 (0.5%) 0.065 
Complete HB 1/3439 (0.03%) 0/4893 (0%) 0.413 
Type II HB 41/3439 (1.2%) 42/4893 (0.9%) 0.131 
WPW 2/3439 (0.06%) 4/4893 (0.08%) 1.000 
Short PR interval 2/3439 (0.06%) 4/4893 (0.08%) 1.000 
PPM 3/3439 (0.09%) 0/4893 (0%) 0.070 
LBBB 17/3439 (0.49%) 8/4893 (0.16%) 0.007 
RBBB 20/3439 (0.58%) 9/4893 (0.18%) 0.002 
LAHB 7/3439 (0.20%) 3/4893 (0.06%) 0.104 
IVCB 12/3439 (0.35%) 12/4893 (0.25%) 0.385 
APC 35/3439 (1.02%) 37/4893 (0.76%) 0.204 
VPC 8/3439 (0.23%) 5/4893 (0.10%) 0.137 
AFIB 30/3439 (0.87%) 6/4893 (0.12%) <0.001 
Atrial Flutter 0/3439 (0%) 0/4893 (0%) N/A 
 
IHD=ischaemic heart disease, LVH=left ventricular hypertrophy, HB=heart block, WPW=Wolff-
Parkinson White syndrome, PPM=pacemaker, LBBB=left bundle branch block, RBBB= right bundle 
branch block, LAHB=left anterior hemi-block, IVCB=intra-ventricular conduction block, APC=atrial 
premature complexes, VPC=ventricular premature complexes, AFIB=atrial fibrillation. P-values from 
Chi-squared test or Fisher’s exact test as appropriate. 
 
 Further analysis of QTc  4.3.1.2
 
In order to obtain a true perspective on whether or not the QTc interval was genuinely 
different between groups, as many possible influences on the QT interval (confounders) 
were removed as possible. Any ECGs with abnormal Minnesota codes were removed and 
women taking any potentially QT prolonging medications were removed from the analysis.  
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Of the 8820 ECGs available, 945 were removed due to abnormalities on Minnesota coding, 
3424 were removed because the women were on potentially QT-prolonging medication 
and 1536 were removed as their medication status was unknown. This left a total of 2915 
women with ECGs (1252 in the nulliparous group and 1663 in the parous group) (Table 
4.5). 
 
Systolic blood pressure and heart rate were significantly higher in nulliparous women, and 
P-axis was significantly more leftward but there were no other significant differences in 
any of the ECG parameters. However, the general trends were the same as before.   
 
Table 4.5 Further analysis following ECG exclusions 
 Nulliparous women 
(n=1252) 
Parous women 
 (n=1663) 
P-value 
Age (yrs) 47±18 47±11 0.843 
BMI (kg/m
2
) 26.1±5.3 26.1±5.2 0.682 
SBP (mmHg) 130±19 126±17 <0.001 
DBP (mmHg) 79±10 78±10 0.411 
HR (bpm) 66±10 65±10 0.030 
P-axis (
o
) 39±27 41±27 0.031 
QRS-axis (
o
) 36±31 36±30 0.440 
T-axis (
o
) 35±21 36±20 0.271 
P wave duration (ms) 105±14 104±13 0.997 
QRS duration (ms) 86±9 86±8 0.410 
PR interval (ms) 158±23 158±22 0.468 
QT interval (ms) 405±31 407±30 0.086 
QTc Hodges (ms) 415±22 415±21 0.642 
 
All measurements are given as mean ±SD. Comparison is by independent t-test for normally 
distributed data and Mann-Whitney U test for non-parametric data. BMI = body mass index, SBP= 
systolic blood pressure, DBP= diastolic blood pressure, HR= heart rate, QTc=corrected QT interval.  
 
 Comparison of ECGs in women with a history of normotensive 4.3.2
pregnancy vs pre-eclampsia 
 
Women with a history of pre-eclampsia had a significantly higher BMI, SBP and DBP.  
Birth weight at index pregnancy and gestational age at index pregnancy were significantly 
lower (Table 4.6). Heart rate was significantly higher and QRS-axis and T-axis were 
different showing a more leftward axis deviation in comparison with normotensive women. 
QTc interval (Hodges) approached statistical significance (p= 0.054). Multiple regression 
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analysis was performed with QTc Hodges as the dependent variable and pre-eclampsia 
status and other variables which were significantly different between groups included in 
the analysis (age, HR, BMI, SBP, birth weight at index pregnancy, gestation at index 
pregnancy, QRS-axis and T-axis). Overall the model was statistically significant p=<0.001 
and F=64.420. Pre-eclampsia was of borderline significance in predicting QTc Hodges 
while adjusting for all other variables (p=0.052), and age, HR, SBP, QRS-axis and T-axis 
were all statistically significant at p=<0.001. While the trend for LVMI Rautaharju and 
Cornell voltage were higher, these differences were not statistically significant (Table 4.7). 
 
 
Table 4.6 Comparison of clinical parameters between women with a history of pre-
eclamptic pregnancy and normotensive pregnancy 
 
 Normotensive 
controls 
(n=4853) 
Pre-eclampsia 
(n=326) 
P-value 
Age (yrs) 46±11 48±9 0.005 
BMI (kg/m
2
) 26.2±5.3 27.9±6.2 <0.001 
SBP mmHg 125±17 132±16 <0.001 
DBP mmHg 77.5±10 83±9 <0.001 
BW at index pregnancy (g) 3385±544 3213±703 <0.001 
Gestation at index pregnancy 
(wks) 
39.6±1.9 38.7±2.4 <0.001 
Age at index pregnancy (yrs) 27±5 27±5 0.331 
Years since index pregnancy 
(yrs) 
23.5±11.3 25.1±7.4 0.664 
 
All measurements are given as mean ±SD. Comparison is by independent t-test for normally 
distributed data and Mann-Whitney U test for non-parametric data. BMI = body mass index, SBP= 
systolic blood pressure, DBP= diastolic blood pressure, BW= birth weight. 
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Table 4.7 Comparison of ECG parameters between women with a history of pre-
eclamptic pregnancy and normotensive pregnancy 
 
 Normotensive 
controls 
(n=4853) 
Pre-eclampsia 
(n=326) 
P-value 
HR bpm 64±10 66±10 0.001 
P-axis (
o
) 41±27 41±24 0.260 
QRS-axis (
o
) 37±30 29±31 <0.001 
T-axis (
o
) 36±20 34±21 0.010 
P duration (ms) 104±13 105±13 0.058 
QRS duration (ms) 87±10 87±11 0.409 
PR interval (ms) 159±24 160±24 0.492 
QT interval (ms) 408±30 408±32 0.638 
QTc Hodges (ms) 415±21 418±23 0.054 
 (n= 2674) (n= 132)  
LVMI Rautaharju (g/m
2
) 89.4±29.2 90.6±22.6 0.304 
Cornell voltage (μV) 1535±440 1598±446 0.086 
Cornell product (mV.ms) 133.6±45.3 139.8±44.3 0.105 
Sokolow-Lyon criteria (μV) 1991±571 1950±555 0.418 
 
All measurements are given as mean ±SD. Comparison is by independent t-test for normally 
distributed data and Mann-Whitney U test for non-parametric data. HR= heart rate, LVMI= 
left ventricular mass index.  
 
There were no significant differences between the number of women in each group 
fulfilling ECG criteria for LVH. The Cornell voltage and the Sokolow-Lyon criteria 
denominator numbers are different for the normotensive group because the number of 
ECGs with that information available was different. A significantly higher number of 
women with pre-eclampsia fulfilled criteria for longer QTc interval (Table 4.8). 
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Table 4.8 Comparison of Generation Scotland subjects meeting criteria for LVH and 
prolonged QTc between women with a history of normotensive pregnancy vs pre-
eclampsia   
 Normotensive 
controls  
Pre-eclampsia  P-value 
Number fulfilling Cornell 
voltage criteria for LVH 
(>2000 μV) 
348/2674 (13%) 24/132 (18.2%) 0.087 
Number fulfilling Cornell 
product criteria for LVH 
(>244mV.ms) 
51/2671 (1.9%) 2/132 (1.5%) 1.000 
Number fulfilling Sokolow-
Lyon criteria for LVH (>3500 
μV) 
35/2668 (1.3%) 0/132 (0%) 0.409 
Number with QTc >450ms 310/4847 (6.4%) 31/325 (9.5%) 0.027 
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 Minnesota classifications 4.3.2.1
 
There were no significant differences between groups on Minnesota code classification. 
Table 4.9 details the precise breakdown of classifications.  
 
Table 4.9 Minnesota code classifications between women with a history of 
normotensive pregnancy vs pre-eclampsia 
 
Minnesota code 
classification 
Normotensive Pre-eclampsia P-value 
IHD 354/4588 (7.72%) 27/305 (8.85%) 0.473 
LVH 22/4588 (0.48%) 2/305 (0.66%) 0.659 
Complete HB 0/4588 (0%) 0/305 (0%) N/A 
Type II HB 39/4588 (0.85%) 3/305 (0.98%) 0.744 
WPW 4/4588 (0.09%) 0/305 (0%) 1.000 
Short PR interval 4/4588 (0.09%) 0/305 (0%) 1.000 
PPM 0/4588 (0%) 0/305 (0%) N/A 
LBBB 8/4588 (0.17%) 0/305 (0%) 1.000 
RBBB 9/4588 (0.20%) 0/305 (0%) 1.000 
LAHB 3/4588 (0.07%) 0/305 (0%) 1.000 
IVCB 11/4588 (0.24%) 1/305 (0.33%) 0.538 
APC 34/4588 (0.74%) 3/305 (0.98%) 0.500 
VPC 4/4588 (0.09%) 1/305 (0.33%) 0.275 
AFIB 5/4588 (0.10%) 1/305 (0.33%) 0.320 
Atrial Flutter 0/4588 (0%) 0/305 (0%) N/A 
IHD=ischaemic heart disease, LVH=left ventricular hypertrophy, HB=heart block, WPW=Wolff-
Parkinson White syndrome, PPM=pacemaker, LBBB=left bundle branch block, RBBB= right bundle 
branch block, LAHB=left anterior hemi-block, IVCB=intra-ventricular conduction block, APC=atrial 
premature complexes, VPC=ventricular premature complexes, AFIB=atrial fibrillation. P-values from 
Chi-squared test or Fisher’s exact test as appropriate. 
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 Further analysis of QTc 4.3.2.2
 
Of the ECGs in the 5179 women who had children, 510 were removed due to 
abnormalities on Minnesota code classification, 2073 were then removed due to potentially 
QT prolonging medications and 933 were removed due to unknown medication status and 
could therefore potentially have been on QT prolonging medication. This left a total of 
1663 women with ECGs for analysis of QTc interval (Table 4.10). 
 
Table 4.10 ECG analysis following exclusions in women with history of normotensive 
pregnancy vs pre-eclampsia  
 
 Normotensive 
pregnancy 
(n=1587) 
Pre-eclampsia 
(n=76) 
P-value 
Age (yrs) 47±11 49±9 0.082 
BMI (kg/m
2
) 26.0±5.2 28.1±5.8 0.001 
SBP (mmHg) 126±17 135±15 <0.001 
DBP (mmHg) 78±10 85±9 <0.001 
HR (bpm) 65±10 66±11 0.188 
P-axis (
o
) 41±27 39±22 0.314 
QRS-axis (
o
) 36±30 26±27 0.002 
T-axis (
o
) 36±20 31±18 0.033 
P wave duration (ms) 104±13 104±14 0.539 
QRS duration (ms) 86±8 86±8 0.672 
PR interval (ms) 158±22 158±23 0.720 
QT interval (ms) 407±30 407±32 0.951 
QTc Hodges (ms) 415±21 418±21 0.277 
All measurements are given as mean ±SD. Comparison is by independent t-test for normally 
distributed data and Mann-Whitney U test for non-parametric data. BMI = body mass index, SBP= 
systolic blood pressure, DBP= diastolic blood pressure, HR= heart rate, QTc=corrected QT interval.  
 
QTc interval was longer in the pre-eclampsia group, however this was not of statistical 
significance. BMI and blood pressure were significantly higher in the pre-eclampsia group 
and QRS-axis and T-axis were also significantly different between groups.  
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 Discussion 4.4
 
 Findings 4.4.1
 
Nulliparous women had higher BMI and blood pressure than parous women, and showed a 
more leftward cardiac axis on ECG. They also had a significantly longer P-wave duration, 
PR interval and QTc than parous women.  
 
In women with a history of pre-eclampsia in comparison with women who had a 
normotensive pregnancy there was also a significantly higher BMI, SBP and DBP. Birth 
weight and gestational age at index pregnancy were lower, heart rate was higher, and there 
was leftward axis deviation. QTc interval (Hodges) approached statistical significance (p= 
0.054). Some of these findings are in keeping with the previous literature (213;385). 
 
On analysis of ECG criteria for LVH, there was no statistically significant difference in the 
proportion of women fulfilling criteria when comparing groups based on parity or on 
presence or absence of pre-eclampsia. When comparing the proportion with a longer QTc 
(>450ms) there were statistically significant difference in both investigations, with 
nulliparous having a longer QTc than parous and women with a history of pre-eclampsia 
having a longer QTc than women with a normotensive pregnancy.  
 
It is not possible to know when these changes developed or if they were present before or 
during pregnancy. On the investigation of women who were nulliparous vs parous, it 
seems as though pregnancy was potentially a protective factor, although it is also possible 
that women with better baseline health were more likely to achieve pregnancy. 
 
 Strengths 4.4.2
 
There were a considerable number of ECGs available for analysis and on review of the 
literature this study is one of the largest ECG studies relating to hypertensive disorders of 
pregnancy described. This study is also analysing ECGs at a longer time-point after index 
pregnancy (>20years) than other similar studies in the literature and the variety of 
information allowed for comprehensive assessment. 
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To the best of the author’s knowledge the pre-eclampsia cases identified truly had pre-
eclampsia, and the normotensive controls were normotensive. In the preparation of the data 
for chapter 3 any women with ICD-8 (earlier) classification of pre-eclampsia but not ICD-
9 or ICD-10 classification of the condition had been excluded because it was thought that 
ICD-8 classification would be less reliable and they could not be “normotensive controls” 
if it was possible that they had experienced pre-eclampsia.  
 
 Limitations 4.4.3
 
Due to the nature of the ECG information given, and the fact that I did not personally 
review all paper copies of the ECGs, it was not possible to compare some ECG parameters 
with some of those in the literature which have been found to be of interest in women with 
a history of hypertensive disorder of pregnancy e.g. QT dispersion (QTd) or P-wave 
dispersion (Pd) (200;215).  
 
The total number of pregnancies was not taken into account, and this could potentially 
have biased the results. For example, a woman with only one lifetime pregnancy has a 
different cardiovascular risk to a woman with more than one lifetime pregnancy. Women 
who only have pre-eclamptic pregnancies have different cardiovascular risks to those with 
a mixture of normal pregnancies and pre-eclamptic pregnancies.  
 
There is no data on paternity of the pregnancies, so it is not known whether or not this 
might have contributed to the index pregnancy status or the status of subsequent 
pregnancies. It is also impossible to decipher the reason for the number of pregnancies 
women had from notes or hospital records and these decisions are personal and may be 
related to life-circumstances. In some women, life-threatening complications at delivery 
may have instigated advice that they do not have any more children, or may even have 
necessitated procedures such as hysterectomy which would have made it impossible to 
conceive again. The exact nature of “non-recurrence” of pre-eclampsia itself may have 
implications on cardiovascular risk.  
 
 Conclusion 4.4.4
 
ECGs in women with a history of pre-eclampsia show subtle cardiac changes which could 
be associated with the increased blood pressure experienced in these women. Mean age of 
women in this study was late forties at the time of these assessments. Future areas of study 
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would be to determine at what age these changes first start to evolve. When these women 
are described as having higher blood pressures, they are not yet within the hypertensive 
range, and the majority of the ECG criteria are not within the diagnostic range for evidence 
of LVH or risk of arrhythmia, so they would not necessarily be picked up at screening. The 
utility of ECG as a screening method for cardiovascular disease in these women merits 
further investigation.  
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5 Cardiovascular Consequences of Pre-eclampsia Vascular 
Study 
 
 Introduction 5.1
 
In comparison with women who had normotensive pregnancies, women with hypertensive 
disorders of pregnancy have a 2-fold increased subsequent risk of cardiovascular disease 
(6;179). There are several features common to both pre-eclampsia and cardiovascular 
disease, for example endothelial dysfunction. Evidence of vascular dysfunction may persist 
beyond pregnancy into the post-partum period, however previous studies have been 
inconsistent in their findings regarding whether or not these abnormalities persist for 
longer periods (136;142;143;395).  
 
A recent systematic review and meta-analysis analysed markers of vascular dysfunction 
after hypertensive disorders of pregnancy (179). Vascular function studies had to be 
performed at least 3 months postpartum for the study to be included and a total of 37 
studies were included in the meta-analysis. Studies assessing endothelial function using 
flow-mediated dilatation (FMD) showed such great heterogeneity between studies that 
results could not be pooled for analysis. Overall, women with hypertensive disorders of 
pregnancy showed evidence of arterial stiffness in comparison with women with 
normotensive pregnancy when assessed by augmentation index (AIx) and carotid-femoral 
pulse wave velocity (cfPWV) and there was also evidence of subclinical vessel 
atherosclerosis with a higher carotid intima-media thickness (cIMT). None of the 
individual studies included in the meta-analysis assessed AIx, cfPWV, cIMT and FMD all 
together, in the same study at the same study visit (179). 
 
Against this background the aims of this chapter were chiefly to investigate for any 
evidence of subclinical vascular damage in women with pre-eclampsia vs normotensive 
controls and, if there were any differences found between groups, to investigate factors 
which might be driving these differences.  
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 Methods 5.2
 
 Participant recruitment 5.2.1
 
Patients were recruited from the Generation Scotland Scottish Family Health Study 
(GS:SFHS), the previous Proteomics in Pre-eclampsia (PIP) Study and from the Glasgow 
Western Infirmary blood pressure clinics as described in Chapter 2.  
 
Generation Scotland participants for this study had previously been determined during the 
course of the record-linkage work for Chapter 3. Pre-eclampsia cases and normotensive 
controls had been identified and 329 cases and 658 matched controls were established for 
the biomarker studies described in Chapter 6. For the purposes of the COPS vascular study 
it was planned for these cases and controls to be invited to participate. There were 116 
cases from Glasgow, 168 from Edinburgh/Dundee and 45 from Aberdeen.  Although 
GS:SFHS was a Scotland-wide study, initial recruitment for the COPS vascular study 
began with the Glasgow-based cases. GS:SFHS controls based in Glasgow were also 
invited to participate. The Generation Scotland team sent out 1) a COPS study invitation 
letter, 2) a COPS study patient information sheet and 3) a copy of the COPS study consent 
form to all women. Based on initial recruitment from this region, GS:SFHS participants 
from other parts of Scotland were also invited to attend. When women attended for a study 
visit, their “case” or “control” status was assessed at the time of the study questionnaire, 
and this status was verified with Generation Scotland and anonymity was maintained. All 
results were concordant, and in a subgroup of the COPS study Generation Scotland cohort, 
maternity records were also checked for concordance with COPS study questionnaire, as 
discussed further in section 5.2.2. 
 
The PIP study had recruited pregnant women from the Queen Mother’s Hospital (prior to 
its closure), the Princess Royal Maternity Hospital, Southern General Hospital and the 
Ayrshire Maternity Unit. Information for previous participants who attended the BHF 
GCRC for clinical studies as part of the PIP study was available on the PIP study database. 
Eligible women were sent a COPS study invitation letter, patient information sheet and a 
copy of the consent form by the research nurse. The PIP study cohort were younger than 
GS:SFHS participants, and their pregnancies were more recent. All maternity records had 
been reviewed at time of recruitment to the PIP study for “case” or “control” status to be 
established. Any additional pregnancies in PIP study controls, which had occurred since 
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the end of the PIP study, might have potentially influenced the classification of these ladies 
for the COPS study, therefore any subsequent pregnancies in women classified as 
“controls” in the PIP study were reviewed as mentioned in section 5.2.3. 
 
Recruitment from the blood pressure clinic was by the author or the COPS study research 
nurse who would attend the blood pressure clinics and review the lists of patients for any 
women who fulfilled inclusion criteria for COPS. The study was discussed with any 
interested women who fulfilled the inclusion criteria and they were given a copy of the 
invitation letter, information sheet and consent form. It was arranged that they would 
contact us a few days later to confirm whether or not they wished a study appointment. 
Patient information leaflets were also left with the blood pressure clinic nurse who was 
informed about the study and would pass on the information to any interested ladies if we 
were not able to attend the clinic. There was also interest from friends and colleagues of 
participants who had found out about the study by “word of mouth” and had made contact. 
They were sent the study information documents and were recruited to the clinic group as 
this best represented their age group. 
 
In recruiting women from these groups it was hoped that various age-ranges and lengths of 
time since pregnancy would be available for the study. A total of 86 cases and 80 controls 
were recruited as follows: 46 cases and 23 controls from the GS:SFHS study, 19 cases and 
20 controls from the PIP study and 21 cases and 37 controls from the blood pressure clinic 
group. A copy of the patient invitation letters and patient information sheets specific to 
each group are found in Appendices 1-9. 
 
 Maternity records 5.2.2
 
In Scotland, maternity records have a minimum retention period of 25 years since the last 
birth (396). It was anticipated from the outset that it might not be possible to identify and 
validate information for all the participants in the vascular study. 
 
Women with a history of pre-eclampsia and controls as identified by Generation Scotland 
and identified through the PIP study were considered to be reliably characterised. Previous 
record linkage studies using SMR coding in a similar manner have shown maternity data to 
be reliable (376) and it has been assessed by ISD Scotland Data Quality Assurance (375). 
Amongst study participants recruited from the blood pressure clinic group, we requested 
notes for 10 cases (47.6% of cases) and 24 controls (64.9% of controls) it was possible to 
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review maternity records for 7 cases (70% requested) and 15 controls (62.5% requested). 
Concordance with maternity record obstetric history and participant self-reported obstetric 
history was 100%. A small proportion from the Generation Scotland group were also 
checked (12 cases and 12 controls were requested, n=24 in total). Review of 6 cases (50%) 
and 8 controls (66.7%) was possible. Concordance between hospital maternity record and 
participant self-reported obstetric history was 100%. In the PIP study group, 8 women had 
had subsequent pregnancies since the PIP study. Five of them had been in the “case” group 
for the PIP study, and their index pregnancies were identifiable. For the remaining 3 
women, who had been in the “control” group for PIP, they reported no symptoms or birth 
characteristics suggestive of pre-eclampsia and their “control” status for the COPS study 
was confirmed on review of their maternity records. 
 
 Definition of index pregnancy 5.2.3
 
The index pregnancy was defined in the same way as it had been for the record-linkage 
study in Chapter 3. Miscarriages or pregnancy losses at <20 weeks were excluded as index 
pregnancies, because pre-eclampsia can only be diagnosed beyond 20 weeks gestation. In 
the “control” group, the index pregnancy was the first pregnancy. If the first pregnancy 
fulfilled the above exclusion, the first pregnancy which continued past 20 weeks was used 
instead. In the “case” group, the first pregnancy fulfilling ISSHP guidelines for pre-
eclampsia (described in Chapter 1) with “2+” protein on dipstick was used as the index 
pregnancy. Cases of haemolysis, elevated liver enzymes and low platelets (HELLP) and 
eclampsia were labelled as pre-eclampsia for the purposes of this study.  
 
 The COPS Vascular Study 5.2.4
 
Patients who fulfilled inclusion criteria for the study gave written informed consent. Study 
participants were invited either in the morning or the afternoon, depending on availability, 
and time of study visit was noted. Subjects were asked to refrain from caffeine, alcohol or 
smoking for 6 hours before the test and have only a light meal. The study visit is described 
in more detail in Chapter 2. It began with a questionnaire including obstetric history 
(Appendix 10) and height and weight measurements. Blood pressure measurements were 
taken and blood and urine samples obtained. A standard 12-lead ECG was also performed. 
Individual vascular studies were carried out in the following order: pulse wave analysis, 
pulse wave velocity, carotid ultrasound and flow-mediated dilatation (Figure 5.1). Study 
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visits were carried out either by myself or by research nurse Joanne Flynn who was fully 
trained in all aspects of the COPS study.  
 
Figure 5.1 COPS Vascular study protocol detailing the order of tests. 
ECG - electrocardiogram 
 
 
 Study visit 5.2.5
 
All clinical vascular studies were carried out at the British Heart Foundation Glasgow 
Cardiovascular Research Centre (BHF GCRC).  
 
 Vascular studies  5.2.6
 
 Training 5.2.6.1
 
Before the study commenced both the author and research nurse (JF) had trained for over 4 
months in the vascular techniques as part of a previous study “Target organ damage in 
predicting cardiovascular risk” which used the same standard operating procedures.  More 
Questionnaire 
Clinical measurements 
Phlebotomy / urine sample 
ECG 
Pulse wave analysis 
Pulse wave velocity  
Carotid ultrasound 
Flow-mediated dilatation 
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intensive training in carotid ultrasound scanning was also provided at the Department of 
Vascular Medicine, Academical Medical Centre, Amsterdam with Mr Johan Gort and Dr 
Eric de Groot.  
 
 COPS vascular studies 5.2.6.2
 
Supine blood pressure was measured using the same calibrated oscillometric device 
(Omron 705-IT) in the same arm as sitting blood pressure. Participants were asked to 
refrain from talking during the study.   
 
 Pulse wave analysis 5.2.6.3
 
PWA was performed using applanation tonometry with the SphygmoCor® system (AtCor 
Medical, Sydney, Australia). The tonometer was connected to an electronics module and 
peripheral pulse pressure waveform at the right radial artery. Subjects were rested in a 
supine position and the wrist was slightly dorsiflexed. Using the tonometer (Millar 
Instruments, Houston, Texas, USA) gentle pressure was applied to the area of maximal 
pulsation of the radial artery while the wrist was supported. Tonometer position was 
adjusted until the best quality waveforms were seen and a 10 second recording of pulse 
pressure tracings was made. The SphygmoCor® system utilises software which calculates 
the aortic pulse waveform and aortic systolic and diastolic blood pressures using a 
validated transfer function. The tracings were then inspected on the SphygmoCor® 
software (Figure 5.2). Tracings should exhibit an initial sharp upstroke, rising to an initial 
peak, a second shoulder, and a notch marking the closure of the aortic valve. If these 
features were not present the tonometer was repositioned and further waveform recordings 
obtained until the relevant features were seen. Quality control indices were also checked. 
These consisted of pulse height variation <5%, diastolic variation <5%, shape variation 
<5%, average pulse height >100units. These contributed to the overall operator index 
which was only accepted if >80%. The augmentation index was also adjusted to a heart 
rate of 75 beats per minute (AIx@HR75) by the software. This was noted along with the 
aortic systolic and diastolic blood pressure readings. PWA readings were made in duplicate 
and an average of the two readings used in subsequent analyses. 
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Figure 5.2 Augmentation index on pulse wave analysis 
This is the augmentation index measurement for COPS study participant C-00152-C. On the left is the 
radial waveform in white and on the right is the central waveform. The operator index is 100%. 
Augmentation index at the bottom of the screen is 29%, and 27 % after adjusting for heart rate of 
75bpm (see value 27% under the picture of the central waveform). 
 
 Pulse wave velocity 5.2.6.4
 
Carotid-femoral PWV (cfPWV) is considered to be the “gold standard” measurement of 
arterial stiffness (162). Examples of tracings in a COPS study subject are shown in Figure 
5.3. Pulse wave velocity was calculated using the foot-to-foot flow wave velocity 
technique (162) and is the distance: transit time ratio. It is calculated using the following 
equation: PWV (m/s) = distance (metres)/time (seconds). Distance is “travel distance” 
which is the subtracted distance (sternum-carotid distance subtracted from the sternum-
femoral distance).  
 
The SphygmoCor® Vx device (AtCor Medical, Sydney, Australia) was used to measure 
carotid-femoral pulse wave velocity (cfPWV) non-invasively in the supine position. Three 
ECG leads were attached to the chest and the tracing was inspected to ensure sinus rhythm. 
This ECG gating on the R-wave permits the time lapse between pulse waves at the 
proximal and distal sites to be measured sequentially. Applanation tonometry was 
performed using a high-fidelity tonometer (Millar Instruments, Houston, Texas, USA). The 
onset of the pressure pulse was measured using the “intersecting tangent method” (397).  
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A Carotid 
 
B Femoral 
 
 
Figure 5.3 Pulse wave velocity  
PWV tracings from A) the carotid and B) the femoral artery from COPS participant C-00152-C are 
shown.  
 
Distal measurements were made at the site of maximal pulsation of the femoral artery and 
proximal measurements were made at the site of maximal pulsation of the carotid artery. 
The distance between right carotid pulsation and the suprasternal notch was measured in 
millimetres. The right femoral artery was then located at its point of maximal pulsation, 
and the distance from the suprasternal notch to femoral artery (via the umbilicus) was 
measured in millimetres.  
 
PWV studies were recorded for up to 15 seconds at a time, and at least two readings 
meeting quality control criteria were recorded. Readings should have a standard deviation 
of <10%. An average of the two readings was used in later analysis.  
 
 Carotid intima-media thickness measurements (cIMT) 5.2.6.5
 
Carotid intima-media thickness (cIMT) was assessed using Acuson Sequoia 512 ultrasound 
scanner (Siemens, Erlangen, Germany). An 8L5, 5-8 MHz linear-array transducer, was 
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used in B-mode at a depth of 40mm and frequency 8MHz. Still images and dynamic clips 
were recorded at the distal common carotid artery (CCA), carotid bulb and internal carotid 
artery (ICA) on both the right and left sides at an ear-to-ear angle in accordance with 
recommendations from the Vascular Imaging laboratory at the Academic Medical Centre, 
Amsterdam, Netherlands (Figure 5.4). ECG was recorded simultaneously to enable images 
to be measured on the R wave. The mean of the right and left readings were used as the 
measurement for each of the three sections imaged. Internal carotid artery Doppler velocity 
was measured (in metres per second) to assess for significant stenosis, and readings 
>1.25m/s were referred for a follow-up scan and further assessment if required. In the 
COPS vascular study 2 subjects were referred on for further assessment.   
 
Each scan was saved as a DICOM (Digital Imaging and Communications in Medicine) 
file. Images were measured offline using the Syngo Workplace Siemens Arterial Health 
Package 3.5 (Siemens Medical Solutions USA Inc. CA). Measurements were made on a 
1cm length of the far wall of the common carotid, bulb and internal carotid arteries. All 
scans were analysed by the author, blinded to the subject’s ID code and case/control status. 
 
The same software was also used to measure the plaque score. A plaque was defined 
according to the Mannheim consensus (181;182) as: 
 
“a focal structure encroaching into the arterial lumen of at least 0.5mm or 50% of 
the surrounding carotid intima-media thickness (cIMT) value, or demonstrating a 
thickness >1.5mm as measured from media-adventitia interface to intima-lumen 
interface.” 
 
The plaque score itself was calculated according to a previously defined equation (398) 
such that the number of sites with plaque detected (from the right and left CCA, bulb and 
ICA) was divided by the total number of sites with analysable images, then multiplied by 
six. It was not possible to assess plaque volume using the software available at time of 
analysis.  
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 A 
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 C 
 
 
Figure 5.4 Carotid ultrasound images 
A) the common carotid artery (CCA), B) the carotid bulb C) the internal carotid artery (ICA). 
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 Flow-mediated dilatation 5.2.6.6
 
Flow-mediated dilatation (FMD) was measured with the subject supine using Doppler 
ultrasound at the brachial artery. A blood pressure cuff was applied to the forearm, distal to 
the artery. The brachial artery was identified scanning longitudinally using the Siemens 
Sequoia 512, 8L5 linear array transducer (the same transducer as for cIMT measurement), 
set at 8MHz, a depth of 30mm, and positioned at 5-10cm proximal to the antecubital fossa 
using a stereotactic clamp. Simultaneous electrographic recordings were made and all 
images were triggered on the R wave. Baseline artery diameter was measured at end-
diastole.  
 
Baseline images were recorded for 3 minutes. The forearm blood pressure cuff was then 
inflated to supra-systolic pressures (at least 200mmHg or 50mmHg above systolic blood 
pressure if this was higher) for 5 minutes. The cuff was released and recordings of the 
scanned artery were made for 5 more minutes. Four women did not have the test performed 
due to a history of Raynaud’s and five women had FMD performed on the left arm due to 
previous breast surgery on the right side.   
 
Images were analysed offline using software Brachial Analyzer, Medical Imaging 
Applications LLC, Coralville, IA, USA (Figure 5.5). All images were analysed by one 
reader (the author), blinded to the subject’s ID case/control status. The flow-mediated 
dilatation is expressed as the percentage change in arterial diameter pre and post cuff 
occlusion relative to the baseline diameter. A “region of interest” ROI box was placed over 
the image at a region where near and far walls of the brachial artery were visualised. 
Automated software determined the vessel borders and the analysis was run. All images 
were reviewed and excluded if confidence interval for the measurement was less than 70%. 
The baseline diameter was calculated as an average of the baseline images 1 minute prior 
to cuff inflation. Maximum diameter (or “peak” diameter) was taken as the average of the 
highest reading and the two readings immediately on either side of it (three readings in 
total).  
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    A)      B) 
 
 
Figure 5.5 Flow-mediated dilatation images 
 
A) Position of inflation cuff over forearm and positioning of ultrasound probe over the brachial artery 
(from Charakida et al (113) with permission) B) Brachial Analyzer software measuring the brachial 
artery diameter using a region of interest (ROI) box. 
 
 Intra-operator and inter-operator assessment  5.2.6.7
 
Because all study measurements were performed either by the author or a trained research 
nurse (JF), it was important to assess for intra-and inter-operator differences in the more 
operator-dependent studies: carotid ultrasound and flow-mediated dilatation.  
 
For carotid ultrasound intra-observer coefficient of variation was <6% for both the author 
and research nurse in all 3 sections of the carotid artery imaged. Mean absolute differences 
were <0.055mm. These results are well within the recommendations by the American 
Society of Echocardiography (180). They also comply with the recommendation of mean 
absolute difference <0.15mm from the Department of Vascular Medicine, Academic 
Medical Centre, Amsterdam. Intra-class correlation coefficient between operators was 
0.955 (95% CI 0.839-0.988) at the CCA, 0.984 (95% CI 0.926-0.996) at the carotid bulb 
and 0.944 (95% CI 0.790-0.986) at the ICA.  
 
Twenty-five cIMT scans were picked at random for repeat measurement to assess reader 
reproducibility of the author. Scans were read in a blinded fashion. Results can be seen in 
Table 5.1. 
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Table 5.1     Reader reproducibility for carotid IMT measurements 
 
COPS 
study ID 
Mean of 
right and 
left CCA 
(mm) 
Mean of 
right 
and left 
bulb 
(mm) 
Mean of 
right and 
left ICA 
(mm) 
Repeat 
mean of 
right 
and left 
CCA 
(mm) 
Repeat 
mean of 
right and 
left bulb 
(mm) 
Repeat 
mean of 
right and 
left ICA 
(mm) 
C-00006-P 0.5500 0.5675 0.4080 0.5305 0.5445 0.4280 
C-00011-P 0.6780 0.5745 0.5660 0.6610 0.5550 0.5430 
C-00018-C 0.6955 0.5945 0.4245 0.6840 0.5810 0.4490 
C-00035-P 0.5620 0.5125 0.3180 0.5795 0.5075 0.3070 
C-00038-P 0.5790 0.5795 0.4510 0.5920 0.5695 0.4775 
C-00044-P 0.5070 0.6255 0.4005 0.5160 0.6200 0.3980 
C-00049-P 0.5630 0.6050 0.5760 0.5390 0.5925 0.5420 
C-00060-G 0.4705 0.5495 0.4845 0.4750 0.5420 0.4655 
C-00063-G 0.8080 0.7770 0.6120 0.7930 0.7700 0.5815 
C-00073-C 0.6180 0.5445 0.3475 0.6335 0.5310 0.3690 
C-00081-C 0.5495 0.6765 0.3845 0.5700 0.6875 0.3685 
C-00085-G 0.5825 0.6325 0.5735 0.5835 0.6470 0.5690 
C-00114-G 0.7085 0.7105 0.7120 0.6670 0.7025 0.6560 
C-00118-G 0.5535 0.5455 0.3965 0.5460 0.5475 0.4025 
C-00120-C 0.5155 0.6355 0.5350 0.5000 0.6565 0.5110 
C-00126-C 0.6000 0.5900 0.5570 0.5860 0.5740 0.5325 
C-00129-G 0.6480 0.5805 0.5050 0.6545 0.5950 0.4955 
C-00133-G 0.7620 0.7470 0.5575 0.7500 0.7365 0.5685 
C-00136-C 0.6010 0.9240 0.4600 0.6190 0.9035 0.4760 
C-00137-G 0.5575 0.6395 0.6365 0.5490 0.6195 0.6455 
C-00142-G 0.6050 0.7055 0.5560 0.5860 0.7135 0.5260 
C-00147-C 0.6275 0.6890 0.5555 0.6375 0.6685 0.5295 
C-00159-C 0.5750 0.5660 0.4100 0.5565 0.5870 0.4300 
C-00162-C 0.5695 0.5125 0.5790 0.5975 0.4975 0.6045 
C-00165-C 0.5535 0.5685 0.5180 0.5795 0.5720 0.4840 
       
Intraclass correlation coefficient 
 ICC (95% CI) F P-
value 
CCA 0.973 (0.940-0.988) 0.360 0.554 
Bulb 0.988 (0.972-0.995) 0.383 0.063 
ICA 0.967 (0.927-0.985) 1.977 0.173 
 
CCA= common carotid artery, ICA= internal carotid artery,  
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For flow-mediated dilatation the intra-observer coefficients of variation were <10% for 
both the research nurse and the author, and intra-class correlation coefficient between 
operators was >0.900 for both operators.  
 
Twenty-five FMD scans were again picked at random to be re-read (blinded) for reader 
reproducibility assessment as detailed in Table 5.2. 
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Table 5.2 Reader reproducibility for flow-mediated dilatation measurements  
 
COPS study 
ID 
Baseline 
diameter 
(mm) 
Maximum 
diameter 
(mm) 
FMD 
(%) 
Repeat 
baseline 
diameter 
(mm) 
Repeat 
maximum 
diameter 
(mm) 
Repeat 
FMD 
(%) 
C-00015-P 3.79 3.99 5.3 3.84 4.05 5.47 
C-00017-P 2.74 2.99 9.1 2.79 2.99 7.17 
C-00018-C 5.3 5.53 4.3 5.29 5.52 4.3 
C-00022-P 3.06 3.24 5.9 3.09 3.25 5.2 
C-00034-P 3.3 3.46 4.8 3.29 3.46 5.2 
C-00047-C 3.3 3.62 9.7 3.27 3.55 8.56 
C-00049-P 3.58 3.91 9.2 3.58 3.90 8.94 
C-00050-G 4.74 4.83 1.9 4.73 4.81 1.7 
C-00060-G 4.02 4.12 2.5 4.03 4.10 1.7 
C-00068-G 3.52 3.7 5.1 3.49 3.68 5.44 
C-00072-G 3.68 4.15 12.8 3.69 4.14 12.2 
C-00085-G 4.11 4.34 5.6 4.12 4.38 6.3 
C-00092-C 3.81 4.09 7.3 3.80 4.07 7.1 
C-00101-G 3.59 3.75 4.5 3.61 3.75 3.88 
C-00105-G 4.5 4.6 2.2 4.48 4.59 2.46 
C-00115-G 4.76 4.83 1.5 4.77 4.85 1.68 
C-00121-G 4.12 4.39 6.6 4.13 4.40 6.54 
C-00128-G 3.98 4.2 5.5 3.97 4.21 6.05 
C-00131-C 3.78 4.07 7.7 3.79 4.08 7.65 
C-00139-G 4.01 4.13 3.0 4.00 4.13 3.25 
C-00140-G 3.71 3.86 4.0 3.72 3.89 4.57 
C-00146-G 4.11 4.2 2.2 4.10 4.18 1.95 
C-00147-C 3.78 4.15 9.8 3.78 4.13 9.26 
C-00153-C 4.21 4.42 5.0 4.24 4.42 4.25 
C-00158-C 3.78 3.91 3.4 3.79 3.88 2.37 
 
Intraclass correlation coefficient 
 ICC (95% CI) F P-value 
Baseline diameter (mm) 0.999 (0.998-1.00) 1.115 0.301 
Maximum diameter (mm) 0.999 (0.997-1.00) 0.307 0.584 
FMD % 0.973 (0.938-0.988) 3.362 0.079 
 
FMD = flow-mediated dilatation 
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 Statistical analysis 5.2.7
 
Coefficients of variation described in this chapter were calculated using MedCalc 
Statistical Software version 17.5 (MedCalc Software bvba, Ostend, Belgium). The Venn 
diagram (Figure 5.6) was drawn using Venny 2.1 software (399). Other statistical analysis 
was performed using IBM SPSS Statistics for Windows version 22 (Armonk, NY, USA: 
IBM Corp), Minitab version 17 (Minitab Inc, State College, PA, USA). Normality of data 
distribution was assessed using the Kolmogorov-Smirnov test. All data that were not 
normally distributed were transformed. Data are described in the tables for this chapter as 
mean ± standard deviation unless otherwise stated. Comparisons were made using 
independent t-test for normally distributed data and Mann-Whitney U test for non-
parametric data. Chi-squared test or Fisher’s exact test were used to compare categorical 
variables. Further comparisons were made using univariate and multivariate analysis. A p-
value of <0.05 was considered to be significant.  
 
 Results 5.3
 
 Comparisons between index pregnancies with pre-eclampsia and 5.3.1
normotensive controls 
 
There were 80 normotensive controls and 86 women with a history of pre-eclampsia 
recruited. Descriptive statistics for baseline results from clinical examination, 
questionnaire and lipid results are shown in Table 5.3.  
 
Study participants were matched as closely as possible for age at time of recruitment and 
overall this result was not significantly different between cases and controls. There was a 
significant difference in weight, BMI, SBP, DBP and current diagnosis of hypertension 
between groups.   
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Table 5.3 Results for all 166 COPS study participants 
 Normotensive 
Controls (N=80) 
Pre-eclampsia 
Cases (N=86) 
P-value 
Age at study visit (yrs) 48.8±8.5 47.6±10.1 0.406 
Height (cm) 162.7±6.7 161.4±6.5 0.193 
Weight (kg) 70.1±11.2 76.4±15.0 0.004 
BMI (kg/m
2
) 26.6±4.5 29.4±6.1 0.001 
Mean
*
 SBP sitting (mmHg) 123±10 130±14 <0.001 
Mean
*
 DBP sitting (mmHg) 78±7 83±8 <0.001 
Resting HR (bpm) 71±9 73±11 0.123 
SBP supine (mmHg) 119±11 126±15 <0.001 
DBP supine (mmHg) 74±8 77±9 0.010 
    
Total cholesterol (mmol/L) 5.4±1.0 5.3±1.0 0.538 
Triglycerides (mmol/L) 1.36±0.72 1.35±0.71 0.941 
HDL (mmol/L) 1.52±0.33 1.49±0.34 0.761 
Non-HDL cholesterol (mmol/L) 3.85±0.10 3.86±0.99 0.986 
    
Current diagnosis of 
hypertension 
7 (8.8%) 26 (30.2%) 0.001 
Current diagnosis of diabetes 0 (0%) 5 (5.8%) 0.060 
Current smoker 11(13.8%) 7 (8.1%) 0.245 
Data are presented as mean ± SD for continuous data or as a proportion for categorical data. BMI = 
body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, HDL = high density 
lipoprotein. * Mean of the 2
nd
 and 3
rd
 blood pressure readings taken.  
 
For those participants with a diagnosis of hypertension, the breakdown of specific 
antihypertensive medications taken is shown below in Table 5.4. There were 1/7 (14.3%) 
participants on more than two antihypertensives in the normotensive pregnancy group and 
6/26 (23%) in the pre-eclamptic pregnancy group. Fisher’s exact test revealed no 
difference (p=value 1.000). The largest number of antihypertensive medications 
simultaneously being taken was four. 
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Table 5.4 Frequencies of antihypertensive medications 
 
Antihypertensive medication 
groups 
Normotensive 
pregnancy controls  
with current 
diagnosis of 
hypertension (N=7) 
Pre-eclampsia 
pregnancy cases 
with current 
diagnosis of 
hypertension 
(N=26) 
ACE inhibitor 2 11 
Beta-blocker 2 5 
Calcium channel blocker 1 6 
Diuretic 3 10 
Angiotensin-II  receptor 
antagonist  
2 9 
Alpha-adrenoceptor blocker 0 1 
Total number of medications 10 42 
 
ACE = Angiotensin converting enzyme 
Analysis of birth characteristics as shown in Table 5.5 revealed a significantly lower 
gestational age at delivery and a significantly lower birth weight in women with a history 
of pre-eclampsia in comparison with normotensive controls.  For twin pregnancies, the 
mean of the two birth weights was used as the overall birth weight for that pregnancy. 
After adjusting birth weight for gestational age using the z-score, there was no longer a 
statistically significant difference although the trend still reflected a lower birthweight in 
women with a history of pre-eclampsia.  
 
Table 5.5 Comparison of birth characteristics of index pregnancy 
 
 Normotensive 
Controls (N=80) 
Pre-eclampsia 
Cases (N=86) 
P-value 
Liveborn singleton pregnancy 78 (97.5%) 81(94.2%) 0.445 
Liveborn twin pregnancy 2 (2.5%) 4 (4.7%) 0.683 
Stillbirth 0 1 (1.1%) 1.000 
Age at index pregnancy (yrs) 30±6 29±6 0.226 
Time since index pregnancy at 
study visit (yrs) 
19.2±10.9 19.2±10.2 0.933 
Gestation at delivery (wks) 39.7±2.1 37.7±3.2 <0.001 
Birthweight (g) 3397±530 2996±716 <0.001 
Birthweight z-score -0.203±0.853 -0.286±0.843 0.536 
C-section  19/80 (23.8%) 29/86 (33.7%) 0.157 
Data are presented as mean ± SD for continuous data or as a proportion for categorical data.  
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In order to visualise the links between pregnancies with higher risk features (such as low 
birth weight, gestational age at delivery <37weeks, C-section), a Venn diagram was 
constructed as seen Figure 5.6. Out of all index pregnancies there were a total of 86 cases 
of pre-eclampsia, 23 deliveries with birthweight <2500g, 26 preterm deliveries and 48 
women requiring C-section.  The total number of women represented by these four 
outcomes combined was 108.  
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Figure 5.6 Venn diagram of outcome of index pregnancies  
Data are represented as the count per section e.g. 17 women experienced pre-eclampsia and had a C-
section but did not have a low birth weight baby (<2500g) or a pre-term delivery (<37 weeks gestation). 
Percentages shown are the proportion of women represented by the count in that particular section in 
comparison with the total count of women who experienced low birth weight, pre-eclampsia, C-section 
or pre-term delivery. No woman is counted twice.  
BW = birth weight.  
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 Summary of all pregnancies 5.3.2
 
When the information from all pregnancies in all women was assessed and combined 
(Table 5.6) there were a total of 217 pregnancies in the 80 women in the control group and 
243 pregnancies in the 86 women in the pre-eclampsia group.  Of the 243 pregnancies in 
the pre-eclampsia group, 105 were diagnosed with pre-eclampsia and an additional 21 
were diagnosed with pregnancy-induced hypertension. Controls did not experience 
pregnancy induced hypertension in any pregnancy. There was a significant difference in 
gestation at delivery and birth weight between groups. Gestation at delivery, and birth 
weight were significantly lower in the pre-eclampsia group (Figure 5.7) however this 
difference was no longer significant on adjustment of birth weight for gestational age using 
z-scores. The number of C-section deliveries was not statistically different between groups 
with 41 (18.9%) of controls vs 50 (20.6%) cases, p=0.737.  
 
Table 5.6 Comparison of birth characteristics for all pregnancies 
 Normotensive Controls 
N=217 pregnancies  
(in 80 women) 
Pre-eclampsia Cases 
N=243 pregnancies
 
(in 86 women) 
Singleton livebirth pregnancies 166 (76.5%) 184 (75.7%) 
Multiple gestation livebirth 
pregnancies (twins) 
3 (1.4%) 5 (2.0%) 
Stillbirth 1(0.5%) 6 (2.5%) 
Miscarriage/loss at <20 weeks 47 (21.7%) 48 (19.8%) 
Breakdown by number of pregnancies per woman 
Only 1 pregnancy 7 12 
Total of 2 pregnancies 40 31 
Total of 3 pregnancies 18 21 
Total of 4 pregnancies 6 12 
Total of 5 pregnancies 5 4 
Total of 6 pregnancies 3 5 
Total of 7 pregnancies 0 0 
Total of 8 pregnancies 0 1 
Total of 9 pregnancies 1 0 
 
Data shown in the top half of the table are as proportions of all pregnancies in that group, e.g. there 
were 166 livebirths out of 217 pregnancies. The lower half of the table describes the count of women 
who had the number of pregnancies detailed in each group.  
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Figure 5.7 Bar charts of mean birth weight and mean gestational age at delivery for all pregnancies. 
Error bars for 95% confidence interval are shown. 
 
The significantly lower birth weight and gestational age at delivery in women with pre-
eclampsia was present not only for the index pregnancy, but for all pregnancies. In order to 
determine whether there was some pre-disposition for subclinical problems in other 
pregnancies which were non-hypertensive, but occurred in the pre-eclampsia cases group, 
the data were further explored as detailed in Table 5.7. First, the original data for all 
pregnancies were compared again with twin pregnancies removed, as these are more likely 
to have lower birth weights and earlier gestation at delivery and could potentially have 
biased the results (there were 3 twin pregnancies in the control group and 5 in the pre-
eclampsia group). Next, the original dataset was re-examined with all index pre-eclamptic 
pregnancies in the “cases” group and all other pre-eclamptic or hypertensive pregnancies 
outwith the index pregnancy also removed. This analysis was also repeated with twin 
pregnancies removed in case of bias (there were 3 twin pregnancies in the control group 
but no twin pregnancies were left in the cases group).   
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Table 5.7 Further analysis of birth weight and gestational age in livebirths 
 Normotensive 
controls 
Pre-eclampsia 
cases 
P-value 
All livebirth pregnancies n=169 n=189  
Gestation at delivery (wks) 39.76 ± 1.85 38.45 ± 2.79 <0.001 
Birth weight (g) 3488.4 ± 500.3 3226.0 ± 707.3 <0.001 
Birth weight z-score -0.076 ± 0.818 -0.086 ± 0.893 0.914 
All livebirth pregnancies 
above excluding twin 
pregnancies  
n=166 n=184  
Gestation at delivery (wks) 39.85 ± 1.70 38.53 ± 2.75 <0.001 
Birth weight (g) 3513.8 ± 461.5 3252.6 ± 692.5 <0.001 
Birth weight z-score -0.060 ± 0.818 -0.0645 ± 0.8911 0.965 
 
 
All livebirth pregnancies 
excluding all pre-eclampsia 
and pregnancy-induced 
hypertension  
n=169 n=63  
Gestation at delivery (wks) 39.76 ± 1.85 39.88 ± 1.81 0.884 
Birth weight (g) 3488.4 ± 500.3 3576.1 ± 606.3 0.360 
Birth weight z-score -0.076 ± 0.818 0.1035 ± 0.999 0.207 
All livebirth pregnancies 
above excluding twin 
pregnancies  
n=166 n=63  
Gestation at delivery (wks) 39.85 ± 1.70 39.88 ± 1.81 0.729 
Birth weight (g) 3513.8 ± 461.5 3576.1 ± 606.3 0.271 
Birth weight z-score -0.060 ± 0.818 0.1035 ± 0.999 0.167 
Data are presented as mean ± SD.  
 
The significant difference in gestation at delivery and birth weight remained between 
groups even with the removal of twin pregnancies. However, after removing all cases of 
pre-eclampsia (and pregnancy-induced hypertension) in any pregnancy from the “cases” 
group, there was no significant difference in the comparison of birth weight or gestation at 
delivery for normotensive pregnancies in cases vs control pregnancies. There was no 
difference in birth weight z-score in any of the comparisons.  
 
 Results of vascular studies 5.3.3
 
Women with a history of pre-eclampsia had a significantly higher heart-rate adjusted 
augmentation index (AIx@HR75), mean arterial pressure (MAP), and central SBP and 
DBP compared with controls (Table 5.8).  PWV was also greater in cases vs controls. 
FMD was lower in cases than controls. On further analysis of FMD itself, baseline brachial 
artery diameter and post-inflation diameter were similar. There was no difference in cIMT 
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however there was a statistically significant difference in plaque score between groups. 
Figures 5.8 and 5.9 show graphical presentations of these findings. In the control group 
31.6% women had at least one carotid plaque and 51.2% of women with a history of pre-
eclampsia had carotid plaque present on ultrasound. 
 
Table 5.8 Results of vascular studies for all 166 COPS study participants 
 
 Normotensive 
Controls (N=80) 
Pre-eclampsia Cases 
(N=86) 
P-value 
Mean AIx @ HR 75bpm (%) 22.5±9.6 25.7±11 0.023 
Mean aortic SBP (mmHg) 110±11 118±16 <0.001 
Mean aortic DBP (mmHg) 75±8 78±9 0.007 
Mean arterial pressure 
(MAP) 
89.9±8.5 95.4±11.1 <0.001 
Mean cfPWV (m/s) 7.1±1.1 7.8±1.6 0.001 
Mean cIMT CCA (mm) 0.622±0.112 0.655±0.132 0.088 
Mean cIMT BULB (mm) 0.679±0.146 0.676±0.148 0.807 
Mean cIMT ICA (mm) 0.553±0.135 0.552±0.125 0.961 
Plaque count 25/79 (31.6%) 43/84 (51.2%) 0.011 
Plaque score 0.384±0.603 0.733±0.852 0.006 
Baseline brachial artery 
diameter (mm) 
3.62±0.45 3.65±0.49 0.686 
Maximum brachial artery 
diameter (mm) 
3.87±0.47 3.86±0.49 0.918 
%FMD 7.01±3.31 5.93±3.29 0.016 
AIx@HR75 – augmentation index (here it is adjusted for heart rate), HR – heart rate, SBP – systolic 
blood pressure, DBP – diastolic blood pressure,  cfPWV – carotid-femoral pulse wave velocity, cIMT – 
carotid intima-media thickness, CCA – common carotid artery, ICA – internal carotid artery, FMD – 
flow-mediated dilatation. Data are presented as mean ± SD for continuous data or as a proportion for 
categorical data. For AIx@HR75, aortic blood pressures and cfPWV, “mean” is the mean of 2 
readings recorded at the study visit. For cIMT measurements “mean” is the mean of the value from 
the right and left sides.  
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Figure 5.8 Results of COPS vascular studies 
a) Mean heart-rate adjusted augmentation index (AIx@HR75) on pulse wave analysis 
measured as percent b) Mean carotid-femoral pulse wave velocity in metres/second (PWV) c) 
carotid intima-media thickness at common carotid artery in millimetres (cIMT)   d) flow-
mediated dilatation (FMD) in pre-eclampsia measured as a percent. All data are grouped by 
pre-eclampsia case or control status. 
 
 
 
 
Figure 5.9   Bar chart of carotid plaque presence 
Pre-eclampsia cases are coloured green and normotensive controls are in blue. 
a) b) 
c) d) 
p=0.023 p=0.001 
p=0.088 p=0.016 
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For all subsequent analyses Pearson’s or Spearman’s correlation were used as appropriate 
and for regression the data fulfilled the assumptions of multiple regression analysis.  
 
 Heart-rate adjusted augmentation index  5.3.3.1
 
Heart-rate adjusted augmentation index (AIx@HR75) was not significantly correlated with 
weight, BMI, resting heart rate, or HDL. It did correlate significantly with age (ρ=0.531, 
p=<0.001), height (ρ= -0.350, p=<0.001), SBP (ρ=0.450, p=<0.001), DBP (ρ=0.340, 
p=<0.001), MAP (ρ=0.570, p=<0.001) total cholesterol (ρ=0.238, p=0.002), non-HDL 
cholesterol (ρ=0.283, p=<0.001) and triglycerides (ρ=0.285, p=<0.001). It did not correlate 
with age at index pregnancy, gestation at index pregnancy, birth weight or birth weight z-
score, but it was significantly correlated with years since index pregnancy (ρ=0.509, 
p=<0.001). See figures 5.10 and 5.11 for scatterplots. 
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  a)             b) 
 
 
c)            d) 
     
 
 Figure 5.10 Scatterplots of age, height, systolic blood pressure and diastolic blood pressure 
against mean heart-rate adjusted augmentation index 
a) scatterplot of age vs mean AIx@HR75, b) scatterplot of height vs mean AIx@HR75, c) 
scatterplot of SBP vs AIx@HR75,  b) scatterplot of  DBP vs AIx@HR75.  
AIx@HR75 = heart-rate adjusted augmentation index, SBP = systolic blood pressure in 
mmHg, DBP = diastolic blood pressure in mmHg. 
Spearman’s correlation coefficients (rho) have been calculated. Regression lines have been 
added only to indicate direction of the relationship. 
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a)      b)      
        
c)       d) 
        
          
e) 
 
Figure 5.11 Scatterplots of other variables against heart-rate adjusted augmentation index 
a) scatterplot of MAP vs AIx@HR75, b) scatterplot of total cholesterol vs AIx@HR75, c) 
scatterplot of non-HDL cholesterol vs AIx@HR75, d) scatterplot of triglycerides vs 
AIx@HR75   e) scatterplot of years since index pregnancy vs AIx@HR75. AIx@HR75 = 
heart-rate adjusted augmentation index, MAP = mean arterial pressure, HDL = high-density 
lipoprotein. 
Spearman’s correlation coefficients (rho) have been calculated. Regression lines have been 
added only to indicate direction of the relationship. 
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Figure 5.12 Boxplot of AIx@HR75 by diagnosis of hypertension 
 
 
 
There was a significant difference in AIx@HR75 when separated by women with a 
diagnosis of hypertension and those without, on independent samples t-test (p=0.012) 
(Figure 5.12), but there was no difference in smoking status. 
 
Age, height, SBP, DBP, MAP, cholesterol, non-HDL cholesterol, triglycerides, time since 
pregnancy and diagnosis of hypertension were entered into a multiple regression model as 
independent variables, along with history of pre-eclampsia. AIx@HR75 was the dependent 
variable. History of pre-eclampsia was not a statistically significant determinant of 
AIx@HR75 (p=0.472). Therefore, history of pre-eclampsia is not an independent 
determinant of AIx@HR75 later in life. Age, height and MAP were significant 
determinants of AIx@HR75. The same was seen when a more comprehensive model 
which included other cardiovascular risk factors was used. In this model age, BMI, SBP, 
cholesterol, diabetes, smoking and pre-eclampsia status were entered as independent 
variables. Pre-eclampsia p-value=0.146 indicating it was not a determinant of AIx@HR75. 
Age and SBP were significant determinants of AIx@HR75 (both p-values <0.001). 
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 Carotid-femoral pulse wave velocity  5.3.3.2
 
Carotid-femoral pulse wave velocity (cfPWV) was not significantly correlated with height, 
resting heart rate, total cholesterol or birth weight z-score. However it was significantly 
correlated with age (r=0.420, p=<0.001), weight (r=0.272, p=0.001), BMI (ρ=0.353, 
p=<0.001), SBP (r=0.503, p=<0.001), DBP (r=0.327, p=<0.001), MAP (r=0.522, 
p=<0.001), non-HDL cholesterol (r=0.190, p=0.029) and triglycerides (ρ=0.247, p=0.002) 
(Figure 5.13). 
 
Age at index pregnancy was significantly negatively correlated with cfPWV (ρ= - 0.218, 
p=0.005) and years since index pregnancy was significantly positively correlated (ρ= 
0.453, p=<0.001) (Figure 5.14). There was a significant difference in cfPWV between 
hypertensive cases and controls on independent samples t-test (p=<0.001) (Figure 5.15), 
but there was no difference in smoking status. 
 
On multiple regression analysis, which included all of the above significant variables and 
pre-eclampsia, a history of pre-eclampsia was not statistically significant at p=0.978. Only 
MAP was significant in determining cfPWV with p=0.012. Pre-eclampsia was therefore 
not an independent determinant of cfPWV and on entering a model of pre-eclampsia with 
classical cardiovascular risk factors it was still not significant in determining cfPWV later 
in life (p=0.153). In this model age, SBP and BMI were all significant with p=<0.001 for 
each of them.  
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   a)                 b) 
  
          
    c)                   d) 
         
     e)                   f) 
 
        
 
Figure 5.13 Scatterplot 1 of variables against carotid femoral pulse wave velocity 
a) scatterplot of age vs log cfPWV   b) scatterplot of weight vs log cfPWV   c) scatterplot of BMI vs log 
cfPWV  d) scatterplot of SBP vs log cfPWV   e) scatterplot of DBP vs log cfPWV f) scatterplot of MAP 
vs log cfPWV . CfPWV = carotid-femoral pulse wave velocity, BMI = body mass index, SBP = systolic 
blood pressure, DBP = diastolic blood pressure, MAP = mean arterial pressure.  
Where Spearman’s correlation coefficients (rho) have been calculated, regression lines have been 
added only to indicate direction of the relationship. 
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a)      b) 
 
 
c)      d) 
 
 
Figure 5.14 Scatterplot 2 of variables against carotid femoral pulse wave velocity 
a) scatterplot of non-HDL cholesterol vs log cfPWV b) scatterplot of triglycerides vs log cfPWV, c) 
scatterplot of age at index pregnancy in yrs vs log cfPWV,  d) scatterplot of time since index pregnancy 
vs log cfPWV. CfPWV = carotid-femoral pulse wave velocity, HDL = high-density lipoprotein.  
Spearman’s correlation coefficients (rho) have been calculated. Regression lines have been added only 
to indicate direction of the relationship. 
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Figure 5.15 Boxplot of log cfPWV by hypertension status 
 
 Flow-mediated dilatation 5.3.3.3
 
Flow-mediated dilatation was only significantly negatively correlated with weight (r= -
0.186, p=0.029) (Figure 5.16). There was no difference with hypertension status or 
smoking status on independent samples t-test.  
 
On multiple regression, for the first model, pre-eclampsia was entered with weight. Pre-
eclampsia was significant (p=0.041) in determining FMD. Weight was no longer 
significant. Following this, pre-eclampsia was entered into a model with, age, BMI and 
SBP and it was found to be statistically significant in determining FMD (p=0.022). None 
of the other variables were significant. As expected there was an inverse correlation 
between baseline brachial artery diameter and flow-mediated dilatation (r=-0.351, 
p<0.001). However, history of pre-eclampsia remained a significant determinant of FMD 
even if baseline brachial artery diameter was entered into the above regression models 
(data not shown).  
 
Finally, on entering pre-eclampsia into a model with classical cardiovascular risk factors 
(age, BMI, SBP, total cholesterol, diabetes, smoking status) the overall model was not 
significant (F=1.633, p=0.132). However pre-eclampsia remained significant in 
determining FMD after adjusting for all other variables. (p=0.040). No other variable in the 
model was significant in determining FMD. 
 
 
Chapter 5  164 
 
1
6
4
 
 
 
 
 
Figure 5.16 Scatterplot of weight against flow-mediated dilatation 
 
 
 Carotid plaque score 5.3.3.4
 
Plaque score did not correlate with age, blood pressure, MAP, cholesterol, non-HDL 
cholesterol, triglycerides or high-density lipoprotein. It did correlate with BMI (ρ=0.161, 
p=0.041) and AIx @HR75 (ρ=0.174, p=0.026) but not with PWV or FMD. Mean cIMT at 
the common carotid artery and mean cIMT at the carotid bulb were correlated with plaque 
score (ρ= 0.229, p= 0.003 and ρ=0.244, p=0.002 respectively) but not mean cIMT at the 
internal carotid artery.  
 
Entering the significant variables along with pre-eclampsia into a binary logistic regression 
model for the presence or absence of carotid plaque, pre-eclampsia was a determinant of 
presence of carotid plaque (p=0.019). On entering the cardiovascular model of age, BMI, 
SBP, total cholesterol, diabetes, and smoking status, pre-eclampsia remained significant in 
determining plaque presence after adjusting for the other cardiovascular risk factors 
(p=0.018). None of the other variables was significant in determining the presence of 
carotid plaques.  
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 Further subgroup analysis 5.3.4
 
Previous studies assessing vascular function after hypertensive disorders of pregnancy 
have found differences according to age of participants at time of recruitment (whether 
older or younger) and depending on length of time since index pregnancy 
(142;143;395;400-402). In the meta-analysis described above (179) the differences in 
vascular function were found to be more notable in younger subjects aged <40years or 
subjects closer to the time of index pregnancy. While adjustments have been made for a 
variety of co-variates on performing regression analysis (section 5.3.3), further subgroup 
analysis was performed, to explore any obvious differences depending on grouping for age 
(Tables 5.9-5.10) or for time since index pregnancy (Tables 5.11-5.12).   
 
Women <50 years at time of recruitment to the COPS study showed significantly higher 
BMI, lower age at time of index pregnancy, lower gestation at delivery and lower birth 
weight in the pre-eclampsia group than the normotensive control group. There were no 
significant differences in blood pressure or vascular function studies in women under 50 
years (Table 5.9). In comparison, women age ≥ 50 years at time of recruitment followed 
the same pattern, for BMI, gestation at delivery and birth weight, but in addition women 
with a history of pre-eclampsia also had significant differences in baseline blood pressure 
readings, central blood pressure, adjusted AIx, cfPWV, cIMT at the common carotid artery 
and flow-mediated dilatation. Women with history of pre-eclampsia also had a higher 
proportion requiring C-section (Table 5.10).   
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Table 5.9 Results for women aged <50years at time of COPS study visit 
 
 Normotensive 
Controls (N=38) 
Pre-eclampsia 
Cases (N=46) 
P-value 
Age at study visit (yrs) 41.2±4.5 39.9±6.6 0.620 
Height (cm) 163.5±6.7 162.0±7.1 0.344 
Weight (kg) 72.3±13.0 77.9±15.9 0.087 
BMI (kg/m
2
) 27.1±5.0 29.8±6.5 0.041 
Mean* SBP sitting (mmHg) 122±10 126±13 0.129 
Mean* DBP sitting (mmHg) 79±3 82±9 0.061 
Resting HR (bpm) 72±10 75±11 0.145 
SBP supine (mmHg) 118±11 123±14 0.068 
DBP supine (mmHg) 74±9 76±11 0.334 
Mean AIx at HR 75bpm 18.6±10.6 20.0±11.0 0.553 
Mean aortic SBP (mmHg) 108±12 112±15 0.134 
Mean aortic DBP (mmHg) 75±9 77±11 0.186 
Total cholesterol (mmol/L) 5.0±0.7 4.9±0.9 0.156 
Triglycerides (mmol/L) 1.3±0.6 1.2±0.6 0.180 
HDL  1.5±0.3 1.4±0.3 0.678 
Mean cfPWV (m/s) 6.9±1.0 7.2±1.1 0.186 
Mean cIMT CCA (mm) 0.587±0.09 0.584±0.09 0.942 
Mean cIMT BULB (mm) 0.621±0.109 0.623±0.135 0.890 
Mean cIMT ICA (mm) 0.518±0.126 0.510±0.117 0.766 
Plaque score 0.287±0.493 0.596±0.795 0.076 
Plaque presence 10/38 (26.3%) 19/45 (42.2%) 0.130 
FMD baseline (mm) 3.58±0.46 3.56±0.49 0.769 
FMD maximum (mm) 3.84±0.46 3.78±0.51 0.590 
%FMD 7.15±3.31 6.23±3.09 0.240 
Age at index pregnancy (yrs) 31.0±6.2 28.2±5.4 0.027 
Yrs since index pregnancy at 
time of study visit (yrs) 
10.6±7.7 12.3±8.3 0.432 
Gestation at delivery (wks) 39.6±1.9 37.3±3.8 <0.001 
Birthweight (g) 3359±605 2981±754 0.017 
C-section  14/38 (36.8%) 16/46 (34.8%) 0.845 
 
BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, HDL = high 
density lipoprotein. AIx – augmentation index (here it is adjusted for heart rate), HR – heart rate, 
cfPWV – carotid-femoral pulse wave velocity, cIMT – carotid intima-media thickness, CCA – common 
carotid artery, ICA – internal carotid artery, FMD – flow-mediated dilatation. Data are presented as 
mean ± SD for continuous data or as a proportion for categorical data. 
* Mean of the 2
nd
 and 3
rd
 blood pressure readings taken. 
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Table 5.10 Results for women aged ≥50years at time of COPS study visit 
 
 Normotensive 
Controls (N=42) 
Pre-eclampsia 
Cases (N=40) 
P-value 
Age at study visit (yrs) 55.7±4.5 56.6±4.2 0.390 
Height (cm) 162.0±6.7 160.7±5.8 0.337 
Weight (kg) 68.2±8.8 74.7±14.0 0.054 
BMI (kg/m
2
) 26.1±3.9 29.0±5.7 0.020 
Mean* SBP sitting (mmHg) 123±10 134±14 <0.001 
Mean* DBP sitting (mmHg) 77±7 83±6 <0.001 
Resting HR (bpm) 70±8 71±11 0.701 
SBP supine (mmHg) 119±10 130±16 <0.001 
DBP supine (mmHg) 74±7 79±8 0.002 
Mean AIx at HR 75bpm 26.1±7.0 32.2±6.5 <0.001 
Mean aortic SBP (mmHg) 113±10 124±15 <0.001 
Mean aortic DBP (mmHg) 75±7 80±8 0.001 
Total cholesterol (mmol/L) 5.7±1.1 5.8±1.0 0.718 
Triglycerides (mmol/L) 1.4±0.8 1.6±0.8 0.260 
HDL  1.6±0.4 1.6±0.4 0.968 
Mean cfPWV (m/s) 7.3±1.1 8.6±1.8 <0.001 
Mean cIMT CCA (mm) 0.655±0.118 0.738±0.124 0.003 
Mean cIMT BULB (mm) 0.733±0.157 0.738±0.140 0.881 
Mean cIMT ICA (mm) 0.585±0.137 0.602±0.118 0.463 
Plaque score 0.473±0.684 0.892±0.897 0.025 
Plaque presence 15/41 (36.6%) 24/39 (61.5%) 0.026 
FMD baseline (mm) 3.65±0.46 3.76±0.48 0.301 
FMD maximum (mm) 3.90±0.48 3.96±0.45 0.537 
%FMD 6.89±3.33 5.55±3.53 0.031 
Age at index pregnancy (yrs) 29±5 30±5 0.628 
Yrs since index pregnancy at 
time of study visit (yrs) 
27.1±6.6 27.1±5.4 0.577 
Gestation at delivery (wks) 39.7±2.3 38.0±2.5 <0.001 
Birthweight (g) 3431±457 3013±681 0.002 
C-section  5/42 (11.9%) 13/40 (32.5%) 0.024 
 
BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, HDL = high 
density lipoprotein. AIx – augmentation index (here it is adjusted for heart rate), HR – heart rate,  
cfPWV – carotid-femoral pulse wave velocity, cIMT – carotid intima-media thickness, CCA – common 
carotid artery, ICA – internal carotid artery, FMD – flow-mediated dilatation. Data are presented as 
mean ± SD for continuous data or as a proportion for categorical data.  
* Mean of the 2
nd
 and 3
rd
 blood pressure readings taken. 
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On subgroup analysis evaluating length of time since index pregnancy, findings were 
similarly different, with more significant results in pregnancies which had occurred longer 
ago.   
 
Women with more recent index pregnancies ≤20 years ago showed significant differences 
in the areas of age at pregnancy (with pre-eclampsia cases being younger at time of 
delivery), gestation at delivery and birthweight (both of these values being lower in the 
pre-eclampsia group). There were no other significant differences between cases and 
normotensive controls (see Table 5.11), in particular, there were no differences in vascular 
study results.  
 
In contrast, when index pregnancies >20 years ago were analysed, pre-eclampsia cases had 
significantly higher BMI, SBP, DBP, significantly lower gestational age and birthweight at 
delivery and a higher proportion with C-section.  Vascular studies revealed significantly 
higher adjusted AIx, higher central SBP and DBP, higher cfPWV, higher cIMT CCA and 
lower FMD % in the pre-eclampsia group than the controls (see Table 5.12).  
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Table 5.11 Results for women at ≤ 20 years since index pregnancy 
 
 Normotensive 
Controls (N=34) 
Pre-eclampsia 
Cases (N=44) 
P-value 
Age at study visit (yrs) 41±5 41±9 0.764 
Height (cm) 163.8±6.7 161.7±6.8 0.173 
Weight (kg) 72.0±12.2 76.5±16.1 0.180 
BMI (kg/m
2
) 26.9±4.6 29.4±6.7 0.077 
Mean* SBP sitting (mmHg) 122±10 125±11 0.266 
Mean* DBP sitting (mmHg) 79±8 82±8 0.077 
Resting HR (bpm) 71±10 73±10 0.239 
SBP supine (mmHg) 117±11 122±12 0.087 
DBP supine (mmHg) 73±8 75±9 0.338 
Mean AIx at HR 75bpm 17.9±11.1 20.5±11.7 0.331 
Mean aortic SBP (mmHg) 107±12 112±12 0.109 
Mean aortic DBP (mmHg) 74±9 77±10 0.177 
Total cholesterol (mmol/L) 5.0±0.6 4.8±0.8 0.271 
Triglycerides (mmol/L) 1.3±0.6 1.1±0.6 0.100 
HDL  1.5±0.3 1.5±0.3 0.570 
Mean cfPWV (m/s) 6.8±1.0 7.0±1.0 0.372 
Mean cIMT CCA (mm) 0.590±0.100 0.604±0.113 0.617 
Mean cIMT BULB (mm) 0.634±0.124 0.624±0.132 0.644 
Mean cIMT ICA (mm) 0.509±0.107 0.514±0.103 0.848 
Plaque score 0.365±0.612 0.586±0.735 0.191 
Plaque presence 10/34 (29.4%) 19/43 (44.2%) 0.184 
FMD baseline (mm) 3.64±0.46 3.55±0.50 0.386 
FMD maximum (mm) 3.89±0.47 3.77±0.52 0.292 
%FMD 6.84±3.03 6.29±3.09 0.481 
Age at index pregnancy (yrs) 33.1±4.7 30.4±5.5 0.021 
Yrs since index pregnancy at time 
of study visit (yrs) 
8.1±4.9 10.7±6.4 0.123 
Gestation at delivery (wks) 39.4±2.0 37.2±3.6 <0.001 
Birthweight (g) 3326±613 2889±793 0.011 
C-section  15/34 (44.1%) 17/44 (38.6%) 0.626 
BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, HDL 
= high density lipoprotein. AIx – augmentation index (here it is adjusted for heart rate), HR – 
heart rate,  cfPWV – carotid-femoral pulse wave velocity, cIMT – carotid intima-media 
thickness, CCA – common carotid artery, ICA – internal carotid artery, FMD – flow-
mediated dilatation. Data are presented as mean ± SD for continuous data or as a proportion 
for categorical data.  
* Mean of the 2
nd
 and 3
rd
 blood pressure readings taken. 
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Table 5.12 Results for women >20 years since index pregnancy 
 
 Normotensive 
Controls (N=46) 
Pre-eclampsia 
Cases (N=42) 
P-value 
Age at study visit (yrs) 54.7±5.5 55.1±5.2 0.715 
Height (cm) 161.9±6.6 161.1±6.2 0.545 
Weight (kg) 68.8±10.3 76.3±14.1 0.004 
BMI (kg/m
2
) 26.3±4.4 29.5±5.5 0.007 
Mean* SBP sitting (mmHg) 123±10 135±15 <0.001 
Mean* DBP sitting (mmHg) 78±7 84±8 <0.001 
Resting HR (bpm) 71±8 72±11 0.534 
SBP supine (mmHg) 119±9.7 131±17 <0.001 
DBP supine (mmHg) 74±7 79±9 0.004 
Mean AIx at HR 75bpm 25.9±6.6 31.1±7.0 0.001 
Mean aortic SBP (mmHg) 112±11 124±17 <0.001 
Mean aortic DBP (mmHg) 75±7 80±9 0.002 
Total cholesterol (mmol/L) 5.6±1.1 5.8±1.0 0.563 
Triglycerides (mmol/L) 1.4±0.8 1.6±0.8 0.135 
HDL  1.5±0.4 1.5±0.4 0.844 
Mean cfPWV (m/s) 7.3±1.1 8.7±1.7 <0.001 
Mean cIMT CCA (mm) 0.647±0.117 0.709±0.131 0.022 
Mean cIMT BULB (mm) 0.713±0.154 0.731±0.144 0.568 
Mean cIMT ICA (mm) 0.588±0.146 0.593±0.135 0.839 
Plaque score 0.398±0.603 0.888±0.943 0.008 
Plaque presence 15/45 (33.3%) 24/41 (58.5%) 0.019 
FMD baseline (mm) 3.61±0.46 3.77±0.47 0.137 
FMD maximum (mm) 3.86±0.48 3.97±0.43 0.311 
%FMD 7.11±3.51 5.52±3.50 0.018 
Age at index pregnancy (yrs) 27.7±4.9 27.5±4.5 0.715 
Yrs since index pregnancy at time 
of study visit (yrs) 
27.4±5.6 28.0±4.1 0.147 
Gestation at delivery (wks) 39.8±2.2 38.2±2.8 <0.001 
Birthweight (g) 3450±461 3108±615 0.005 
C-section  4/46 (8.7%) 12/42 (28.6%) 0.016 
 
BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, HDL 
= high density lipoprotein. AIx – augmentation index (here it is adjusted for heart rate), HR – 
heart rate, cfPWV – carotid-femoral pulse wave velocity, cIMT – carotid intima-media 
thickness, CCA – common carotid artery, ICA – internal carotid artery, FMD – flow-
mediated dilatation. Data are presented as mean ± SD for continuous data or as a proportion 
for categorical data.  
* Mean of the 2
nd
 and 3
rd
 blood pressure readings taken. 
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 Discussion 5.4
 
 Findings 5.4.1
 
The key findings from this study were: 1) blood pressure was higher later in life in women 
with a history of pre-eclampsia, 2) gestational age at delivery and birth weight were lower 
in comparison with normotensive controls, however birth weight was not significantly 
different after adjusting for gestational age, 3) AIx @HR75, cfPWV and FMD were all 
significantly different between cases and controls but only FMD was determined by pre-
eclampsia status when adjusted for relevant confounders, and 4) women with a history of 
pre-eclampsia had a higher plaque score.  
 
This impaired FMD was not accounted for by other cardiovascular risk factors and it 
would appear that pre-eclampsia was an independent risk factor for impaired FMD in this 
study. Decreased FMD in women with a more remote history of pre-eclampsia in this 
study is different to the findings of other studies examining endothelial function after a pre-
eclamptic pregnancy. FMD has been found to be significantly lower in cases with pre-
eclampsia, closer to the time of the index pregnancy (136;138;139) and normalising after a 
decade (142;143). However, it is not surprising that FMD, a measure of endothelial 
function, would be the first modality to show evidence of change as endothelial function 
would be expected to be the earliest evidence of cardiovascular disease, as it precedes 
more structural alterations of cardiovascular disease in the blood vessels such as 
atherosclerosis. Henriques et al (402) found evidence of decreased FMD at 15 years 
following a pre-eclamptic pregnancy. On review of the literature this appears to be the only 
other study to date which shows any evidence of endothelial dysfunction after ~10 years 
when analysed by FMD. Regarding the women in whom there has been normalisation of 
endothelial dysfunction at 10 years after pre-eclampsia, it is not possible to know whether 
they would have started to show any evidence of endothelial dysfunction if they had been 
examined again at 15 years. Likewise, it is not possible to know what the vascular findings 
of COPS study subjects would have been 10 or 15 years ago. In this respect, the value of 
long-term prospective follow-up studies is considerable.  
 
Another source of potential difference between studies is the study protocol ranging from 
number of patients recruited, preparation of patient (fasting vs non-fasting), timing of the 
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study visit (morning vs afternoon), number of operators, differences in FMD equipment 
and analysis software to name a few. There are many confounders which must be taken 
into account when comparing studies.  
 
In the COPS study, age was not a predictor of FMD and it was important to establish 
whether or not age was driving the difference observed between cases and controls. There 
is evidence that after the age of 50yrs, FMD will decrease by 0.49% per year in women 
(403). Of note is also the seemingly low value for FMD in the COPS study population in 
general, even among the controls, in comparison with other studies in the field. However, 
in a study of age-related changes in vascular function (404), 56 healthy women aged 35 
years had FMD 5.7±3.5% and 47 women aged 55 years had FMD 2.6±2.3% (one woman 
in this group had suffered previous myocardial infarction and four women were on 
antihypertensive medication). These values, even in young healthy 35 year olds are lower 
than those found in the COPS study.  Overall, the COPS FMD values in the control 
population were more consistent with the values for women in a study which specifically 
aimed to establish reference values for FMD (405), which lends confidence to the 
conclusions reached in the COPS study.   
 
cIMT values were not different between groups in the COPS vascular study and there are 
conflicting reports in the literature regarding change in cIMT. There is evidence that pre-
eclampsia does not significantly increase carotid intima-media thickness (143). However 
there are a few studies which have shown some evidence of an increased cIMT. A study by 
Goynumer et al reported a significantly higher cIMT an average of 19 months after index 
pregnancy (138). Akhter et al (406) calculated the individual intima and individual media 
layers of the common carotid artery (CCA) and found that in women with severe pre-
eclampsia there was a significantly thicker CCA intima and intima/media ratio but the 
intima-media thickness itself was not significantly different between groups. Aykas et al 
(407) found increased cIMT at 5 years after index pregnancy. In the COPS study carotid 
plaque presence and plaque score were significantly higher in the pre-eclampsia group than 
controls and carotid plaque presence has been found to be an important predictor of 
cardiovascular risk in women (196). 
 
How might the difference in carotid plaques be explained against the absence of a 
difference in cIMT? First it is important to understand how different risk factors might 
influence cIMT and carotid plaque presence. In a recent study of 553 patients (337 women 
and 216 men) which sought to assess the different effects of traditional cardiovascular risk 
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factors on cIMT and plaque presence (408), the authors found that the probability of 
plaque occurrence was higher in patients with coronary artery disease and dyslipidaemia 
and was influenced by age but not hypertension or diabetes. Hypertension most increased 
cIMT, and when associated with coronary artery disease, diabetes and dyslipidaemia. 
cIMT measurements were significantly increased in the presence of hypertension, while 
blood lipid levels were more associated with carotid plaque formation (408;409). 
Hypertension was not found to contribute to the presence of plaque. In the COPS study on 
subgroup analysis of older women, there was a significantly higher cIMT along with a 
significant increase in blood pressure which would be in keeping with the literature. While 
there was a significantly higher plaque score, there was no difference in cholesterol level. 
There could be other confounders associated with the presence of carotid plaque (such as 
socioeconomic status) which were outwith the scope of this study, and further research is 
warranted. 
 
 Strengths 5.4.2
 
Sample size for the COPS vascular study exceeds many previous studies in the field (139-
142;178;400;402;407;410-415).  The benefits of a larger sample size include decreasing 
the likelihood of a false result. This is particularly important when the findings of a study 
contradict a substantial proportion of other published work in the field.  
 
There were a wide range of vascular studies performed in COPS, with thorough 
consideration as to how to detect any evidence of early subclinical vascular damage. In a 
recent meta-analysis of vascular dysfunction (179), none of the 37 studies included had 
evaluated as many different modalities for assessing vascular function (in one study visit) 
as COPS and this is a particular strength.  
 
The age range of recruitment meant further exploration of the data was possible such as 
how parameters varied depending on age or time since index pregnancy. For example, 
younger women were less likely to have differences in vascular function, and such 
differences were more exaggerated in women further from the time of index pregnancy. 
 
Another strength of this study is that it focussed on women at longer time-points since the 
index pregnancy than most other studies. The range for inclusion was up to 30yrs after 
pregnancy and average time since index pregnancy was ~20years. It is possible that 
vascular changes and evidence of endothelial dysfunction after a pregnancy complicated 
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by pre-eclampsia may vary over time, and while most other studies have continued for up 
to 10-11 years after the index pregnancy (142;143), relatively few have explored vascular 
function beyond this time (400). There have been reports in the literature of normalisation 
of endothelial dysfunction (which was present in the postpartum period) by 10 years after 
delivery (142;143).  
 
 Limitations 5.4.3
 
In the COPS study women were non-fasted, attended in the morning or the afternoon 
(timing of study visit was noted), were at varying stages throughout the menstrual cycle or 
postmenopausal and were inconsistencies regarding medication (e.g. hormonal 
contraception, hormone replacement therapy, antihypertensive therapies). These 
differences were not corrected for on analysis.  
 
Another weakness of the COPS study was that not all maternity records were reviewed. 
Some previous studies have used questionnaires and self-reported history of pregnancy in 
ascertainment of hypertension in pregnancy or pre-eclampsia in pregnancy. One such study 
at the Mayo Clinic, Minnesota (416) sought to validate a pre-eclampsia questionnaire and, 
when compared with Maternity records, they verified a diagnosis of pre-eclampsia, 
eclampsia or toxaemia with 80% sensitivity and 96% specificity. The study was published 
in 2008 and was based on pregnancies between 1960-1979, so all participant recall was for 
events more than 20 years previously (416).  However, there is always a potential for 
differing terminology over time affecting the recall diagnosis in more remote pregnancies. 
Nevertheless, maternity records which were checked in the COPS study showed excellent 
concordance with the study questionnaire data. Moreover, hypothetically, if any women 
had been misclassified and had been allocated to the wrong group, a detectable difference 
in the vascular study between groups would have been less likely, not more likely.  
 
For the COPS vascular study there were two operators, and while we were both equally as 
skilled and trained in performing vascular studies, this could potentially have introduced 
bias. The literature suggests very good reproducibility and repeatability for heart-rate 
adjusted augmentation index (AIx) and carotid-femoral pulse wave velocity (cfPWV) 
(417;418). Carotid intima-media thickness (cIMT) and flow-mediated dilatation (FMD) 
have also been found in previous studies to be reproducible (116;118;419-421). However, 
cIMT and FMD are considered to be more operator-dependent than other methods, and in 
view of this we trained extensively together, to acquire the same level of expertise. Intra-
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operator and inter-operator assessments were performed with excellent agreement as 
outlined in section 5.2.6.7. 
 
Sub-group analysis according to severity of pre-eclampsia, as assessed for example by 
gestational age at delivery or by the presence of eclampsia or HELLP syndrome was not 
performed. While this would have been possible, given the information available, any 
results would have been likely to have been underpowered due to small sample size.  
 
The index pregnancy was defined as in section 5.2.3. This was not necessarily the first 
pregnancy for controls, if they happened to experience a miscarriage initially, nor was it 
necessarily the first pregnancy in the pre-eclampsia group. Miscarriages have been found 
to confer an increased risk of cardiovascular disease (383;422). The fact that there is 
inconsistency between women as to which actual chronological pregnancy was being used 
is something which was not corrected for, and it would not be possible to exclude some 
level of bias or confounding as a result. However, both cases and controls were equally 
subject to the possibility of exclusion of a pregnancy from being an index pregnancy (no 
miscarriages or loss of a pregnancy at <20weeks gestation were used as the index case in 
either the pre-eclampsia group or the control group). The actual number of the pregnancy 
classified as “index pregnancy” (e.g. 1st, 2nd, 3rd) was noted. 
 
 Conclusions 5.4.4
 
This study identified several key differences between women with a history of pre-
eclampsia and women with normotensive pregnancies. Firstly, the differences in blood 
pressure persist beyond pregnancy and may be the very first marker of evolving 
cardiovascular disease, therefore in any women with a history of pre-eclampsia, blood 
pressure should be kept under review. Secondly, this study confirmed what is already 
known, about the birth characteristics of pregnancies which are associated with a higher 
degree of vascular dysfunction, specifically a lower birthweight and earlier gestation of 
delivery. Thirdly, what this study adds to the current literature, is the finding of decreased 
flow-mediated dilatation at a later age, many years after index pregnancy, even after 
adjusting for age, BMI and blood pressure. Pre-eclampsia is an independent risk factor for 
impaired endothelial function in women with a more remote history of the condition. When 
one considers the natural history of cardiovascular disease and its evolution, one might 
naturally expect measurement of endothelial function (as assessed by FMD) to show 
evidence of change before vessel stiffness (as assessed by AIx and cfPWV) or evidence of 
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atherosclerotic change in the carotid artery (as assessed by cIMT). Given this context, the 
difference in FMD is perhaps less unexpected, however it has not previously been reported 
in women this long after pregnancy to the best of the author’s knowledge. 
 
This study lends weight to the role for vascular studies in risk stratification for women with 
a history of pre-eclampsia. Such studies can reveal evidence of subclinical vascular 
damage and could be invaluable as an adjunct in the overall comprehensive assessment of 
risk in these women.  
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6 Biomarkers in women with a history of pre-eclampsia 
 
 Introduction 6.1
 
The link between cardiovascular disease and pre-eclampsia has been well established, 
however, the underlying mechanisms of this relationship are still not well understood.  
Confirmation of a history of pre-eclampsia has been recommended in guidelines for 
cardiovascular disease in women (89), and monitoring of blood pressure in these women 
has also been suggested as blood pressure is known to be increased in women after pre-
eclampsia. However, when we consider that there is a continuum in the evolution of 
cardiovascular disease (423), there may be crucial time points, even prior to later 
development of hypertension, where we might intervene in detecting a woman’s 
cardiovascular risk. Vascular dysfunction (as identified in study participants in the 
previous chapter) is an early marker of cardiovascular risk, correlating with future risk of 
cardiovascular events and precedes structural vascular damage (424).   
 
It is hoped that biomarkers may emerge to play a key role in the identification of early 
disease and add to a woman’s own personalised risk assessment of likelihood of 
developing cardiovascular disease. Endothelial dysfunction and inflammation are key 
components of both pre-eclampsia and cardiovascular disease. Biomarkers relating to these 
processes have been studied extensively, including their potential role in prediction of pre-
eclampsia and assessment of disease severity. Indeed, with regard to endothelial 
dysfunction there are several important mediators which are upregulated in pre-eclampsia. 
These include von Willebrand factor, cellular fibronectin, cell adhesion molecules (such as 
P-selectin, VCAM-1 and ICAM-1) and cytokines (such as TNFα and IL-6) (425). 
Generalized vasoconstriction as seen in pre-eclampsia may be due in part to nitric oxide 
deficiency. Oxidative stress from generation of free radicals also contributes to endothelial 
dysfunction, not only in pre-eclampsia, but also in atherosclerosis (425). Pro-angiogenic 
effects of VEGF are antagonised by sFlt-1 thus enhancing endothelial dysfunction and 
contributing to proteinuria and hypertension. PlGF levels in the maternal circulation are 
also reduced. 
 
Nevertheless, the investigation of biomarkers after hypertensive disorders of pregnancy has 
not proven to be forthcoming with any clear answers. Biomarkers which are key in the 
evolution and prediction of pre-eclampsia may not play as important a role in predicting 
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cardiovascular risk later in life. Variation between studies such as length of time since 
index pregnancy, varying study populations and sample size further complicate the issue 
when attempting to generalise and apply the results of these studies to the population as a 
whole.  
 
There are a few recent systematic reviews and meta-analyses of biomarkers after 
hypertensive disorders of pregnancy (179;250;426). In pooled analyses, Grand’Maison et 
al (179) found mean levels of sFlt-1 were slightly higher in women with a history of 
hypertensive disorder of pregnancy, but VEGF revealed no significant differences between 
groups. Visser et al also reported on studies investigating biomarkers of angiogenesis. 
They described a few individual studies with two studies reporting higher VEGF and sFlt-1 
levels (251;252) in women with a history of hypertensive disorders of pregnancy. Two 
studies described higher TNFα levels (256;271), and one study lower TNFα levels (270) in 
these women. 
   
On examination of biomarkers of inflammation, Grand’Maison et al (179) reported similar 
levels of ICAM-1 and VCAM-1 between the groups of women. Visser et al (250) also 
showed no significant difference overall in mean ICAM levels between women with a 
history of hypertensive pregnancy and controls. Mean VCAM levels similarly showed no 
significant differences between groups. Overall, IL-6 levels and E-selectin levels were 
higher in women with a history of hypertensive pregnancy disorders. A study by Freeman 
et al (256) which is referenced in one of the pooled analyses (250), found an increased IL-
6/IL-10 ratio in women 20 years after index pregnancy. Plasma ICAM-1 and VCAM-1 
levels were also higher in this group of women in this study.    
 
In addition to the more conventional biomarkers previously studied in relation to 
cardiovascular disease and hypertensive disorders of pregnancy, such as inflammatory 
markers and adhesion molecules, this chapter also sought to investigate markers of 
cardiovascular damage and collagen turnover. These included high sensitivity cardiac 
troponin (hsTnT) and N-terminal pro brain natriuretic peptide (NT-proBNP) as markers of 
cardiovascular damage, and carboxy-terminal telopeptide (C1TP), carboxy-terminal 
propeptide of type 1 procollagen (P1CP) and tissue inhibitor of metalloproteinase-1 
(TIMP-1) as markers of collagen turnover.  
 
NT-proBNP and cardiac troponin T (TnT) have both been found to be independent 
predictors of incident cardiovascular disease and coronary heart disease in a study of 
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asymptomatic individuals with multi-ethnic background (427). NT-proBNP is established 
as an important biomarker in heart failure (428). It has also been found to be significantly 
higher in women with a history of pre-eclampsia in comparison with controls in a 
systematic review and meta-analysis of shared biomarkers between diastolic heart failure 
and pre-eclampsia (429). High sensitivity cardiac troponin (hsTnT) has been investigated 
in heart failure (430;431) and has also been found to be independently associated with 
incident coronary heart disease, death and heart failure in a large cohort (432).  
 
Markers of collagen turnover have also been linked to several different areas of 
cardiovascular disease (433). Cardiac fibroblasts (CFBs) produce extracellular matrix 
proteins to maintain the integrity of the cardiac extracellular matrix (ECM).  They also 
produce regulatory proteins such as matrix metalloproteinases (MMPs) and their inhibitors 
(TIMPs). TIMP-1 levels rise in heart disease; it is usually expressed at low levels in the 
healthy heart (433). In a study of TIMP-1, C1TP and P1CP in hypertensive patients, all 
three were significantly increased (434). More specific to pre-eclampsia, TIMP-1 levels 
have previously been found to be increased (435;436), in these women. 
 
Urinary proteomic biomarkers have been developed for early diagnosis in several diseases 
such as stroke (437), chronic kidney disease (438), coronary artery disease (439), and pre-
eclampsia (340). Coronary artery disease (CAD238) and kidney disease (CKD273) panels 
were analysed as described in this chapter to investigate whether there were any 
differences between cases and controls. In addition, the pre-eclampsia panel was included 
to establish if it was able to differentiate between cases and controls at a much later time 
point after pregnancy. 
 
The overall aims of this chapter were to investigate whether there were any significant 
differences in biomarkers such as inflammatory cytokines, adhesion molecules, markers of 
cardiac damage, markers of collagen turnover and urinary proteomic panels in women with 
pre-eclampsia and normotensive controls years after delivery. 
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 Methods 6.2
 
 Patient recruitment 6.2.1
 
For the biomarker studies discussed in this chapter, samples were studied from two 
separate cohorts: women who had participated in GS:SFHS and women who attended for 
the COPS vascular studies. Generation Scotland study samples were prepared at the time 
of the study visit as mentioned in section 6.2.3.1. 
 
For women who attended for the COPS vascular study, their samples were prepared at the 
time of the study visit as outlined in Chapter 2. 
 
 Identification of samples for biomarker studies 6.2.2
 
 The Generation Scotland cohort 6.2.2.1
 
Women with a history of pre-eclampsia had already been identified as part of the 
Generation Scotland record linkage study in Chapter 3. Of the pre-eclampsia cases 
identified, 329 had samples available and they were each matched to two normotensive 
controls (658 controls in total). Each case therefore had a corresponding control 1 and 
control 2. Matching was based on smoking history, year of birth, BMI and systolic blood 
pressure. From this, a matched set of 56 cases with their 112 corresponding controls for 
biomarker studies was derived. Cases were chosen according to median time since index 
(pre-eclamptic) pregnancy. Cases were taken from the right and left of the median and for 
the final cohort, by the time of biomarker studies, median length of time since index 
pregnancy was 32yrs. Of the total 168 participants (56 cases and 112 controls) identified, 4 
serum samples were not available (1 case, 2 x control 1, and 1 x control 2). Due to the 
methods of statistical analysis for a matched pairs design, biomarker data was excluded 
from analysis for the missing case and its corresponding controls. The Generation Scotland 
cohort underwent biomarker analysis on the Randox Investigator platform (section 6.2.4.1) 
and ELISA studies (section 6.2.4.2). 
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 COPS vascular study cohort 6.2.2.2
 
Of the COPS vascular study participants, 40 cases and 40 controls were picked for 
biomarker studies. These samples were not specifically matched as the COPS vascular 
study was still recruiting at the time biomarker studies began. Serum samples were 
available for analysis on the Luminex® MAGPIX® platform on 37 cases and 37 controls 
and urine samples were available for urinary proteomic analysis in 38 cases and 38 
controls.  
 
 Sample preparation 6.2.3
 
 Generation Scotland sample preparation 6.2.3.1
 
Generation Scotland samples were collected and stored according to standard operating 
procedures. A laboratory information management system (LIMS) was utilised and 
samples were barcoded. The barcode acted as a unique identifier and linked all data 
collected with blood and urine samples obtained at the study visit. A total of 35ml of blood 
was collected from GS:SFHS participants: 1 x 9ml EDTA (lavender top), 3 x 5ml serum 
gel separator (SST) (gold top), 1 x 9ml ACD (yellow top), 1 x 2ml fluoride oxalate (grey 
top).  The fluoride oxalate and 1 SST gold top tube were forwarded to local NHS 
biochemistry laboratories for biochemistry analysis (glucose, urea and electrolytes, lipids). 
Samples were then forwarded to the local Generation Scotland site, which for Glasgow 
was BHF GCRC. 1 x 9ml EDTA was stored at -80
o
C until sent to the Wellcome Trust 
Clinical Research Facility in Edinburgh for further processing. Cryotubes were used for 
urine 4 x 1ml aliquots and serum (prepared from gold top SST tubes) 4 x 1ml aliquots, all 
stored at -80
o
C.  
 
For the purposes of the studies outlined in this chapter, requested serum samples were 
thawed before processing and Mr Jim McCulloch at BHF GCRC oversaw the forwarding 
of a 150ul aliquot was to Dr Anne Marie Jennings at Randox for processing as described in 
section 6.2.4.1, and a 300ul aliquot to Dr Susanna Ravassa at the University of Navarra, 
Pamplona for ELISA studies mentioned in section 6.2.4.2.  
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 COPS study sample preparation 6.2.3.2
 
Samples were collected from the antecubital fossa, centrifuged at 2500 rpm for 15 minutes 
at 4
oC, and for the purposes of future biomarker analysis 0.5μl aliquots of serum and 
plasma were placed in cryotubes and stored at -80
o
C. Otherwise, a lavender EDTA tube for 
future DNA analysis and a blue tempus RNA tube were also stored at -80
o
C. Urine was 
stored in 3 x 1ml cryotube aliquots. Samples were then thawed prior to testing. A 50ul 
aliquot of serum was forwarded to Ms Liliya Sharafetdinova at the BHF GCRC for 
processing on the Luminex® MAGPIX® platform, as described in section 6.2.4.3. A 700ul 
aliquot of urine was forwarded to the University of Glasgow ICAMS Proteomics 
Laboratory for urinary proteomic analysis, also performed by Ms Liliya Sharafetdinova as 
outlined in section 6.2.4.4 and overseen by Dr William Mullen. 
 
 Biomarker studies 6.2.4
 
 Randox Investigator platform studies 6.2.4.1
The Randox Evidence Investigator platform was used to assess biomarkers in the Adhesion 
Panel (VCAM-1, ICAM-1, E-selectin, P-selectin and L-selectin) and in the Cytokine High 
Sensitivity Array Panel (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, VEGF, IFNγ, EGF, 
MCP-1 and TNFα) . Samples were analysed by Dr Ann Marie Jennings (Randox 
Laboratories, County Antrim, UK), using Biochip Array Technology.  
 
A 9x9mm biochip was used to analyse multiple different biomarkers at once for each 
sample. This was achieved through the pre-fabrication of discrete test regions (DTRs) with 
immobilised antibodies which were specific for a different biomarker at each region, 
therefore one biochip (with multiple markers) was used for each sample. The biochips 
were arranged in carriers with 3x3 biochips, and these were then handled in trays with a 
capacity of 6 carriers for each tray. Chemiluminescent immunoassay technology was used, 
with an increase in chemiluminescence signal occurring if there was an increased level of 
the biomarker present. The mechanism for this was that increased levels of the marker 
would enhance the amount of binding of antibody labelled with horseradish peroxidase 
(HRP), which would in turn enhance the amount of signal emitted.  Digital imaging 
technology picked up the light signals from each region of the biochip and compared them 
against calibrated values. The concentration of the biomarker was calculated from this 
information. Biochips specific for the Adhesion molecules panel and the Cytokine High 
Sensitivity Array Panel were used for the purposes of this study. 
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Table 6.1 Sensitivities and assay precision for Randox Cytokine High 
Sensitivity Array and Adhesion Molecules array 
Analyte Sensitivity Reported intra-
assay precision 
Reported inter-
assay precision 
Cytokine high sensitivity array 
IL-1α 0.19 pg/ml 9.7-11.4% 8.9-15.5% 
IL-1β 0.26 pg/ml 7.4-9.3% 8.7-11.8% 
IL-2 0.90 pg/ml 5.8-7.8% 6.5-8.2% 
IL-4 2.12 pg/ml 8.1-9.5% 8.6-11.8% 
IL-6 0.12 pg/ml 7.8-11.9% 7.4-8.4% 
IL-8 0.36 pg/ml 7.0-9.4% 9.2-11.1% 
IL-10 0.37 pg/ml 5.6-6.8% 6.5-7.5% 
VEGF 1.53 pg/ml 7.3-10.8% 7.2-12.0% 
IFNγ 0.44 pg/ml 7.4-10.1% 6.4-11.4% 
EGF 1.04 pg/ml 9.2-9.6% 8.5-11.7% 
MCP-1 0.66 pg/ml 5.8-12.2% 7.2-12.8% 
TNFα 0.59 pg/ml 7.1-12.7% 6.7-8.6% 
Adhesion molecules array 
VCAM-1 4.1 ng/ml 7.7-9.2% 5.9-9.6% 
ICAM-1 1.7 ng/ml 6.4-9.4% 3.5-8.3% 
E-Selectin 0.1 ng/ml 5.2-7.4% 7.5-8.6% 
P-Selectin 1.9 ng/ml 6.1-9.6% 4.8-7.2% 
L-Selectin 3.2 ng/ml 6.1-9.1% 7.7-13.4% 
 
 ELISA studies 6.2.4.2
Markers of collagen turnover and cardiac damage were analysed by Dr Susana Ravassa at 
the University of Navarra, Pamplona, Spain, and tests were carried out on available kits 
according to manufacturer protocols and specifications. Carboxy-terminal telopeptide of 
type 1 collagen (C1TP) was tested by enzyme immunoassay (Orion Diagnostica, Espoo, 
Finland), carboxy-terminal propeptide of type 1 procollagen (P1CP) was analysed by 
ELISA (Quiadel Corporation, San Diego, USA) and tissue inhibitor of metalloproteinase 1 
(TIMP-1) was analysed by ELISA (GE Healthcare, Little Chalfont, UK).   
For biomarkers of cardiac damage, high sensitivity cardiac troponin T (TnT) was analysed 
by ELISA (Roche Diagnostics, Basel, Switzerland) and N-terminal prohormone of brain 
natriuretic peptide (NT-proBNP) was similarly tested by ELISA (Roche Diagnostics, 
Basel, Switzerland).  
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 Luminex® MAGPIX® platform studies 6.2.4.3
Samples were analysed using the Merck MILLIPLEX
®
 MAP Human Th17 Magnetic Bead 
Panel and results analysed using the Luminex
®
 MAGPIX
®
 system which uses light-
emitting diode /charge-coupled device image-based detection.  
Reagents were prepared according to the manufacturer instructions and specifications. All 
reagents were warmed to room temperature before use. Assay buffer (200μl) was added to 
each well of the experiment plate. This was sealed and mixed on a plate shaker at room 
temperature for 10 minutes. The buffer was then removed from the wells thoroughly by 
inverting the plate onto absorbent towels. Control or standard (25μl) was added to 
appropriate wells and 25μl of assay buffer was then added to background and sample 
wells. Appropriate matrix solution (25μl) was added to control, standards and background 
wells. Samples (25μl) were added to the sample wells and beads (25μl) were then added to 
each well. The plate was sealed, covered with foil and incubated for 16-18 hours overnight 
at 4
o
C.
 Well contents were removed and 200μl wash buffer was used to wash the plate 
twice. Detection antibodies (25μl) were added to each well and the plate was sealed, 
covered in foil and incubated at room temperature for an hour. Streptavidin-Phycoerythrin 
(25μl) was added to each well. The plate was then sealed, covered with foil and incubate at 
room temperature for 30 minutes. Well contents were removed and 200μl of wash buffer 
was again used to wash the plate twice. Drive fluid (150μl) was added to all wells and 
beads were re-suspended on a plate shaker for 5 minutes. The plate was then run on the 
MAGPIX
®
 system. Analyte sample concentrations were calculated using Median 
Fluorescent Intensity (MFI) data.  
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Table 6.2 Assay information for the Merck MILLIPLEX® MAP Human TH17 
Panel 
Analyte Minimum Detectable 
Concentration 
(MinDC) 
Reported 
intra-assay 
precision 
Reported 
inter-assay 
precision 
IL-17F 0.009 ng/ml 2% 10% 
GM-CSF 0.146 ng/ml 5% 13% 
IFNγ 1.8 pg/ml 4% 13% 
IL-10 0.3 pg/ml 3% 11% 
CCL20/MIP3α 2.2 pg/ml 5% 10% 
IL-12p70 1.1 pg/ml 3% 8% 
IL-13 2.4 pg/ml 3% 9% 
IL-15 2.7 pg/ml 4% 12% 
IL-17A 2.1 pg/ml 3% 13% 
IL-22 0.021 ng/ml 4% 8% 
IL-9 6 pg/ml 3% 5% 
IL-1β 2.1 pg/ml 4% 11% 
IL-33 6.3 pg/ml 5% 11% 
IL-2 5.1 pg/ml 3% 11% 
IL-21 2 pg/ml 3% 11% 
IL-4 0.009 ng/ml 4% 11% 
IL-23 0.098 ng/ml 3% 9% 
IL-5 1.2 pg/ml 4% 7% 
IL-6 1.7 pg/ml 5% 7% 
IL-17E/IL-25 0.099 ng/ml 5% 10% 
IL-27 0.063 ng/ml 4% 10% 
IL-31 0.021 ng/ml 4% 8% 
TNFα 0.9 pg/ml 4% 11% 
TNFβ 0.021 ng/ml 3% 7% 
IL-28A 0.038 ng/ml 3% 13% 
 
 
 Urinary proteomic studies 6.2.4.4
 
Prior to analysis samples were thawed and a 700μl aliquot of urine was then diluted with a 
700μl volume of 2 mol/L urea and 10 mmol/L NH4OH containing 0.02% sodium dodecyl 
sulphate (SDS). Samples were spun at a temperature of 4
o
C for 1 hour at 3000g using a 
Centrisart ultracentrifugation device (Sartorius, Gӧttingen, Germany). This removed 
proteins with a molecular weight of greater than 20 kDa. Salts, urea and electrolytes were 
then removed by running the filtrate through a PD-10 desalting column (Amersham 
Bioscience, Buckinghamshire, UK) and peptide elution was performed with 0.01% 
aqueous NH4OH. Samples were then lyophilised, suspended in high-performance liquid 
chromatography-grade water, and stored at 4
o
C prior to analysis by CE-MS.  
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CE-MS was performed by coupling a P/ACE MDQ capillary electrophoresis system 
(Beckman Coulter, Fullerton, USA) to a micro time-of-flight (micro-TOF) mass 
spectrometer (Bruker Daltonic, Bremen, Germany). First the silica capillary was rinsed for 
3 minutes with a buffer of 30% methanol and 0.5% formic acid in HPLC grade water. 
Approximately 700nl sample was injected into the capillary. A charge of +30kV was 
applied at the capillary inlet in order to separate peptides, and the entire length of the 90cm 
capillary was kept at a constant temperature of 35
o
C. Before a further sample can be 
processed, the capillary must first be rinsed with 0.1M NaOH, then water for 5 minutes 
followed by running buffer.  
 
Peptides were then identified by their mass/charge ratio. The electro-ionisation (ESI) 
sprayer (Agilent Technologies, California, USA) was grounded and the potential was fixed 
at -4.5kV. Every 3 seconds, spectra were accumulated over a range of mass-to-charge 
ratios (350-3000). The mean was calculated afterwards. Due to the vast amount of 
information which is produced with each CE-MS run, several further steps were necessary 
in data processing. Peaks were detected and their charges calculated by specialised 
software (Mosaiques Visu) (440). The data were then deconvoluted which resulted in a 
single mass being recorded by the software following analysis of many spectral peaks 
which were created from the same molecule at different charge states.  
 
Due to potential confounding (both from patient and sample analytical issues), it was 
important to normalise the data for CE migration time and signal intensity. There are 29 
“housekeeping” peptides which function as internal standards and are unaffected by 
disease states, age or gender (441). These were used to normalise the data. The end result 
of processing was a peak list which characterised each peptide based on its CE migration 
time, molecular mass and signal intensity.  
 
For all samples which passed quality control, the peptide information generated was 
entered into a Microsoft SQL database to facilitate comparison with other samples. 
Features between samples were considered the same if mass deviation was < ±50ppm at 
800 Da and increased to ±75ppm for 20kDa peptides. A unique identification number was 
assigned to each peptide. 
 
In order to perform statistical analysis of CE-MS results between patient groups, a single 
numerical value, the “classification factor” was derived using MosaCluster software. This 
uses support vector machine (SVM) based mathematical modelling. Several urinary 
Chapter 6  187 
 
1
8
7
 
 
proteomic panels have been derived for use in research and for the purposes of the studies 
in this chapter, the CKD273 (438), CAD238 (439) and pre-eclampsia (340) panels were used.  
 
 Statistical analysis 6.2.5
 
Statistical analyses were performed using Minitab v17 (Minitab Inc, State College, PA, 
USA) and SPSS v22 (IBM Corp, Armonk, New York, USA). Normality of the distribution 
was assessed using the Kolmogorov-Smirnov test and visual inspection of histograms and 
plots.  
 
No outliers were removed for the COPS vascular study cohort. For the Generation 
Scotland cohort, a minimal number of outliers were removed for reasons of suspicion of 
technical artefact in the following samples: NT-proBNP (1 case), hsTnT (1 case), IFNγ (1 
case), IL-10 (2 controls), IL-2 (1 case), IL-6 (1 case, 1 control), IL-8 (1 control), TNFα (1 
control). For any biomarker samples with results which registered as less than the limit of 
detection (LOD), a value of half of the limit of detection was used (LOD/2).  
 
Data were transformed as required and expressed as mean ± standard deviation if normally 
distributed and as median (inter-quartile range) if distribution did not normalise following 
transformation. For matched pairs comparison in the Generation Scotland cohort, for 
continuous data, the mean of the two control values was used to represent controls overall, 
thus, for each case there was one corresponding control value. Paired t-test was used to 
compare normally distributed data. If data were not normally distributed and failed to 
normalise on transformation, related samples Wilcoxon signed rank test was used.  Fisher’s 
exact test was used to compare categorical data. For independent samples comparison for 
the unmatched COPS vascular study cohort and the second stage of the Generation 
Scotland cohort tests, independent samples t-test was carried out on normally distributed 
data, and if data were not normally distributed and did not normalise on transformation, 
comparisons were made using the Mann-Whitney U test. Comparison of categorical data 
was performed using Chi-squared test, or Fisher’s exact test as appropriate. Correlations 
were analysed using Pearson’s or Spearman’s correlation coefficient as required.  Further 
analysis was performed using multivariate linear regression where appropriate. This was 
considered to be an exploratory study, therefore a p-value of <0.05 was used as the cut-off 
for significance. 
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 Results 6.3
 
Table 6.3 Generation Scotland study patient characteristics for all original                 
pre-eclampsia cases and matched controls 
Parameter Control (n=658) Case (n=329) P-value 
Age (yrs) 53 (11) 53 (10) 0.125 
BMI (kg/m
2
) 27 (6.8) 27 (8) 0.126 
SBP (mmHg) 129 (21) 130 (23) < 0.001 
DBP (mmHg) 81 (12) 82 (12) < 0.001 
Glucose (mmol/L) 4.6 (0.5) 4.6 (0.7) 0.891 
HDL cholesterol (mmol/L) 1.54 ± 0.3 1.57 ± 0.4 0.579 
Total cholesterol (mmol/L) 5.38 ± 0.8 5.27 ± 1.1 0.072 
Sodium (mmol/L) 140 (2) 140 (2) 0.324 
Potassium (mmol/L) 4.1 (0.3) 4.1 (0.4) 0.996 
Urea (mmol/L) 4.8 ± 0.9 4.9 ± 1.3 0.852 
Creatinine (μmol/L) 67 (10) 66 (13) 0.673 
Birth weight index 
pregnancy (grams) 
3454.5 (472.5) 3300.0 (868.0) <0.001 
Gestation at delivery index 
pregnancy (weeks) 
40 (1) 39 (2) <0.001 
Current hypertension 61/606 (10.1%) 94/322 (29.2%) 0.000 
Current diabetes 8/606 (1.3%) 12/322 (3.7%) 0.029 
Current smoker 93/609 (15.3%) 46/320 (14.4%) 0.772 
 
Results are presented as mean ± standard deviation or median (inter-quartile range) as 
appropriate. Data were analysed using paired t-test or Wilcoxon signed rank. Categorical 
data were analysed using Fisher’s exact test. 
Subjects were matched for Smoking status, year of birth, BMI and systolic blood pressure.  
BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, HDL 
= high density lipoprotein 
 
In the overall cohort of 329 cases and 658 controls, women with a history of pre-eclampsia 
had a statistically significantly higher systolic blood pressure and diastolic blood pressure 
later in life and they were more likely to have given birth to lower birth weight babies and 
at an earlier gestation (see Table 6.3). Descriptive statistics for the cohort which was 
chosen from this group for biomarker studies can be seen in Table 6.4. 
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Table 6.4 Characteristics of Generation Scotland biomarker studies cohort 
Parameter Controls (n=110) Cases (n=55) P-value 
Age (yrs) 56 (2.5) 56 (3.0) 0.819 
BMI (kg/m
2
) 26 (7.5) 26 (8) 0.060 
SBP (mmHg) 134 ± 16 136 ± 18 < 0.001 
DBP (mmHg) 82 ±9 84 ± 10 0.216 
Glucose (mmol/L) 4.65 ± 0.38 4.86 ± 0.86 0.108 
HDL cholesterol (mmol/L) 1.6 ± 0.3 1.5 ± 0.4 0.179 
Total cholesterol (mmol/L) 5.5 ± 0.7 5.7 ± 1.1 0.276 
Sodium (mmol/L) 140.4 ± 1.4 139.8 ± 1.8 0.076 
Potassium (mmol/L) 4.1 ± 0.3 4.0 ± 0.4 0.466 
Urea (mmol/L) 5.0 ± 0.8 5.1 ± 0.9 0.795 
Creatinine (μmol/L) 67.4 ± 7.0 66.4 ± 10.7 0.590 
Birth weight index pregnancy 
(grams) 
3425 (560) 3390 (850) 0.221 
Gestation at delivery index 
pregnancy (weeks) 
40 (1) 40 (1) 0.058 
Current hypertension 14/98 (14.3%) 15/53 (28.3%) 0.051 
Current diabetes 2/98 (2.0%) 3/53 (5.7%) 0.345 
Current smoker 11/99 (11.1%) 5/53 (9.4%) 1.000 
 
Results are presented as mean ± standard deviation or median (inter-quartile range) as 
appropriate. 
Results are from paired t-test or Wilcoxon signed rank. The mean of controls was used to 
provide one overall value for controls for this test. Subjects were matched for Smoking 
status, year of birth, BMI and systolic blood pressure. Categorical data were analysed using 
Fisher’s exact test. 
BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, HDL 
= high density lipoprotein 
 
The difference in systolic blood pressure between cases and controls were also statistically 
significantly different in this smaller cohort whereas birth characteristics did not remain 
statistically significantly different.  Current diagnosis of hypertension and diabetes were 
more prevalent in the overall cohort of 329 cases and 658 controls, however these were not 
significantly different in the smaller biomarker studies cohort. 
Cases and controls had been matched for smoking so there was no significant difference 
between cases and controls for this parameter (see Tables 6.3 and 6.4). 
For the COPS vascular studies cohort, pre-eclampsia cases had significantly higher systolic 
blood pressure and diastolic blood pressure than controls (see Table 6.5). This was 
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consistent across sitting blood pressure, supine blood pressure and the calculated central 
blood pressures on pulse wave analysis. Mean heart-rate adjusted augmentation index was 
also significantly higher in cases, along with mean pulse wave velocity. Gestation at 
delivery and birth weight of index pregnancy were both statistically significantly lower in 
cases and women with pre-eclampsia were more likely to have a diagnosis of hypertension 
or have a blood pressure measurement in the hypertensive range at time of the COPS 
vascular study visit. 
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Table 6.5 Characteristics of the COPS vascular study cohort 
Parameter Controls (n=40) Cases (n=40) P-value 
Age (yrs) 46 (9) 46 (10) 0.761 
BMI (kg/m
2
) 27.3 ± 4.6 27.5 ± 4.4 0.876 
Height (cm) 163.2 ± 7.0 162.2 ± 6.7 0.524 
Weight (kg) 72.7 ± 12.8 72.2 ± 11.7 0.855 
Mean* SBP (mmHg) 122.7 ± 9.4 130.2 ± 15.5 0.012 
Mean* DBP (mmHg) 77.5 ± 7.6 82.5 ± 8.4 0.006 
Resting Heart Rate (bpm) 70 ± 9 72 ± 11
# 
0.477 
Total cholesterol (mmol/L) 5.22 ± 0.82 5.27 ± 0.92 0.768 
Triglycerides (mmol/L) 1.03 (0.95) 1.0 (0.70)
† 
0.472 
HDL cholesterol (mmol/L) 1.3 (0.55)
‡
 1.5 (0.47)
§ 
0.499 
Supine SBP (mmHg) 117 ± 10 125 ± 15 0.005 
Supine DBP (mmHg) 72 ± 7 77 ± 9 0.010 
Mean Central SBP (mmHg) 108 ± 10 116 ± 14 0.004 
Mean Central DBP (mmHg) 73 ± 7 78 ± 9 0.006 
Mean AIx @75  21.4 ± 8.5 25.5 ± 9.0 0.041 
Mean PWV (m/s) 7.08 ± 0.99 7.75 ± 1.71 0.036 
Mean cIMT CCA 0.630 ± 0.114 0.640 ± 0.127 0.713 
Mean cIMT Bulb 0.696 ± 0.139 0.698 ± 0.141 0.956 
Mean cIMT ICA 0.573 ± 0.154
†
 0.561 ± 0.141
#
 0.720 
FMD % 6.41 ± 3.18ª 5.95 ± 3.05
b
 0.541 
Age at index pregnancy (yrs) 30 ± 6 29 ± 4 0.229 
Time since index pregnancy (yrs) 16.5 (17) 19.0 (16) 0.330 
C-section 13 (32.5%) 14 (35%) 0.813 
Gestation at delivery (wks) 40 (2.0) 38 (3.7) 0.000 
Birth weight (g) 3446.7 ± 511 2898.8 ± 756
 
0.000 
Current hypertension diagnosis 3 (7.5%) 11 (27.5%) 0.037 
Hypertensive range blood    
pressure at COPS study visit 
1 (2.5%) 8 (20%) 0.029 
Current diabetes 0 (0%) 1 (2.5%) 1.000 
Current smoking 6 (15%) 3 (7.5%) 0.481 
 
Values are expressed as mean ± standard deviation or median (inter-quartile range) 
depending on distribution of the data. Two-sample t-test or Mann-Whitney U tests were 
performed accordingly. Chi-test/Fisher’s exact test was performed for categorical variables. 
*Mean of 2
nd
 and 3
rd
 blood pressure readings.  
# For this group n=38, † this group n=39,  ‡ this group n= 29, §this group n= 36  
ª this group n=33, 
b
this group n=37. 
BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, HDL 
= high density lipoprotein 
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 Generation Scotland cohort 6.3.1
 
 Results of biomarker studies 6.3.1.1
 
Analysis of biomarker studies in the Generation Scotland cohort was conducted as paired 
tests according to original matching criteria, matching each case to the mean of its two 
controls. In addition I also analysed the dataset as two independent samples so that I was 
able to adjust for a wider range of co-variates. 
 
Table 6.6 Results from Generation Scotland biomarker study group when 
analysed as matched cases and controls 
 Controls (n=55)* Cases (n=55) P-value 
Cytokine high sensitivity array 
IL-1α (pg/ml) 0.225 (0.245) 0.195 (0.145) 0.015 
IL-1β (pg/ml) 0.98 (0.69) 0.98 (1.09) 0.090 
IL-2 (pg/ml) 1.28 (1.55) 0.45 (2.0) 0.736 
IL-4 (pg/ml) 1.94 ± 0.56 1.74 ± 0.55 0.017 
IL-6 (pg/ml) 2.18 ± 1.26 1.91 ± 1.64 0.030 
IL-8 (pg/ml) 17.37 ± 14.5 17.68 ± 16.3 0.594 
IL-10 (pg/ml) 0.764 ± 0.322 0.816 ± 0.540 0.749 
IL-6/IL-10 ratio 3.10 ± 1.93 2.89 ± 2.69 0.075 
VEGF (pg/ml) 128.14 ± 79.73 197.72 ± 179.19 0.085 
IFNγ (pg/ml) 0.31 (0.26) 0.22 (0.03) 0.000 
EGF (pg/ml) 77.81 ± 36.88 81.87 ± 56.30 0.618 
MCP-1 (pg/ml) 234.9 ± 66.2 220.9 ± 84.9 0.338 
TNFα (pg/ml) 3.01 ± 0.84 2.90 ± 1.00 0.494 
Adhesion molecules array 
VCAM-1 (ng/ml) 513.9 ± 106.0 469.9 ± 125.6 0.039 
ICAM-1 (ng/ml) 278.53 ± 73.51 250.35 ± 74.98 0.043 
E-Selectin (ng/ml) 16.47 ± 5.55 16.03 ± 5.33 0.653 
P-Selectin (ng/ml) 190.2 ± 41.6 192.2 ± 57.8 0.840 
L-Selectin (ng/ml) 1548.5 ± 289.6 1487.4 ± 408.7  0.378 
ELISA studies 
NT-proBNP (ng/L) 67.93 ± 33.65 68.00 ± 35.69 0.946 
hsTnT (μg/L) 0.00582 ± 0.0023 0.00579 ± 0.0022 0.939 
P1CP (ng/ml) 82.55 ± 26.28 84.06 ± 28.76 0.797 
C1TP (ng/ml) 3.07 ± 0.87 2.81 ± 0.96 0.169 
TIMP-1 (ng/ml) 388.46 ± 67.13 415.92 ± 91.21 0.094 
* Mean of control 1 and control 2 used  = 55 data entries for analysis. Results are presented 
as mean ± standard deviation or median (inter-quartile range) as appropriate. 
On paired analysis, IL-1α, IL-4, IL-6 and IFNγ were significantly lower in cases than 
controls. VCAM-1 and ICAM-1 were also statistically significantly lower in cases. The IL-
6/IL-10 ratio was lower in cases than controls, but this was not statistically significant. 
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Table 6.7 Results from Generation Scotland biomarker study group when 
analysed as two independent samples 
 Controls (n=107) Cases (n=55) P-value 
Cytokine high sensitivity array 
IL-1α (pg/ml) 0.20 (0.13) 0.20 (0.15) 0.852 
IL-1β (pg/ml) 1.11 (1.23) 0.98 (1.09) 0.192 
IL-2 (pg/ml) 0.45 (1.89) 0.45 (2.00) 0.418 
IL-4 (pg/ml) 1.78 (0.56) 1.62 (0.40) 0.029 
IL-6 (pg/ml) 2.198 ± 1.759 1.908 ± 1.644 0.208 
IL-8 (pg/ml) 12.52 (10.3) 12.69 (11.0) 0.905 
IL-10 (pg/ml) 0.66 (0.39) 0.66 (0.36) 0.955 
IL-6/IL-10 ratio 3.35 ± 2.96 2.89 ± 2.69 0.210 
VEGF (pg/ml) 125.17 ± 93.41 197.72 ± 179.19 0.008 
IFNγ (pg/ml) 0.27 (0.17) 0.22 (0.03) 0.000 
EGF (pg/ml) 69 (80) 72 (87) 0.595 
MCP-1 (pg/ml) 225 (126) 208 (90) 0.299 
TNFα (pg/ml) 3.026 ± 1.206 2.897 ± 1.005 0.498 
Adhesion molecules array 
VCAM-1 (ng/ml) 512.52 ± 149.74 469.87 ± 125.57 0.072 
ICAM-1 (ng/ml)  277.63 ± 95.37 250.34 ± 74.98 0.091 
E-Selectin (ng/ml) 16.34 ± 7.02 16.03 ± 5.33 0.963 
P-Selectin (ng/ml) 190.1 ± 57.78 192.2 ± 57.8 0.887 
L-Selectin (ng/ml) 1480 (506) 1454 (555) 0.286 
ELISA studies 
NT-proBNP (ng/L) 67.28 ± 45.15 68.00 ± 35.69 0.529 
hsTnT (μg/L) 0.00571 (0.0022) 0.00575 (0.0023) 0.241 
P1CP (ng/ml) 82.02 ± 34.73 84.06 ± 28.76 0.497 
C1TP (ng/ml) 3.05 ± 1.22 2.81 ± 0.96 0.307 
TIMP-1 (ng/ml) 387.62 ± 95.55 415.92 ± 91.21 0.047 
 
Results are presented as mean ± standard deviation or median (inter-quartile range) as appropriate. 
 
On analysis as independent samples, IL-4 and IFNγ were still statistically significantly 
lower in cases. VEGF was significantly higher in cases and TIMP-1 was also significantly 
higher in cases. Differences between IL-1α, IL-6 and adhesion molecules VCAM-1 and 
ICAM-1 were no longer of statistical significance. 
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 Univariate and multivariate analyses  6.3.1.2
Interferon-γ did not have any significant correlations with any of the variables investigated. 
 
 
 
Figure 6.1 Scatterplots of IL-4 against birth weight at index pregnancy and HDL cholesterol. 
Correlation coefficients were calculated as Spearman’s (rho).  Regression lines have only been added 
to indicate direction of relationship. 
 
IL-4 was statistically significantly negatively correlated with birth weight at index 
pregnancy and positively with HDL cholesterol. Spearman’s correlation revealed ρ= -
0.231, p=0.004 for birth weight and ρ=0.168, p=0.033 for HDL cholesterol. Multiple 
regression analysis could not be reported as some of the important assumptions of the test 
were violated.  
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Figure 6.2 Scatterplots of log10VEGF against BMI, HDL cholesterol, sodium and potassium. 
Regression lines have been added to show direction of relationship. 
 
Log-transformed VEGF was found to be statistically significantly correlated with four 
variables; BMI, HDL cholesterol, sodium and potassium. VEGF was positively correlated 
with BMI (ρ=0.173, p=0.028) and potassium (ρ=0.191, p=0.016), and negatively 
correlated with HDL cholesterol (ρ= -0.242, p=0.002) and sodium (ρ= -0.175, p=0.026). 
See Figure 6.2. 
Multiple regression analysis was then performed, to study the differences in VEGF whilst 
controlling for potential confounders. In the first model, parameters that were significantly 
different between cases and controls were entered as co-variates (Table 6.8). In a second 
model, adjustment for traditional cardiovascular risk factors was made (Table 6.9). 
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Table 6.8 Model 1 multiple regression for log10VEGF results 
Parameter B SEB β P-value 
Pre-eclampsia 0.123 0.055 0.169 0.025 
BMI 0.004 0.005 0.059 0.490 
HDL cholesterol - 0.167 0.073 - 0.192 0.024 
Sodium - 0.031 0.013 - 0.177 0.021 
Potassium 0.112 0.060 0.140 0.063 
B = unstandardized regression coefficient, SEB = standard error of the coefficient,  β = standardised 
coefficient. 
 
Table 6.9 Model 2 multiple regression for log10VEGF results 
Parameter B SEB β P-value 
Pre-eclampsia 0.155 0.060 0.212 0.010 
Age 0.016 0.016 0.083 0.318 
BMI 0.013 0.005 0.217 0.016 
SBP 0.000 0.002 0.008 0.930 
Total cholesterol 0.016 0.029 0.045 0.589 
Diabetes - 0.048 0.163 - 0.025 0.768 
Current smoker 0.095 0.098 0.080 0.336 
B = unstandardized regression coefficient, SEB = standard error of the coefficient,  β = standardised 
coefficient. 
 
Log-transformed TIMP-1 was statistically significantly correlated with HDL cholesterol 
and creatinine. Due to distribution of HDL and creatinine, nonparametric testing was 
required. HDL cholesterol was negatively correlated with log10TIMP-1, (ρ = -0.207, 
p=0.008), and creatinine was positively correlated (ρ = 0.185, p = 0.018). See Figure 6.3. 
Comparison of mean log-transformed TIMP-1, when grouped by hypertension or current 
smoking was not significant. 
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Figure 6.3 Scatterplots of log10 TIMP-1 against creatinine and HDL cholesterol  
 
Multiple regression analysis was again performed. Model 1 consisted of pre-eclampsia 
status, HDL cholesterol and creatinine which had all been significantly different between 
cases and controls (Table 6.10). Statistically significant independent variables in the model 
were HDL cholesterol and creatinine. Pre-eclampsia was not a statistically significant 
determinant. The second model, as before, was made up of pre-eclampsia and classical 
cardiovascular risk factors. Not one of the independent variables was individually 
statistically significant (see Table 6.11).  
 
Table 6.10 Model 1 multiple regression for log10TIMP-1 results 
Parameter B SEB β P-value 
Pre-eclampsia 0.032 0.016 0.147 0.053 
HDL cholesterol - 0.051 0.020 - 0.201 0.010 
Creatinine 0.002 0.001 0.181 0.019 
B = unstandardized regression coefficient, SEB = standard error of the coefficient,  β = standardised 
coefficient. 
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Table 6.11 Model 2 multiple regression for log10TIMP-1 results 
Parameter B SEB β P-value 
Pre-eclampsia 0.030 0.018 0.143 0.091 
Age - 0.003 0.005 - 0.061 0.480 
BMI 0.001 0.002 0.057 0.532 
SBP 0.000 0.001 - 0.030 0.741 
Total cholesterol - 0.002 0.009 - 0.016 0.852 
Diabetes 0.037 0.048 0.066 0.450 
Current smoker 0.004 0.029 0.010 0.904 
 
B = unstandardized regression coefficient, SEB = standard error of the coefficient,   β = standardised 
coefficient. 
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 COPS biomarker studies cohort 6.3.2
 Results from Luminex® MILLIPORE® MAP studies 6.3.2.1
Table 6.12 Results from MAGPIX® platform analysis in the COPS vascular 
cohort 
Biomarker Controls (n=37) Cases (n=37) P-value 
IL-17F (ng/ml) 0.0432 ± 0.0136 0.0495 ± 0.0227 0.309 
GM-CSF (ng/ml) 0.2997 ± 0.192 0.3546 ± 0.242 0.295 
IFNγ (pg/ml) 68.12 ± 22.96 75.25 ± 21.29 0.170 
IL-10 (pg/ml) 17.11 ± 5.42 18.83 ± 6.64 0.227 
CCL20/MIP3α (pg/ml) 51.14 ± 13.80 60.40 ± 21.36 0.037 
IL-12p70 (pg/ml) 44.88 ± 13.15 49.70 ± 17.18 0.212 
IL-13 (pg/ml) 114.70 ± 42.19 127.80 ± 46.18 0.207 
IL-15 (pg/ml) 39.67 ± 13.49 40.90 ± 13.78 0.699 
IL-17α (pg/ml) 38.32 ± 13.23 42.19 ± 13.63 0.219 
IL-22 (ng/ml) 1.0527 ± 0.231 1.1612 ± 0.381 0.260 
IL-9 (pg/ml) 36.83 ± 13.17 39.06 ± 13.36 0.471 
IL-1β (pg/ml) 22.718 ± 10.08 23.819 ± 8.21 0.608 
IL-33 (pg/ml) 132.2 ± 33.3 147.5 ± 54.4 0.278 
IL-2 (pg/ml) 32.94 ± 14.0 34.46 ± 11.9 0.615 
IL-21(pg/ml) 81.08 ± 24.71 91.79 ± 32.59 0.122 
IL-4 (ng/ml) 0.1471 ± 0.0529 0.1693 ± 0.0890 0.322 
IL-23 (ng/ml) 4.316 ± 1.158 4.714 ± 1.61 0.309 
IL-5 (pg/ml) 21.85 ± 8.57 23.42 ± 6.84 0.387 
IL-6 (pg/ml) 32.09 ± 11.84 33.49 ± 9.97 0.584 
IL-17E/IL-25 (ng/ml) 0.898 (0.429) 0.988 (0.461) 0.417 
IL-27 (ng/ml) 1.328 ± 0.328 1.436 ± 0.538 0.476 
IL-31 (ng/ml) 0.6232 ± 0.165 0.7030 ± 0.291 0.281 
TNFα (pg/ml) 40.76 (9.67) 41.04 (13.54) 0.344 
TNFβ (ng/ml) 0.2275 ± 0.1095 0.2369 ± 0.0776 0.673 
IL-28A (ng/ml) 2.025 (0.544) 2.172 (0.564) 0.405 
IL-6/IL-10 ratio 1.86 ± 0.27 1.82 ± 0.30 0.517 
 
Values are expressed as mean ± standard deviation or median (inter-quartile range) depending on 
distribution of the data. Two-sample t-test or Mann-Whitney U tests were performed accordingly. 
Data was transformed to attempt normalisation if not normally distributed initially.  
 
Results from Luminex® MAGPIX® studies revealed CCL20/MIP3α to be significantly 
higher in pre-eclampsia cases (see Table 6.12). IL-6/IL-10 ratio was lower in the pre-
eclampsia group which was similar to the finding using the Randox panel in the Generation 
Scotland (GS) cohort.  
 
Between GS and COPS cohorts, in biomarkers that were similar between panels (IL-1β, 
IL-2, IL-4, IL-6, IL-10, TNFα, IFNγ) the trend for results were consistent between panels 
only for one biomarker, IL-10.  
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 Results from urinary proteomic studies 6.3.3
 
Urinary proteomic studies were carried out on 76 available urine samples (38 cases and 38 
controls) from the COPS vascular study cohort (Figure 6.4). There were no statistically 
significant differences between controls and cases. For the CAD238 panel mean 
classification factor for controls was -0.699 (± standard deviation 0.259) and for cases -
0.670 (±0.336), p=0.672. For the CKD273 panel controls had a mean value of -0.326 
(±0.297) vs cases -0.357 (±0.241), p=0.625 and for the pre-eclampsia panel controls had a 
mean of -1.213 (±0.441) vs cases -1.187 (±0.347) p=0.774.  
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Figure 6.4 Boxplots of urinary proteomic panel results. A) the CAD238 panel B) the 
CKD273 panel C) the pre-eclampsia panel. Controls are depicted on the left in green, 
and cases on the right in red. 
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 Discussion 6.4
 
 Findings 6.4.1
 
In attempting to explain the vascular findings from chapter 5, most notably the presence of 
endothelial dysfunction in women with a history of pre-eclampsia, it was hoped that the 
biomarker studies would yield functional insights. Most interesting of all is probably the 
unexpected finding of VEGF levels being higher in women with a history of pre-
eclampsia. VEGF levels tend to be reduced in women experiencing pre-eclampsia, as sFlt-
1 is an inhibitor of VEGF, and sFlt-1 levels are raised in pre-eclampsia and have been 
found to be raised in women with evidence of endothelial dysfunction after pre-eclampsia 
(442). 
 
Although previous studies have been contradictory regarding VEGF levels after pre-
eclampsia, a recent systematic review and meta-analysis (250) reported a higher median 
VEGF level in women with a history of hypertensive disorders of pregnancy. However, 
only two studies relating to VEGF were evaluated and both were small, with the larger 
describing 29 cases and 32 controls (252). While it is unclear what the specific cause of 
raised VEGF level is in these women, one must consider the fact that in previous studies of 
patients with cardiovascular disease, increased levels of circulating VEGF have been 
reported (244;443).  
 
Different trends in the direction of biomarkers in common between the two cohorts were 
found. Possible reasons for this include the length of time since index pregnancy and 
differences in sample preparation. Women from the COPS study were younger and median 
time since index pregnancy was 16.5 years in controls and 19 years in cases. For the 
Generation Scotland cohort median time since pregnancy was >30 years. In addition, of 
note is the fact that samples were from two different cohorts, meaning that they were 
collected slightly differently, and COPS samples had been collected within months of 
analysis not years. Another possible reason for inconsistencies between panels is that 
outliers were removed for one group. There was no indication to remove outliers for the 
COPS vascular cohort, however, due to the extreme nature of some of the outliers in the 
GS cohort, and the fact that they could have been due to technical issues, outliers were 
removed in this group.  
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The IL-6/IL-10 ratios were not different between cases and controls in either cohort in this 
study, and they were in fact in the opposite direction to some of the key reports in the field 
(256). 
 
 Strengths 6.4.2
 
For this study 2 controls were matched to each case in the Generation Scotland cohort in an 
attempt to increase the power. Also, a p-value of <0.05 was used as the cut-off for 
significance, as the individual biomarker tests were treated as independent hypotheses and 
this was viewed as a hypothesis generating experiment. In order to confirm the results, 
additional cohorts would be required.  
 
In addition, this study consisted of two different patient populations from two different 
time points since pre-eclamptic pregnancy and as such was able to compare biomarkers in 
this context. In particular, there are few studies which have analysed samples in women so 
long after pre-eclamptic pregnancy. It is important to consider that where women are 
positioned on their own cardiovascular disease continuum will vary as they get older, and 
by simultaneously evaluating women who are all at differing time-points since index 
pregnancy, one might be able to observe alterations in biomarkers over time since index 
pregnancy more swiftly and in a more comprehensive manner.  
 
Another strength of this study was the availability of vascular results in addition to the 
clinical measurements and obstetric history in the COPS vascular study cohort.  
 
 Limitations 6.4.3
 
Identical biomarker panels were not analysed in both the Generation Scotland and COPS 
vascular cohorts. It is therefore impossible to know if the results would have been different 
depending on the age of subjects or using samples prepared differently. A more thorough 
evaluation would have been to perform identical biomarker studies in both cohorts. 
Some of the biomarkers such as IFNγ, IL-2, IL-4, IL-6, IL-10 and TNFα were present in 
both panels used and were therefore evaluated by two different methods in two different 
cohorts. Nevertheless, taking into consideration the results of the biomarker studies, it 
would be useful to evaluate VEGF in the COPS vascular cohort in future.  
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Study samples were prepared and stored at different times and the protocols between 
Generation Scotland and the COPS vascular study for sample storage were not identical. 
Some samples will have been years older than others, and stored in different sites in 
different freezers from one another. In studies recruiting over even longer periods of time 
and over several different sites, there will always be inconsistencies even within the same 
study population, regarding how old the samples are. If there is a large variation in sample 
time points between subjects in studies recruiting over long periods of time, then sample 
age should be noted so it can be taken into consideration if necessary. The COPS vascular 
study cohort was recruited over a shorter period of time than the GS:SFHS and samples 
were prepared by the same technician and analysed within a much shorter time-frame than 
GS:SFHS samples. This study was also underpowered to fully assess the potential 
differences in biomarkers in women with a history of pre-eclampsia and those with 
normotensive pregnancies.   
 
 Conclusion 6.4.4
 
In conclusion, in this chapter the biomarker studies did not entirely agree with the previous 
literature, indicating not only that characterising specific biomarkers and their roles in 
cardiovascular disease is complex, but also that different biomarkers may have different 
influences at different time-points after pregnancy and this should be taken into 
consideration when evaluating biomarkers for potential future use in this context. 
There are not many other studies investigating women at this length of time since index 
pregnancy, and it is possible that findings more consistent with the findings of this study 
will present themselves over time. It is also possible that due to the underlying 
cardiovascular health of the Scottish population, which is worse than other areas of the 
United Kingdom (444), environment and genetics may play a far greater role than 
previously thought. 
 
The role of biomarkers not only in the prediction of pre-eclampsia and disease severity, but 
also in the management of these pregnancies (during the immediate delivery and post-
partum period) and their role in the elucidation of cardiovascular disease later in life, is 
likely to continue to evolve rapidly over the next decade. Rigorous reporting, 
standardization of techniques for more direct comparison between studies, and adequate 
sample size and power are just a few of the issues going forward.  
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It is not realistic to expect that only one or two individual biomarkers will emerge as the 
answer to predicting cardiovascular disease risk after pre-eclampsia, and that is no longer 
what is expected in the field. Further research is required to clarify some of the 
discrepancies in results. A realistic goal for the future might be a biomarker panel, specific 
for cardiovascular disease risk in women with a history of pre-eclampsia. 
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7 Discussion 
 
Pre-eclampsia is a serious condition, specific to pregnancy and is traditionally diagnosed as 
increased blood pressure in the presence of proteinuria with onset >20 weeks gestation. 
Updated guidelines allow for the diagnosis in the absence of proteinuria if other 
concerning features are present (15). It remains a main cause of maternal, fetal and 
neonatal mortality particularly in low- and middle- income countries (58;445). Women 
with a history of pre-eclampsia are recognised to be at an increased risk of cardiovascular 
disease later in life and there is ongoing debate as to whether pre-eclampsia itself 
independently predisposes to this future risk of cardiovascular disease, through processes 
initiated at the time of pre-eclamptic pregnancy, or whether pre-eclampsia is an indicator 
of a woman’s innate higher risk of future cardiovascular disease. While the studies 
described in this thesis do not directly address this question, they were designed to further 
explore the association between cardiovascular disease risk and pre-eclampsia.  
 
The aim of the work presented in this thesis was to address the gap in knowledge regarding 
mechanisms of the link between pre-eclampsia and cardiovascular disease. I first sought to 
confirm the relationship between cardiovascular risk and pre-eclampsia in a Scottish 
cohort, and I then addressed the nature of this relationship through a series of studies 
designed to assess vascular function, biomarkers and any evidence of cardiac disease on 
electrocardiogram. A theme throughout the work presented is that the strict phenotype of 
“pre-eclampsia” was pursued for “cases” in preference to “gestational hypertension”, 
because it is possible that pre-eclampsia and other, less severe forms of hypertensive 
disorders of pregnancy may have differing underlying pathologies.  
 
 Cardiovascular risk after pre-eclampsia 7.1
 
The first study, described in Chapter 3 used the Generation Scotland: Scottish Family 
Health Study (GS:SFHS) cohort was able to confirm previous findings in the Scottish 
population and other countries, that pre-eclampsia does confer future risk of cardiovascular 
events. In this cohort I found that women with a history of pre-eclampsia were at a 2-fold 
increased risk of developing cardiovascular disease later in life.  
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A recent systematic review and meta-analysis of cardiovascular health following 
pregnancies with pre-eclampsia investigated the future risk of coronary heart disease, heart 
failure, composite cardiovascular disease, stroke, death due to cardiovascular disease or 
coronary heart disease and death caused by stroke (446). This was after adjustment for 
possible confounders such as body mass index, age and diabetes mellitus. It found that pre-
eclampsia was associated with a 4-fold increase in the incidence of heart failure and a 2-
fold increase in the risk of stroke, coronary heart disease and death from cardiovascular 
disease or coronary heart disease in the future.  The study also found that the risk of stroke, 
heart failure or death from cardiovascular disease was higher during the 10 years 
immediately after the affected pregnancy than the following 10 years (446).   
 
 Electrocardiographic studies 7.2
 
In order to evaluate the cardiovascular risk in women with a history of pre-eclampsia, I 
analysed results from the ECGs of women with a history of pre-eclampsia vs normotensive 
pregnancy in the GS:SFHS. There is evidence of cardiac changes consistent with exposure 
to a higher blood pressure in women with a history of pre-eclampsia in comparison with 
normotensive women and in nulliparous vs parous women. There is also evidence of a 
greater proportion of women with a longer QTc than normal in women who are nulliparous 
vs parous or women with a history of pre-eclampsia vs normotensive pregnancy. As a 
result such women may be at greater risk of cardiac arrhythmias and more serious 
complications.  
 
 Results of Vascular studies 7.3
 
To investigate the potential mechanisms underlying the increased cardiovascular risk 
following pre-eclampsia, I recruited women to the COPS vascular study and assessed 
clinical and vascular parameters in this cohort of Scottish women.  
 
Blood pressure was found to be elevated in women with a history of pre-eclampsia and 
heart-rate adjusted AIx, cfPWV and FMD were all statistically significantly different 
between cases and controls (as was plaque score and presence of plaque). However, only 
the difference in FMD remained, with pre-eclampsia being an independent predictor of 
FMD after adjusting for other co-variates. These findings are inconsistent with most other 
studies described in the literature, but these studies were performed at ~10 years after pre-
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eclampsia, which was not as long since index pregnancy as our study. There could now be 
new evidence of endothelial dysfunction again at an older age. This would possibly be 
consistent with the findings of Ramsay et al (158) who found decreased endothelial 
function (microvascular dysfunction) in women 15-25years after pre-eclamptic pregnancy. 
This group also found similar responses in pregnant women with type 1 diabetes. Some 
other studies which used the same laser Doppler perfusion imaging found evidence of the 
opposite pattern in the microvascular response, when FMD found a decreased response 
(i.e. increased response in microvascular beds was indicative of decreased response in 
larger vessels). Further research may help to clarify these findings.  
 
 Biomarker studies 7.4
 
Given the findings of the vascular studies, it was hypothesised that important potential 
biomarkers implicated in the picture of endothelial dysfunction years after pre-eclampsia 
might be revealed. Results of chapter 5 showed that there is no single biomarker to explain 
the risk of cardiovascular disease following pre-eclampsia. While the results did not reveal 
any robust biomarker that is associated with a history of pre-eclampsia, this does not mean 
that there is no biomarker that could predict cardiovascular events in these women. 
However, I did not specifically address the question of which biomarker predicts 
cardiovascular events, nor was my study designed to do so. I did not study women who had 
developed cardiovascular disease already, after pre-eclampsia, but rather I compared 
women who developed pre-eclampsia during their remote pregnancy with women who had 
experienced normotensive remote pregnancies. This was done with a view to comparing 
which biomarkers may be useful in determining some of the differences observed in the 
vascular and record-linkage studies between these two groups of women.  
 
The finding of a raised VEGF level in women with a history of pre-eclampsia and lower 
FMD, as seen in chapter 4, is a pattern that has been seen before, out-with pre-eclampsia 
research. For example, in a study examining endothelial dysfunction, abnormal 
thrombogenesis and abnormal angiogenesis in hypertensive men (443) 76 men (aged 40-
60yrs) with a diagnosis of hypertension were compared with 48 normotensive controls. 
FMD was significantly lower in the hypertensive group and VEGF levels significantly 
higher along with tissue factor (TF) and von Willebrand factor (vWF). After intensified 
blood pressure and hypercholesterolaemia treatment, the levels of TF, vWF and VEGF all 
decreased and FMD increased. Considering that in chapter 4 women with a remote history 
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of pre-eclampsia were found to have a higher blood pressure than controls, it is possible 
that there are similar underlying mechanisms involved. 
 
Another complicating factor to consider is the heterogeneity of certain biomarkers across 
other diseases and conditions (not just specific to pre-eclampsia or cardiovascular disease). 
Also, the expectation of patients and health clinics must take into account the fact that risks 
will change over time and where a patient is on the cardiovascular disease continuum will 
change. While early changes may not be picked up on one appointment, how long should 
the interval be between this point in time and screening again? Five years may be sufficient 
time for a patient to develop and die from more serious sequelae.  Other considerations 
would be the clinical utility of the biomarker test and whether it would be cost-effective 
and timely to deliver. 
 
 
 Limitations 7.5
 
The studies were underpowered to investigate timing of onset of pre-eclampsia or 
investigate recurrent pre-eclampsia. Further exploration of the timing of pre-eclampsia 
could be important when one considers that women with early onset pre-eclampsia at less 
than 32 weeks (compared with ≥37 weeks) are at a 20-fold increased maternal mortality 
risk (22;447). 
 
I also did not adjust for menopause as a co-variate. The study would have been 
underpowered to analyse women according to menopausal status, and due to the fact that 
the menopause evolves over a period of time and is not a suddenly apparent finding, and 
considering that our data was questionnaire based and menopausal status was not assessed 
by any biochemical measurement, the data would not have been reliable. However, 
menopause does have effects on the blood pressure. Systolic blood pressure is increased, 
most likely secondary to increased angiotensin II receptor expression, withdrawal of 
vasodilator effects of endogenous oestrogen, reduced endothelial nitric oxide production, 
increased salt sensitivity and arterial stiffness (448;449). An isolated increase in systolic 
blood pressure is a predictor of later cardiovascular disease in both men and women (449).  
 
Similarly, I did not adjust for type of contraception, and oral contraceptive use has been 
associated with increases in blood pressure and risk of cardiovascular events (448). Such 
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increases are thought likely secondary to renin-angiotensin aldosterone activation, salt and 
water retention and increased arterial stiffness.   
 
Another factor which was not adjusted for was socio-economic status. Low maternal socio-
economic status is a strong risk factor for pre-eclampsia (450) and higher incidence of 
cardiovascular disease has been found in more deprived areas (451). Further consideration 
of socio-economic status is warranted, especially considering the inequalities in health and 
levels of socio-economic deprivation in Glasgow, the city from which the highest number 
of study participants were recruited. The prevalence of cardiovascular disease in Glasgow 
is higher in comparison with other UK cities, and five out of the ten local authorities with 
the highest cardiovascular disease mortality rates in the UK are found in Scotland (444). 
Glasgow had the highest cardiovascular disease death rates at under 75 years (144/100,000 
population) and at all ages (400/100,000) in a recent study (444). 
 
 Future directions 7.6
 
Improving knowledge about the consequences of pre-eclampsia, not only amongst patients, 
but in the wider medical community is warranted. The legacy of pre-eclampsia is important 
not only for women, but also their children, as offspring are also at risk of cardiovascular 
disease. Previous studies have revealed sub-optimal knowledge amongst health care 
physicians (452;453), but with pre-eclampsia featuring in the American Heart Association 
2011 guidelines for the prevention of cardiovascular disease in women (89), it is hoped 
that this will change. Nevertheless, efforts to educate patients and physicians should focus 
on appropriate post-partum information about the consequences of pre-eclampsia, as 
mentioned in the NICE guidelines for hypertension in pregnancy (2). Communication and 
swift easy transfer of information between primary and secondary care would facilitate 
thorough and comprehensive follow-up for these women. General Practitioners are tasked 
with the routine care and follow-up of these women in the community and require adequate 
resources for monitoring. They have long-term responsibility for these patients and 
therefore require the appropriate information in a timely fashion.  
 
Further education about the prediction and prevention of pre-eclampsia will also be of 
benefit. For example, an increase in body mass index between pregnancies and obesity 
increases the risk of recurrent pre-eclampsia (454). The NICE guideline advises women 
who have had pre-eclampsia to try to achieve and maintain a body mass index in the 
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healthy range prior to a subsequent pregnancy (2). Furthermore, there is evidence that 
chronic hypertension after hypertensive disorders of pregnancy might be reduced if a 
healthy lifestyle is adhered to, in particular a healthy weight (455).  
 
The dilemma of when and how often to follow-up these women is a matter of ongoing 
debate. Whilst pre-eclampsia increases cardiovascular risk overall, those with recurrent 
episodes of pre-eclampsia are at a higher level of risk and need more attention. According 
to national guidelines in both the United Kingdom and the United States (2;89;90) women 
should be followed up after a pre-eclamptic pregnancy, however, there is a lack of 
evidence concerning the extent of monitoring and length of the follow-up period itself 
(446). Ideally follow-up should be cost-effective and should not have negative effects. 
Further research into the precise methods and length of follow-up should be explored.  
  
Further research is required to advance our understanding of the mechanisms behind the 
link between pre-eclampsia and future cardiovascular disease. In order to unravel the 
complexities of hypertensive disorders of pregnancy, and the likely subtle differences 
between different types of disorder (e.g. term vs pre-term pre-eclampsia), collaboration 
will play an increasingly important role. The generation of large studies and large datasets 
will reduce the likelihood of underpowered studies.  Longitudinal studies including pre-
pregnancy time-points will also be very important. Establishing which risk factors were 
present prior to pregnancy and to what extent (e.g. degree of endothelial dysfunction) will 
provide a definitive answer how much pre-eclampsia and hypertensive disorders of 
pregnancy contribute to cardiovascular risk after such pregnancies. It is likely that a 
woman’s pre-existing, pre-pregnancy constitution, in combination with factors relating to 
pre-eclampsia itself may be responsible for future cardiovascular disease overall.   
 
Maximisation of resources by standardisation of study design is another route by which 
large pieces of information could be utilised efficiently. A standardised outcome set for 
studies of hypertensive disorders of pregnancy is being created by the Core Outcome 
Measures in Effectiveness Trials (COMET) (58). The Global Pregnancy Collaboration 
(CoLab) has already established standardised study design for use in pre-eclampsia 
research (456). 
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 Conclusion 7.7
 
Despite the large amount of research which has already been done to investigate the causes 
of cardiovascular disease in women with a remote history of pre-eclampsia, the precise 
mechanisms responsible for this relationship have yet to be confirmed.  
 
The studies described in this thesis have not identified one particular component which 
explains the increased cardiovascular risk in this group of women, nor have they clarified 
the precise nature of the association between pre-eclampsia and cardiovascular disease. It 
remains unclear whether pre-eclampsia itself is responsible for the increase in 
cardiovascular risk or whether pre-eclampsia is an indication of an enhanced 
cardiovascular risk which pre-dated the pregnancy. However, these results are not 
unexpected due to the complex nature of the condition. There will be many factors which 
contribute to the evolution of pre-eclampsia, and it is possible that the increased 
cardiovascular risk later in life will also be composed of many different elements. Maternal 
constitution is likely to be an important factor in the development of pre-eclampsia and 
later cardiovascular disease, as evidenced by data from the HUNT study (103). 
 
Perhaps more thorough assessment and investigation of these women could yield more 
informative results. For example, the studies included in this thesis did not involve 
performing echocardiography or MRI imaging. Future studies should focus on assessing an 
even greater range of modalities in investigating the relationship between pre-eclampsia 
and cardiovascular disease. Differing follow-up periods, consideration of new studies re-
visiting investigation in existing study cohorts and the possibility of merging study cohorts 
or wider collaboration should also be considered. Follow-up periods could be important in 
further determination of the pathophysiology of cardiovascular risk after pre-eclampsia. 
For example, it would have been interesting to assess findings at later time-points in 
studies of flow-mediated dilatation which detected endothelial dysfunction at 1 year but 
normalisation of these changes by 10 years. It is not possible to know whether 
normalisation of endothelial dysfunction remained in these women at 15 years and 20 
years post-partum.  
 
As the causes of pre-eclampsia and subtle differences in pathophysiology between the 
different types of pre-eclampsia (e.g. early-onset vs late-onset) and other hypertensive 
disorders of pregnancy are further elucidated, mechanisms behind the relationship between 
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pre-eclampsia and cardiovascular disease later in life may be further explored. 
Improvements in the understanding of this condition will help identify which specific 
women are at higher risk of cardiovascular disease, thus allowing more targeted 
interventions in a timely manner. They will also aid in the discovery of novel therapies 
which may be of great benefit to these women.  
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